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Resumen
La Tuberculosis (TB) es una enfermedad infecciosa que causa más de 10
millones de nuevos casos y 1.5 millones de muertes al año. La actual vacuna,
BCG, no es capaz de proporcionar una eficacia consistente, y por ello ex-
iste la imperiosa necesidad de desarrollar nuevas vacunas. En este contexto,
la modelización matemática puede jugar un papel clave en la evaluación y
comparación de estas nuevas vacunas con el propósito final de asistir en la
elaboración de políticas y optimización de las estrategias de vacunación.
El objetivo de esta tesis es la creación de un modelo apropiado para la
evaluación del impacto de estas nuevas vacunas. Para ello centramos nuestros
esfuerzos en dos vertientes distintas: la modelización de la propagación de
la Tuberculosis per se, y la parametrización de estas nuevas vacunas para su
evaluación con estos nuevos modelos. En lo que se refiere a la modelización
de la propagación de la enfermedad, los principales avances propuestos en
esta tesis están relacionados con la estructura de edad de las poblaciones.
Específicamente implementaremos, por primera vez en un modelo de propa-
gación de TB, contactos dependientes de la edad y la evolución temporal de
las pirámides demográficas.
Así, comenzamos la tesis estudiando el problema teórico de implementar
patrones de contacto empíricos dependientes de la edad en distintas esruc-
turas demográficas. Es una tendencia actual en epidemiología utilizar estos
patrones de contacto por edades heterogéneos, superando así la asunción
clásica de mezcla homogénea. Sin embargo, estos patrones de contacto han
sido medidos en poco más de una decena de localizaciones diferentes, y queda
pendiente la cuestión de hasta que punto unos patrones de contacto que cor-
responden a una población específica son transferibles a otra localización
diferente. En esta tesis estudiamos distintos métodos para proyectar matri-
ces de contacto de una población a otra con distinta estructura demográfica,
y analizaremos las difierencias que existen en los patrones de contacto de
distintos países. Este estudio es fundamental para la construcción de nuestro
1
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modelo en el que pretendemos acoplar patrones de contacto por edades con
una evolución temporal de la estructura por edades de la población, de forma
que deberemos adaptar esas matrices de contacto por edades en cada paso
temporal.
En el siguiente capítulo desarrollamos un modelo de propagación de la
Tuberculosis en el que integramos una gran cantidad de datos sobre una
Historia Natural para la enfermedad con 19 estados diferentes (incluyendo
dos estados de latencia, tres tipos distintos de enfermedad con distinta in-
fecciosidad, y distintos resultados del tratamiento). Así, nuestro modelo
utilizará como input, datos de incidencia y mortalidad específicos de cada
país, parámetros epidemiológicos con dependencia de la edad obtenidos de
diferentes estudios, y, como ya hemos avanzado, incorporamos por primera
vez en el campo proyecciones demográficas y matrices de contacto por edades.
En este trabajo identificamos sesgos substanciales arraigados en una descrip-
ción inadequada de estos aspectos, a nivel tanto de incidencia y mortalidad
agregadas como en su distribución por edades.
Una vez que la base del modelo de propagación de Tuberculosis está es-
tablecida, el siguiente paso es el estudio de la parametrización de los efectos
de la vacuna en el contexto del modelo introducido. Aunque nuestro objetivo
último es estudiar el impacto final que tendrán hipotéticas nuevas vacunas, es
fundamental obtener toda la información posible de la actual vacuna BCG,
ya que muchos de los efectos y problemas que tiene esta vacuna podrían
darse también de forma inevitable en las nuevas vacunas. En concreto, so-
bre BCG estudiaremos la serie de ensayos clínicos BCG-REVAC, diseñados
para intentar discernir qué mecanismo producido por exposición previa a mi-
cobacterias (enmascaramiento y/o bloqueo) está detrás de la variabilidad en
la eficacia de BCG medida en distintos lugares. Aunque esta discusión ya
había sido realizada cualitativamente, en esta tesis proponemos varios mod-
elos matemáticos (con bloqueo, con enmascaramiento y con los dos efectos),
comprobamos cúal de ellos ajusta mejor a los datos obtenidos por esta serie
de ensayos clínicos y cuantificamos estos efectos.
A continuación, estudiamos el diseño de ensayos clínicos que se implemen-
tarán sobre las nuevas vacunas y que nos proveerán de toda la información
posible para su evaluación con un modelo de propagación, ya que debido a
la falta de correlaciones de protección de Tuberculosis, los ensayos clínicos
son la única forma de determinar la eficacia de una vacuna.. La formulación
clásica de estos ensayos clínicos ofrece una parametrización muy limitada de
la vacuna. En concreto, ofrece un único dato de eficacia contra enfermedad,
2
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cuando en realidad existen múltiples mecanismos con los que una vacuna
puede interrumpir el ciclo del patógeno, y que permanecen indistinguibles
en un ensayo clínico lo que provoca grandes incertidumbre en la posterior
evaluación de impacto. Estudiaremos un nuevo diseño para estos ensayos
clínicos, capaz de ofrecer una parametrización más completa de la vacuna.
Finalmente, una vez que ya hemos desarrollado un nuevo modelo de
propagación de Tuberculosis y hemos estudiado en detalle la descripción de
las vacunas en este contexto, evaluamos diferentes vacunas hipotéticas. Nos





Tuberculosis (TB) is an infectious disease that causes more than 10 mil-
lion new cases and 1.5 million deaths every year. The current vaccine, Bacille
Calmette-Guérin (BCG), is unable to provide a consistent efficacy, and thus
there is an urgent nedd to develop new vaccines. In this context, mathemat-
ical modelization could play a key role in evaluating and comparing these
new vaccines with the ultimate purpose of assist policy making and optimize
vaccination strategies.
The goal of this thesis is to create the proper modelling framework for the
impact evaluation of these new vaccines. For this we focus our efforts in two
different pathways: the modeling of TB spreading, and the parameterization
of these new vaccines for their evaluation with new models. Regarding the
modeling of TB spreading, the main advances proposed in this thesis are
related with the age structure of the populations. Specifically, we will imple-
ment in a model of TB spreading, for the first time, age-dependent contact
patterns and the temporal evolution of demographic pyramids.
Thus, we start the thesis studying the theoretical problem of imple-
menting empirical age-dependent contact patterns in different demographical
structures. Nowadays is a common trend in epidemiology the use of these
heterogeneous age-dependent contact patterns, thus surpassing the classical
assumption of homogeneous mixing. However, these contact patterns have
been measured in just a few different settings, and the question remains to
what extent contact patterns that correspond to a specific population are
transferable to a different location. In this thesis we study different methods
of projecting contact matrices from one population to another with a differ-
ent demographic structure, and we analyze the differences that exist between
the contact patterns of different countries. This study is fundamental for the
construction of our model in which we intend to couple age-dependent contact
patterns with the temporal evolution of the age-structure of the population,
in a way that oblige us to update contact matrices at each temporal step.
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In the next chapter, we develop a TB spreading model in which we inte-
grate an important amount of different data sources over a Natural History
of the disease with 19 different states (including two latency states, three
different types of disease with different infectiousness, and different treat-
ment outcomes). Thus, our model will use as an input, data of incidence and
mortality specific for each country, age-dependent epidemiological parame-
ters obtained from different studies, and as we said before, we incorporate for
the first time in the field demographic projections and age-dependent contact
matrices. In this work, we identify substantial biased rooted in an inadequate
description of these aspects, at the level of both aggregated incidence and
mortality rates and their distribution across age strata.
Once the base modeling framework for TB spreading is set, the next step
is to study the parametrization of vaccine effects in the context of the model
introduced. Even though our ultimate goal is studying the final impact that
hypothetical new vaccines will have, it is fundamental to obtain all possible
information from current BCG vaccine, since many of the effects and prob-
lems that this vaccine has, could be inevitable by new vaccines. Specifically,
about BCG we will study the series of clinical trials known as BCG-REVAC,
designed to disentangle which mechanism, produced by previous exposition
to mycobacteria (masking and/or blocking), is behind the variability in BCG
efficacy when measured in different locations. Even though this discussion
had already been made qualitatively, in this thesis we propose several math-
ematical models (with blocking, with masking, and with both), we check
which of them fit better to the data obtained from these clinical trials and
we quantify these effects.
After this, we study the clinical trials that will be implemented over
new vaccines and will provide us all possible information for their evaluation
through a spreading model, since due to the lack of TB correlates clinical
trials are the only way of determining the efficacy of a vaccine. The classical
formulation of these clinical trials offer a very limited parameterization of the
vaccine. Specifically, it offers a single value of efficacy against disease, when
actually there are multiple mechanisms with which a vaccine can disrupt the
cycle of the pathogen, and they remain indistinguishable in a clinical trial,
which provoke enormous sources of uncertainty in the posterior evaluation of
impact. We will study a new design for clinical trials, that is able to offer a
more complete parameterization of the vaccine.
Finally, once we have developed a new TB spreading model and we have
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studied in detail the description of vaccines in this context, we evaluate differ-







1.1 Mathematical Epidemiology: Models to fight
infectious diseases
Since before the dawn of civilization, humanity has faced many deadly
epidemics that have decimated its population. The most well known example
probably is the Black Death, responsible for the death of 30-60% of Europe’s
total population between 1347 and 1351.1 At that time, people did not have
the tools or the knowledge to understand why and how that mantle of death
was falling on them. They knew nothing about viruses, bacteria or any other
agents of disease. The most pious among them could only conclude that it
was God’s punishment for their sins. The few physicians, learners of classi-
cal Greek medicine, attributed the disease to miasma,2 a kind of pollution
emanating from rotting organic matter.2,3 Scholars moved later to an astro-
logical theory, when the Medical Faculty of the University of Paris blamed
the conjunction of Saturn, Jupiter and Mars for the disastrous epidemic.2,4
Academics wanted answers, Kings needed solutions and despair grew among
common folk, as the corpses of family and friends piled up in the streets.
Yet, the first successful attempt at understanding, or at least somehow con-
trolling, the spreading of an infectious disease was still centuries away.
Forgetting the irrational explanations based on gods or celestial bodies,
the first step in the right direction was taken by Daniel Bernoulli in the
mid-18th century. His works on inoculation against smallpox,5–7 in which
he exposed the benefits of vaccination, included what is often considered the
first model in mathematical epidemiology.8 Despite the achievements of these
early works, the field was still very far from what it is today. Specifically,
it was lacking a dynamical principle behind the spreading of an infectious
9
CHAPTER 1. INTRODUCTION
disease. The idea of living agents that cause illness can be traced back to the
work of Aristotle (384-322 B.C.).8 The demostration of the existence of these
microorganisms is due to van Leeuwenhoek (1632-1723), and the germ theory
of diseases was then developed by outstanding names such as Jacob Henle
(1809-1885), Robert Koch (1843-1910), Joseph Lister (1827-1912), and Louis
Pasteur (1822-1875).8 Thus, diseases were no longer caused by the wrath
of God, the capricious journeys of planets and stars or some undetermined
effluvium that impregnates the air, but by living microorganisms that could
pass from one host to another.
The English physician and one of the fathers of modern epidemiology,
John Snow, became one of the first challengers of the widely accepted mias-
matic theory, and embraced the principles of a, still in development, germ
theory. In 1855, almost one century after Bernouilli’s work, John Snow was
able to pinpoint the source of a cholera epidemic in London by the study of
the spatial and temporal pattern of the reported cases.9–11 Specifically, he
identified a water pump in Broad Street as the source of the outbreak. Even
though the local authorities followed Snow’s recommendations and disabled
the pump, germ theory was not accepted until years later. Inspired on John
Snow’s discovery, William Budd identified Bristol’s water supply as a source
of typhoid fever in 1873.12,13
The birth of modern compartmental models still had to wait until the
20th century. In 1906, W. H. Hamer proposed that the spread of an infection
should depend on the number of both susceptible and infective individuals
and a mass action law for the rate of new infections.8,14 These ideas still re-
main at the core of the field of mathematical epidemiology, and became the
foundation of compartmental models in epidemiology. In 1911, Ross used a
simple compartmental model of malaria, including humans and mosquitoes,
that showed that the complete eradication of the mosquito population is not
needed for the eradication of the disease.15 This work introduced for the
first time the concept of basic reproduction number (the average number of
secondary infections produced by an infected individual in an otherwise sus-
ceptible host population) although it was not given a name until 1957.8,16
The pioneer work by Ross not only brought many theoretical advances, it
was also supported by field trials leading to a huge success in malaria control.8
Kermack and McKendrick developed the basic compartmental models,
that are still used nowadays, in a set of papers between 1927 and 1933.17–19 In
these works, they introduced the SIR model that divides the population into
three categories: Susceptible (S), Infectious (I) and Recovered (R). According
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to this very simple model, when susceptible individuals maintain a contact
with infectious individuals, they acquire the infection with probability λ:
S + I
λ−→ I + I (1.1)
Simultaniously, at each time step, infected individuals might recover to
the disease with a probability µ:
I
µ−→ R (1.2)
The model uses only two parameters: the infectiousness λ and the re-
covery rate µ. All individuals are considered dynamically equivalent, which
is known as the Homogeneous Mixing Approximation. Therefore, all sus-
ceptible individuals have the same probability of getting infected, which is
proportional to the number of infected individuals. Furthermore, all individ-
uals are considered to be potentially in contact with each other (well-mixed
populations) and the number of infections per unit of time that takes place
is λβSI, where β is the number of contacts hold by an individual per unit
of time, and S and I are the population of the susceptible and infectious
classes (and R is the number of recovered individuals). The dynamics can








Ṙ(t) = µI(t) (1.5)
When a small infectious seed is introduced in a susceptible population, the
SIR model describes a situation where the population of infected individuals
begins growing until it reaches a maximum and then starts to decay as the
recovery class (which does not get the infection again: recovered individuals
are inmune) gains weight in the population. Thus, this model is useful to
describe rapid outbreaks as those produced by influenza-like diseases. How-
ever, the SIR model, as it has been described here, inevitable leads to the
extinction of the disease (as the population of the susceptible state can only
diminish), a situation that unfortunately does not apply to every case.
If the disease does not provide immunity to future re-infections, then we
can consider that infected individuals, when they recover, go back to the
11
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susceptible state. This is known as the SIS model, that can be described








The dynamical behaviour of the SIS model differs greatly of the SIR, as
it allows a stable endemic level for the disease. If we rewrite the previous
equation system as a one-dimensional system (using the condition S = N−I,









The model has two solutions: I = 0 which is the trivial disease-free fixed






which gives a population of infected individuals greater than zero when:




This critical value λc is called epidemic threshold and gives the minimum
infectiousness λ necesary for the disease to survive in an endemic equilibrium.
λc has also a meaning in the context of the SIR model; λ > λc assures the
existence of an outbreak that affects a macroscopic fraction of the population.
These models, despite their simplicity, give us useful insights about the
qualitative behaviour of an epidemic. Terms as the basic reproductive number
and the epidemic threshold are part of the daily vocabulary of epidemiolo-
gists. However, these models are impregnated with simplified assumptions,
in many ocassions unrealistic, that often introduce heavy biases in the results
obtained. The description of the disease itself, for example, with only 3 or
2 different states falls short for many diseases. The incorporation of a non-
infectious exposed state (E) is needed in many cases, obtaining the SEIR
model.20 Different manifestations of the same disease, multiple strains,21,22
or other complex phenomenologies can also be considered.
12
1.2. THE STRANGE LIFE OF M. TUBERCULOSIS
Population dynamics is also over-simplified in these early models. For
simplicity, they consider the total population N as constant, which could
be a good approximation for short-cycle diseases but results unrealistic for
persistent diseases, for which simulations that span longer periods of time,
even longer than the typical life expectancy of individuals, are needed. These
models often rely upon the well-mixing hypothesis, according to which ev-
ery individual of our population is equally capable of interacting with any
other individual. This assumption has been abandoned progressively by more
sophisticated approaches as the heterogeneous mean field,23,24 the implemen-
tation of age-dependent contact matrices,25 or the use of networks of con-
tacts with different topologies in the case of individual-based models.26–30
Currently, many models include even the mobility of individuals between
different locations.31–36
In mathematical modeling there is always a trade-off between simple mod-
els, deprived of almost every detail, that are used to study qualitative be-
haviour; and more detailed models, designed for policy making, used for spe-
cific situations and including quantitative predictions. In sharp contrast to
the SIR or SIS models, we have nowadays highly advanced modeling frame-
works integrating worldwide high-resolution demographic and mobility data
as well as a wide set of disease’s compartmental descriptions.37 Now, it is even
possible to predict the peak of the influenza seasons, weeks in advance.38,39
However, despite the growing confidence of epidemiologists, new threats such
as the recent Ebola outbreak40 or the Zika virus41 keep challenging the field.
And while the focus of epidemiological modeling often remains at these
fast outbreaks, slow killers such as Tuberculosis (TB) stay hidden. It is
precisely the goal of this Thesis to develop a more realistic model of TB
spreading for the evaluation of the impact of new vaccines. An enterprise
that is as difficult as it is necesary.
1.2 The strange life of M. tuberculosis
The disease of Tuberculosis is caused by the pathogen Mycobacterium
tuberculosis (MTB), that was first identified as a pathogen by Robert Koch
in 1882.42,43 The life cycle of MTB inside the host body and the interactions
between host and pathogen are extremely complex, and present a series of




TB is spread through the air when people with active TB in their lungs
cough or sneeze, releasing tiny droplets with the pathogen in it that are later
inhaled by susceptible individuals. Thus, TB does not diverge of the germ
theory that forms the basis of most compartmental models. The first nuance
we have to consider is that, although MTB attacks to the lung 70% of the
cases,44 it can also disseminate to other organs such as lymph nodes, bone
and meninges, causing what is called extra-pulmonary TB.45 The distinction
between different types of TB plays a major role in the correct assessment
of the spreading of the bacterium for two reasons. On the one hand, as only
individuals with the pathogen hosted at the lungs can infect other susceptible
people, non pulmonary TB is considered as mainly not infectious. On the
other hand, diagnosis times for both forms of disease are very different. Non
pulmonary TB, with its wide range of possible manifestations, is in general
more difficult to detect than the pulmonary TB, which poses less of a diag-
nostic challenge for health practitioners.46
Even more important is the fact that most infections never progress to
active disease and remain asympomatic (what is known as Latent TB In-
fection, LTBI).47,48 It is estimated that one third of the world population
suffers from LTBI,48,49 but only about 5–10% of infected individuals will
develop active TB disease in their lifetimes,50,51 a risk that is much higher
among HIV infected individuals.52 The existence of two different time scales
in the process from infection to active disease brings another challenge for
spreading modeling. Thus, while some individuals (fast-progressors) develop
active disease right after infection, those who develop LTBI form a reservoir
of potential transitions to active disease that, even if they occur at a much
slower rate, can not be ignored due to the large fraction of individuals that
suffers from LTBI.
Furthermore, these different immunogenic mechanisms depend on the age
of the host that suffers the infection.53 Fast-progressors are more common
among newborns and adults than among school-aged children.54 Also, adults
tend to develop pulmonary TB (thus being more infectious), while children
usually develop non-pulmonary TB.55
The typical SIR or SEIR models with only 3 or 4 compartments can not
be adapted to the nuanced nature of TB disease. We need to add different
latency states (with different time scales), different forms of active TB (with
different infectiousness) and an age-structure in our population to differen-
tiate all those processes that depend on the age of the host. And that only
covers the basic needs of any good TB spreading model, without accounting
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for other specific situations such as the appearence of drug-resistant strains
or co-infection with HIV. Definitely, we need more complex models.
1.3 A brief look at the epidemiology of TB
Up to this point, one should consider whether it is worth the enormous
effort that supposes the modelization of the spreading of TB, a disease that
seems more typical of romanticism than of the contemporary era. TB is in
fact a very old disease, whose origin can be traced back at least to the migra-
tions of humans out of Africa during the Neolithic period about 70,000 years
ago.56 TB has been without a doubt one of the deadliest diseases that has
persecuted humanity across history, causing the death of one in five adults
in Europe and North America between the seventeenth and nineteenth cen-
turies.57 Fortunately, this picture improved during the last century, and an
increasing availability of antibiotics and diagnosis tools led to a sustained de-
crease in the incidence levels of the disease,58 and even complete eradication
did not seem to be out of reach.59
This optimistic panorama changed in the past few decades, and control
of TB is facing new challenges. The emerging of HIV, with its ability to
compromise the immune system of affected individuals, favors the prolifer-
ation of other epidemics including TB.60–66 The appearance of multi-drug
and extensively drug resistant strains of MTB (i.e. strains that are resistant
to antibiotic treatment) also imposes a major threat.67–70 TB has become a
global emergency, causing 10 million new cases and almost 2 million deaths
every year.71
Nowadays the most important tool that public health authorities have to
fight TB is the BCG (Bacille Calmette-Guerin) vaccine, but the reach of its
immunogenic action is in doubt.72 While it appears to be effective in protect-
ing newborns from the non-pulmonary forms of meningeal and milliary TB,
its effect in adults against the most infectious manifestations of TB is almost
null.73–76 Besides the dependence on age, efficacy of BCG also presents a
dependency with latitude, hinting a possible interference with environmental
mycobateria.76–78
Thus, the development of a new vaccine aimed at either substituting
BCG or enhancing its immunogenic power is considered essential for the
control and eventual eradication of TB.79,80 Several vaccines are right now
under development,81 hoping to complete all different stages within the next
15
CHAPTER 1. INTRODUCTION
few years.82–85 But resources are limited, and not all different approaches
to TB vaccination can be funded. In this context, having a highly detailed
modeling framework is essential to guarantee a correct resource allocation
and to optimize new interventions against TB.
1.4 TB Modeling: what is done, what is left to
do
The field of TB spreading modeling has not remained isolated from this
situation of public-health emergency, and in the past decades has experi-
enced an important growth. In a recent review by Rebecca Harris et al.86,
the authors identify 23 different articles that used modelization to evaluate
TB interventions, 20 of them published after 2000.
We find many different approaches between these articles. The most
common is the use of deterministic compartmental models using difference
or differential equations, in the same spirit of the early works by Kermack
and McKendrick. Up to 18 articles used this methodology.55,87–103 Other pos-
sible methodologies include Markov decision trees,79,104,105 a simpler model
with a fixed number of transmissions per case,106 and a statistical model.107
The range of complexity of these works, in what regards the description of
the disease, comes from the most generic SIR or SEIR models, to models that
address some of the most important treats of TB that we discussed before.
Thus, we can find some models that incorporate two diferent rates of progres-
sion from infection to disease, different forms of active disease with different
infectiousness, and an age-structured population with an age dependent on
some of the dynamical parameters that describe the disease.55,101,108 Some
of these models also address more specific scenarios. The work by Cohen et
al.92 include co-infection of two strains, and the model developed by Knight
et al.101 differentiates the population according to the HIV status (infected
or not).
However, there are still some aspects that would make these models more
realistic. We have discussed the importance that the age of the host has in the
development of the disease. Nevetheless, we find two important oversimplify-
ing hypotheses regarding the age structure of the population in these models.
On the one hand, we have that these models consider constant demographic
pyramids even when the simulations cover very long periods (decades). Thus,
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it remains unexplored how a realistic evolution of the demographic struc-
ture of the population would compromise epidemiological outcomes. On
the other hand, these models assume homogeneous random mixing between
individuals, meaning that individuals mix among them randomly, without
considering the age of the individuals. We know from empirical studies25
that this assumption is not true. Individuals tend to maintain contacts with
people of the same age, with the appearance of some inter-generational con-
tacts, typically connecting members of different generations within the same
family. Although the inclusion of heterogeneous age-dependent contact pat-
terns has been widely implemented recently for short-cycle influenza-like dis-
eases,26,109–113 for the case of TB the implications of heterogeneity remain
vastly unexplored (up to our knowledge there is only one model of TB that
incorporates realistic contacts in a low burden setting114). Besides, the im-
plementation of heterogeneous contacts in recent works has always been done
in bounded settings (both geographically and temporally), leaving unsolved
theoretical and technical challenges.
Ultimately, the goal of these sophisticated models is to serve as a tool for
policy making, allowing to evaluate new interventions, vaccines and treat-
ments. The way we introduce these interventions in our models is also full of
nuances. Specially complex is the situation of TB with tens of new vaccines
under development, very different in nature, around an immunology that is
not completely understood.115 The possibilities of new vaccines comprise a
wide range of effects.116 The challenge for mathematical modeling could not
be greater.
The differences among the wide range of possible vaccines currently un-
der development might affect the age groups on which these are adminis-
tered.115,116 While some of the vaccines are thought as a substitute of BCG,
and therefore to be applied in newborns,117 others are being designed as a
booster of BCG with an optimal age of deployment around adolescence where
BCG loses its efficacy.79 Therefore, the importance of achieving a detailed
description of the coupling between age and TB transmission gains even more
weight, and an oversimplification of demographic evolution and social mix-
ing with unrealistic assumptions is even more likely to introduce substantial
biases to model outcomes. Even though, previous models have compared the
impact and cost-effectiveness of newborn and adolescent vaccination, con-
cluding that adolescent vaccination generates greater and faster impact.101
One of the main goals of this work is that of quantifying the effects on the
impact derived from adolescents versus newborn targetted vaccination cam-
paigns that can be tracked back to over-simplified description of the coupling
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between TB transmission and populations’ age structure.
Another layer of phenomenology has to do with the specific mechanism
with which the vaccine interrupts the pathogen’s life cycle. During many
years it was believed that BCG’s efficacy came from an interrumption in the
progression from infection to disease (what is known as Prevention of Disease
or PoD). Recently meta-analyses of clinical trials showed that it also offers
some protection against the infection itself (Prevention of Infection, PoI).75
But other possible mechanisms remain unexplored: PoD can be achieved by
reducing the rate of progression or by avoiding fast-progression directly and
we do not know the exact effect that takes place, the effect over LTBI is
also unknown, etc. And what is still unknown for BCG, a vaccine that was
discovered 100 years ago, will hardly be unravelled for new vaccines. This
forces modelers to work in a large parameter space and to extract as much
information as possible from clinical trials whose designs are affected by a
series of relevant economic, logistic and conceptual constraints. Clinical tri-
als are the only way to determine the efficacy of a vaccine, as there are no
correlates of protection for TB118–120, a piece of information that is essential
for its posterior evaluation of impact and cost-effectiveness. Unfortunately
the knowledge that we can extract from these trials is very limited, specially
in the complex scenario of TB with multiple possible interruptions of the
pathogen’s cycle that can be triggered by the vaccine. Thus there exists a
urge need of improving the assessment of efficacy provided by these trials.
A final effect that should be taken into account is the sensitization with
environmental non-tuberculous mycobacteria (NTM). Previous sensitization
to NTM can interfere in the assessment of efficacy of a vaccine in two ways:
by blocking its immunogenic power or by offering a protection that masks the
protection given by the vaccine.121 One or both of these effects are thought to
be behind the very dispair efficacies shown by BCG in different settings.121
The implications for modeling is twofold. On the one hand it brings another
age-dependent effect: newborns will not suffer from previous exposure to
NTM. On the other hand, the levels of NTM varies greatly across different
countries, difficulting to transfer results and simulations from one setting to
another.
The BCG-REVAC trials tried to unravel the mechanisms behind this
interference by NTM in the efficacy assessment of BCG.77 By vaccinating
cohorts at different ages in two different cities (Manaus and Salvador, sup-
posed to have different levels of NTM), researchers reached the conclussion
that blocking was the most plausible effect, but they could not quantify its
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impact.
1.5 Structure of the thesis
The challenges faced by the field of TB modeling are numerous. It is the
goal of this thesis to tackle some of them and open new pathways in the field.
After the introduction in Chapter 1, the thesis is organized as follows.
In Chapter 2 we deal with the theoretical challenge that supposes the
implementation of heterogeneous age-dependent contact patterns in the sce-
nario of evolving demographic structures. Although we are more interested
in the modeling of TB spreading, the framework developed in this chapter is
transversal and of interest for the modeling of any disease.
In Chapter 3 we developed a model for TB spreading that, for the first
time, incorporates empiric age-dependent contact rates and realistic evolu-
tion of demographic structure (thus using the framework developed in Chap-
ter 2). We will show in this chapter that the incorporation of these new
features significantly changes epidemiological forecasts.
In Chapter 4 we will study the mechanisms of masking and blocking
produced by previous sensitization with environmental non-tuberculous my-
cobacteria over the inoculation of BCG. We will analyze the BCG-REVAC
trials in order to parameterize these two effects. Our results show that block-
ing has a greater effect than masking, and therefore we should take this into
account when designing new vaccination campaigns.
In Chapter 5 we will focus on the desing of efficacy clinical trials. We
propose new analyses for these trials that will allow for a more complete
parameterization of the effect of a vaccine, which will improve the accuracy
of posterior impact evaluations.
Finally, in Chapter 6 we will use the model developed in Chapter 3 to
evaluate hypothetical new vaccines. For the implementations of these new
vaccines the lessons learnt in Chapters 4 and 5 will also be of use. We will
focus specifically in the controversial debate of stablishing which vaccination
strategy is better: a replacement of BCG with a better vaccine, or a booster
of BCG applied during the adolescence.
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During recent years, models on disease transmission have improved in
complexity and depth, integrating high-resolution data on demography, mo-
bility and social behavior.37,122 Specifically, the topology of social contacts
plays a major role in state-of-the-art modeling.26,109–113 The complete knowl-
edge of the network of contacts through which an epidemic spreads is usu-
ally unreachable or impossible to implement, and for modeling purposes it
is useful to remain at the coarse level of age-groups. Under this view, the
population under study is divided into different groups, according to its age
distribution, and different contact rates are assumed among these groups.
Age-dependent contact patterns give powerful insights on the transmission
of diseases where epidemiological risk is correlated to age, either as a result
of behavioral or physiological factors. Relevant examples are influenza-like
diseases,111–113,123,124 pertussis,125 and varicella.126 Furthermore, they are in-
strumental for modeling and implementing more efficient interventions.127,128
Age-dependent patterns will also be relevant for the assessment of TB
spreading,114,129 which is the reason why this chapter is relevant for this the-
sis. As we have explained throughout the introduction, the effects caused by
the bacteria depend strongly on the age of the host. Not all age groups will
have the same ability to transmit the disease, and therefore it will be essential
to implement realistic social mixing in a model of TB, specially considering
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that this has been a question overly ignored in previous literature.55,101
Notwithstanding that, and given the utmost importance of contact het-
erogeneities, the study of age-dependent social mixing has become a priority
in epidemiology. In 2008, Mossong et al.25 published a seminal work with
the measurements of age-dependent contact rates in eight European countries
(Belgium, Finland, Germany, Great Britain, Italy, Luxembourg, Netherlands
and Poland) via contact diaries. Other authors have replicated this work
in other countries such as China,130 France,131 Hong-Kong,132 Japan,133
Kenya,134 Russia,135 Uganda,136 and Zimbabwe,137 thus expanding signifi-
cantly the available data on social mixing in the last few years. In these
studies, participants are asked how many contacts they have during a day
and with whom. This allows to obtain the (average) number of contacts that
an individual of a particular age a has with individuals of age-group a′. The
resulting matrix is not symmetric due to the different number of individuals
in each age-group. However, it is precisely the demographic structure what
imposes constraints in the entries of this matrix, as reciprocity of contacts
should be fulfilled at any time (i.e., the total number of contacts reported
by age-group a with age-group a′ should be ideally equal in the opposite
direction). Therefore, an empirical contact matrix, that has been measured
on a specific population, should not be used directly, without further consid-
erations, in another population with a different demographic structure.
This issue has important consequences in the field of disease modeling.
As contact matrices play a key role in disease forecast, it is essential to assure
that the matrices implemented are adapted to the demographic structure of
the population considered in order to avoid biased estimations. For some
short-cycle diseases like influenza, the time scale of the epidemic is much
shorter than the typical times needed for a demographic structure to evolve.
That means that, typically, the demographic structure can be safely consid-
ered constant,124 and the eventual evolution of the contact matrix can be
neglected throughout the simulation of an outbreak. For these diseases, the
problems might arise when modelers use contact matrices that are not up
to date. For instance, one might wonder whether the patterns reported in
Mossong et al. 25 in 2008 can be used nowadays, a decade later, during which
all the European countries analyzed in that study aged significantly. The
same issue appears when a contact matrix measured in a given location (e.g.,
a specific country) is directly used to simulate disease spreading in another
region or country with a different population structure.
The previous considerations are even more troublesome for the case of
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persistent diseases that need long-term simulations (as will be the case with
TB), for which the hypothesis of constant demographic structures does not
hold anymore.129 In those cases, contact matrices should continuously evolve
during the simulation to reflect the effect that an evolving demography should
exert on contact structures. As the goal of this thesis is precisely to develop a
model for TB spreading that includes realistic demographic projections and
empiric contact patterns, we should solve this problem before.
Furthermore, it remains to be known up to what extent the variations be-
tween contact matrices coming from different countries are due to differences
in the demographic structures, divergent cultural traits and/or methodolog-
ical differences between studies. For instance, elderly people exhibit higher
contact rates with children in African countries than in Europe.137 This could
be explained by the different demographic structures: one might expect to
observe higher contact rates toward the younger age strata in Africa than in
Europe because their populations have a higher density of young individu-
als. However, it is not clear yet whether the demographic structure is the
only driver of geographical heterogeneity between empirical contact matrices.
The main focus of this chapter is to study how contact matrices among
age-groups, originally obtained for a specific setting (country and year), can
be adapted to different demographic structures ,i.e., to another (location
and/or time) setting. To this end, we first study the magnitude of the reci-
procity error incurred when the adaptation of empirical social contacts to
different age structures is ignored, thus justifying the need of studying possi-
ble projections that solve this problem. Next, we analyze different methods
to perform these adaptations, highlighting the differences induced in the con-
tact patterns by the use of these methods. We also compare empirical contact
matrices of 16 countries in different areas worldwide filtering the influence
of the demographic structure. This allows to isolate what are the differences
that are caused by other factors such as cultural traits. Finally, we imple-
ment a SEIR model to study the differences in prospected incidences that
arise when applying the methods analyzed to project social contact matri-
ces. The considerations made in this chapter will be crutial for the posterior
development of a TB spreading model.
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2.2 Materials and Methods
2.2.1 Data used
For this work we have gathered 16 different contact matrices coming from
several countries: 8 from the POLYMOD project25 (Belgium, Finland, Ger-
many, Great Britain, Italy, Luxembourg, Netherlands and Poland), China,130
France,131 Hong-Kong,132 Japan,133 Kenya,134 Russia,135 Uganda,136 and
Zimbabwe.137
Data regarding the time evolution of demographic structures, either ob-
served in the past or projected until 2050, has been retrieved from the UN
population division database.138
2.2.2 Different Scales to define Contact Patterns
The contact matrices are often described with the matrixMa,a′ that is the
number of contacts that an individual in age group a maintains (on average)
with individual in age group a′ during a certain period of time. We will refer
to this quantity as the intensive scale. However, sometimes two other scales
are used:
• Extensive scale: Ca,a′ that is the total number of contacts between
age-groups a and a′.
Ca,a′ = Ma,a′Na (2.1)
• Density scale: Fa,a′ that is the fraction of contacts between age-groups








where Na is the population of age group a.
These two scales are symmetric by construction. Therefore they might
seem a better option to work with, as they directly avoid the problem of
non-reciprocity. However, unlike Ma,a′ they do not remain invariant when
the total number of individuals increases maintaining the shape of the de-
mographic structure, so a correction for the total population will always be
needed. In this work, we describe magnitudes in the intensive scale mostly,
but the translation to other scales is always possible through equations 2.1
and 2.2. It is also possible to work with any of these scales as long as the
force of infection is properly defined.
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2.2.3 Treatment of empirical survey matrices
We need to perform some transformations before we can compare the
different empirical studies:
• Most of the studies report the matrix in the intensive scale (Ma,a′).
Some of these studies however (specifically France,131 Japan,133 and
China130) report their results using the density scale (see equation 2.2)
except for a global factor. Thus, we transform them so they operate in
the scale of Ma,a′ , assuming the demographic structure as reported by
the United Nations (UN) Population Database138 for the specific year
of the survey.
• The studies use different age granularities. We adapt all surveys to
the division of age groups used by the POLYMOD project, i.e., 15 age
groups: 0-5, 5-10, 10-15,..., 65-70, 70+. For this adaptation sometimes
we have to aggregate age-groups (some studies have more divisions for
young children) but mostly we have to divide age-groups. In order to
do so, we assume homogeneity inside the broader original age-groups.
The studies with less age-groups (China that has 4, and Kenya that
has 6) are therefore more sensitive to this process.
In Table 2.1 we summarize the information about the 16 empirical con-
tact matrices collected for this work.
Country Year Age Groups Participants Reference
Belgium May 2005 - September 2006 (2005) 15: 0-5, 5-10,...,65-70,70+ 750 Mossong et al. (POLYMOD)25
Finland May 2005 - September 2006 (2005) 15: 0-5, 5-10,...,65-70,70+ 1006 Mossong et al. (POLYMOD)25
Germany May 2005 - September 2006 (2005) 15: 0-5, 5-10,...,65-70,70+ 1341 Mossong et al. (POLYMOD)25
Great Britain May 2005 - September 2006 (2005) 15: 0-5, 5-10,...,65-70,70+ 1012 Mossong et al. (POLYMOD)25
Italy May 2005 - September 2006 (2005) 15: 0-5, 5-10,...,65-70,70+ 849 Mossong et al. (POLYMOD)25
Luxembourg May 2005 - September 2006 (2005) 15: 0-5, 5-10,...,65-70,70+ 1051 Mossong et al. (POLYMOD)25
Netherlands May 2005 - September 2006 (2005) 15: 0-5, 5-10,...,65-70,70+ 269 Mossong et al. (POLYMOD)25
Poland May 2005 - September 2006 (2005) 15: 0-5, 5-10,...,65-70,70+ 1012 Mossong et al. (POLYMOD)25
France February - May 2012 15: 0-5,5-10,...,65-70,+70 2033 Béraud et al.131
Russia January - February 2016 12: 0-5,5-10,...,50-55,+55 505 Ajelli and Litvinova135
China 2009 - 2010 (2009) 4: 0-5,6-19,20-64,+65 1821 Read et al.130
Japan Spring 2011 12: 0-2,3-5,6-11,12-14,15-19,20-29,...,70-79,+80 3146 Ibuka et al.133
Hong Kong 2015-2016 (2015) 15: 0-5,5-10,...,65-70,+70 1149 Leung et al.132
Kenya August 2011 - January 2012(2011) 6: 0-1, 1-5, 6-15, 16-19, 20-49, +50 1080 Kiti et al.134
Uganda January - March 2014 10: 0-2, 2-4,5-9, 10-14, 15-24,...,55-64,+65 568 Le Polain de Waroux et al.136
Zimbabwe March - August 2013 16: 0-5,5-10,...,70-75,75-80 2490 Melegaro et al.137
Table 2.1: Information about the 16 contact matrices collected.
When the period of the study comprises more than one year, we specify
in parenthesis the year taken as reference for posterior analysis.
From each one of these studies, and after performing the transforma-
tions previously specified (when needed) we obtain a contact matrixM (surv.)a,a′ .
However, due to limitations in the survey and errors in the reporting process,
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these matrices will not fulfil reciprocity perfectly. Thus, we perform an initial
correction for reciprocity, that consists of averaging the number of contacts





























where na is the number of participants in age-group a and Na is the pop-
ulation of age-group a in the corresponding country during the specific year
of the survey as extracted from the UN database.138 Thus, we are applying a
weighted average that needs the age-distribution of the participants. When
that information is not available, we perform a regular average. This process
can also induce some bias since for some cases, the survey of contacts has
been performed in some specific settings (rural or semi-urban) that might
not be representative of the whole country. This correction of reciprocity has
been used before, either to present empirical data137 or to ensure reciprocity
in a simulation by adapting the contact patterns to the specific demographic
structure considered.139,140 The possibility to use this pair-wise correction,
which we will label later as Method 1 (M1) to solve the problem of reci-
procity will be explored in this chapter.
In equation 2.4, we have named the resultant matrix M (rec.)a,a′ , where the
super-index indicates that the matrix fulfils reciprocity. We still apply one
more transformation, that consists of normalizing the matrices so that the






























Hence, we are not addressing the average intensity of contacts (and how
it differs between countries) and we focus exclusively on the relative differ-
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ences between age-groups. Although geographical differences in global con-
tact rates is a problem of interest, we have not studied them for three main
reasons. First, for France, Japan and China, the studies report a matrix
that is proportional to Fa,a′ and we do not have direct information on the
intensity of contacts. Second, it depends on the definition of contact itself
and therefore methodological biases could arise. Most studies define a con-
tact as any interaction that includes physical touching and/or face-to-face
conversation for a minimal time period (that varies between studies), and
even report data on physical contact separatedly, but some only consider one
type of contact (only physical contacts in Kenya,134 and only conversation
in Russia135 and Uganda136). And third, for many problems, the scaling of
this contact matrix is performed independently and therefore not having the
overall intensity of contacts is irrelevant.113,129
After this process we end up with the matrix M (rec.+norm.)a,a′ (that we will
name simply asMa,a′ from now on) for each one of the 16 countries for which
we have contact data. We assume that, except for the limitations in the
survey, these matrices are valid in their respective countries during the year
when they were measured.
2.2.4 Projections of a Contact Matrix
The basic problem explored in this work is: how can we transform the
(empirical) contact matrixMa,a′ , that has been measured for a specific demo-
graphic structure Na, into a different contact matrixM ′a,a′ that is compatible
with a different demographic structure N ′a? This could mean to adapt data
obtained in one specific country to another different region that has a dif-
ferent demography. But the problem can appear even if we remain in the
same geographical setting, as a contact matrix measured at a specific time
τ , could not be valid for an arbitrary time t if the demographic structure
of that population has changed. In the following sections, we formulate the
problem of non-reciprocity and we present and discuss different methods of
using contact matrices in an arbitrary demographic structure.
2.2.4.1 Method 0 (M0): Unadapted Contact Matrix. The prob-
lem of non-reciprocity
The number of contacts must fulfil reciprocity, i.e., there is the same
number of total contacts from age-group a to age-group a′ than from a′ to a.
This imposes the following closure relation for the contact matrix:
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where Na is the number of individuals of age-group a.
Therefore, in the case of an evolving demographic structure for which the
ratio Na
Na′
is not constant; the contact matrix Ma,a′ must change with time.
Otherwise we will have non-reciprocal contacts (contacts that inconsistently
appear in one direction but not in the other). When comparing different
methods for correcting for reciprocity we will usually also compare with the
case in which this problem is completely ignored, and the matrix Ma,a′ is
taken directly from the survey without any further consideration. We will
refer to this case as Method 0 (M0).
The following methods correct this problem, introducing different trans-
formations of the original contact matrixMa,a′ , that was measured in a demo-
graphic structure Na, into a new contact matrix M ′a,a′ that is well adapted
to a new demographic structure N ′a (at least avoiding the problem of no
reciprocity).
2.2.4.2 Method 1 (M1): Pair-wise correction
The basic problem that we want to avoid is to have a different number of
contacts measured from a to a′ than from a′ to a. Thus, an immediate cor-
rection would be to simply average those numbers, so the excess of contacts
measured in one direction is transferred to the reciprocal direction. This





















Previous works that have used this approach include Apolloni et al. 112
and Riolo et al. 141
2.2.4.3 Method 2 (M2): Density correction
An alternative approach is to adapt contact patterns to different demo-
graphic structures correcting by the density of available contactees, which we
formalize with the following equation:
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Thus, we interpret that the matrix Ma,a′ is the product of two factors:
• The intrinsic connectivity matrix: Γa,a′




Thus, we are assuming that an individual has an intrinsic preference over
certain age-groups depending on its age, captured by Γa,a′ , and the final con-
tact rate is modified according to the density of available contactees.
The matrix Γa,a′ corresponds, except for a global factor, to the contact
pattern in a “rectangular” demography (a population structure where all age
groups have the same density). We can obtain these matrices Γa,a′ , that are





which allows to rewrite equation 2.9 as a function of the original matrix
Ma,a′ :




This methodology for adapting contact patterns has already been used by
De Luca and collaborators, introducing the matrix Γa,a′ directly in the force
of infection.113 Also a similar correction is used in Prem et al.142 to adapt
European contact matrices to other countries (although this work integrates
more data beyond demographic structures).
2.2.4.4 Method 3 (M3): Density correction + Normalization
A cardinal feature of M2 is that it does not preserve the mean connec-
tivity of the entire network of contacts. As a result, depending on the initial
contact matrix and the dynamics of the demography, the evolution of the
contact structure can produce average connectivities that depart strongly
from its initial value. For the sake of disease modeling, this situation is
essentially irrelevant if the contact rate of the outbreak to model can be cal-
ibrated at its early stages (i.e. its reproductive number). In that case, any
global scaling factor multiplying the contact matrix is absorbed by the esti-
mation of a larger or smaller infectiousness β. However, if that is not the case
and epidemiological parameters measured in the past (i.e. a pathogen’s infec-
tiousness) are used to generate forecasts of independent outbreaks that might
occur later in time, the overall scaling factor of the contact networks become
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extremely relevant. In such scenario, to couple an a-priori characterization
of a pathogen’s infectiousness on top of contact networks with different mean
connectivities will artificially inflate or shrink the size of modeled epidemic
events as a function of time. Although considering an evolution of the mean
connectivity as demography changes might be reasonable, the inability of M2
of producing contact matrices of stable mean connectivities might suppose a
liability in some scenarios. This is the approach we will take in the model of
TB spreading, as will be motivated later.
Taking that potential issue into consideration, we have proposed an alter-
native approach that, in addition of correcting for the densities of contactees,
preserves the mean connectivity of the overall system across time. Thus, an
evolution of the mean connectivity could always be forced by adding a global
factor in a controlled way.































Notice that all methods trivially coincide in the year in which the data
was obtained (i.e. when the survey was done). Also the definition of Γa,a′
does not change between M2 and M3 in these cases, as the initial Ma,a′ has
been normalized to have a mean degree of 1, and we extract it with the same
equation as before (eq. 2.10).
2.2.5 Properties of projection methods
In this section we will study analytically some properties of the different
methods we have just introduced. We will quantify these properties in sec-
tion 2.3
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The different methods of transforming a matrix Ma,a′ into a matrix M ′a,a′
when moving from a demography Na to a demography N ′a that we have
studied can be formulated as:
• M0: Unadapted Contact Patterns.
M ′a,a′ = Ma,a′ . (2.15)





















• M2: Density Correction




• M3: Density Correction + Normalization












The main property that a Contact Matrix should fulfill is reciprocity in
the number of contacts:







Thus, when moving to a different demographic structure (where, in gen-
eral, the ratio Na′
Na














However, it is easy to see that the rest of the methods do preserve reci-
procity:
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is the same for M ′a,a′
and for M ′a′,a.
As a global measure of the reciprocity error (E ∈ [0, 1]) we use the total




















It will be zero for methods M1, M2 and M3. The evolution of the reci-
procity error E for the 16 countries considered (as their own demographic
structure evolves in time) is shown in Figure 2.1 (panel C).
2.2.5.2 Intrinsic Connectivity
Let us define the matrix Ha,a′ as the contact pattern resulting after as-
suming homogeneous mixing (also known as proportional mixing) embedded









Thus, we can define the intrinsic connectivity Γa,a′ as the ratio between
the contact rate and what we would have in the case of homogeneous mixing
(Γa,a′ = Ma,a′/Ha,a′ = Ma,a′ NNa′ ). The entries of this matrix will be larger
than 1 if the connectivity between age-groups a and a′ is more than what
would be expected under the homogeneous mixing scenario, and viceversa.
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It is not constant.






































It is not constant.
• Intrinsic Connectivity with M2:




















































Only M2 (and M3 except for a global factor) preserves the intrinsic con-
nectivity. M0 and M1 however, change the tendency of mixing between
different age-groups. In order to understand the importance of this, let us
suppose that we have an initial matrix that follows the assumption of homo-
geneity (i.e., Ma,a′ = Ha,a′ =⇒ Γa,a′ = 1). Then, we would have that from
an initial situation of homogeneous mixing we end up with heterogeneities
artificially produced by the change on the shape of the demographic pyramid
if we follow methods M0 or M1, while M2 will still provide homogeneous
mixing regardless of the demographic structure. The error in Intrinsic Con-
nectivity is shown for Poland and Zimbabwe at different years in Figure 2.1
(panels D and E).
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that we described in equation 2.2. The method M2 can also be
seen as the one that preserve the density scale applying a correction for the





The mean connectivity 〈k〉, i.e, the average number of contacts per indi-







We have normalized the empirical contact matrices to have a mean con-
nectivity of 1. When transferring these contact matrices to different de-
mographies we have that the mean connectivity might change depending on
the method:

































As M1 consists of a re-arrengment of the contacts that already exist in
M0 to correct reciprocity, it can be shown that they actually share the
same mean connectivity.














































In order to study the error incurred when using M0, we transform the
contact matrices obtained from empirical studies in different countries to new
matrices that correspond to the same location but at different years (that
could be past records or future projections). As the population changes over
time, the new matrices incorporate the population demographies of the same
countries across time. We define the reciprocity error as the coefficient of
variation of the number of contacts measured in both directions, which gives







It is an antisymmetric matrix, in which a positive value of the entry (a, a′)
means that there are more contacts from a to a′ than in the opposite direc-
tion, and viceversa. A value of 0 would mean that the contacts between a
and a′ are well balanced.
In Figure 2.1 we represent the demographic structures of Poland (panel A)
and Zimbabwe (panel B) for different years alongside the corresponding non-
reciprocity matrices. In the case of European countries (Poland in panel A
as an example), demographic structures have suffered from an aging process
during the last decades, which is predicted to continue in the future. This
aging tends to provoke negative values under the diagonal for the matrices
NRa,a′ when we assumed past demographic structures, while the opposite will
occur in the future. The behaviour for African countries (Zimbabwe in panel
B) is slightly different, as their demographies have been more stable for the
last decades, and only now they are beginning to age faster. In brief, when
we use directly a contact pattern in a demographic structure that is younger
than when it was measured, it will lead to an overestimation of the contact
rate of (and the force of infection corresponding to) the youngest age-groups.
The opposite will occur when we use contact patterns in an older population.
In figure 2.1C we represent the evolution of the proportion of non-reciprocal
contacts for all 16 countries considered (as defined in equation 2.24). This
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Figure 2.1: Analysis of methods M0 and M1. A-B: Demographic struc-
tures for different years and the respective non-reciprocal matrices NR′a,a′ for
Poland and Zimbabwe respective using M0. C: Evolution of the total fraction





) for Poland and Zimbabwe respectively, in four different years
(10/20 years before/after the measurement of the contact patterns) for M1.
The original data corresponds to 2005 for Poland and 2013 for Zimbabwe.
magnitude is equal to zero in the year when the contact matrix was mea-
sured, as we have applied a correction for the empirical matrices to fulfill
reciprocity at the reference setting. However, it dramatically increases as we
move far from the year of the survey. In the examples shown here, only two
years before/after the survey time, the fraction of non-reciprocal contacts
already reaches 5%. Note that methods M1, M2 and M3 are well balanced
by construction, thus NRa,a′ = 0 for every (a, a′) when using any of them.
2.3.2 Intrinsic Connectivity error
We next study the evolution of the ratio between the age-dependent con-
tact rates and an homogeneous mixing scenario. This ratio gives us the
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matrix Γa,a′ , defined as the intrinsic connectivity in equation 2.10. As ex-
plained in section 2.2.5.2, the entries of Γa,a′ are bigger than 1 when the
interactions between age-groups a and a′ surpasses what it is expected from
the case of homogeneous mixing, and smaller than 1 in the opposite case.
In Figure 2.1D and 2.1E we show 4 snapshots of the ratio of the intrin-
sic connectivity and the original survey (Γ′a,a′/Γa,a′) obtained using M1 for
Poland and Zimbabwe respectively. Each panel corresponds to an adapta-
tion of the contact matrix to the population demography of the countries 10
and 20 years before and after the survey (i.e., the 4 matrices correspond to
t = τ −20y, t = τ −10y, t = τ +10y and t = τ +20y, where τ corresponds to
the time when the survey that determined the contact patterns took place).
We can see that, even if M1 corrects the appearance of non-reciprocity, this
method changes the tendency of some age-groups to mix with respect to
others. Specifically, we can see that M1 will over-represent contacts between
young individuals (and under-represent contacts between old individuals) as
the population gets older.
Furthermore, the previous results are quantitatively important. For in-
stance, if we were to use the contact matrices that we have from Poland
(measured in 2005) today (2018), we would have that the ratio Γ′a,a′/Γa,a′
surpasses 1.5 for some specific age-group pairs, while it goes down to almost
0.5 in others, or, in other words, the usage of M1, which does not take into
account the changes in the fractions of individuals in each age-strata that oc-
curred between 2005 and 2018, causes a bias of more than 50% in the contact
densities projected between certain age groups. Consequently we say that
M1 does not preserve intrinsic connectivity. The density correction (M2)
avoids this problem, as it explicitly considers a fixed intrinsic connectivity
matrix (Γa,a′ as defined in section 2.2.4) that is modified according to the
density of each age-group (see equation 2.9).
2.3.3 Evolution of mean connectivity
In Figure 2.2A-B we represent the contact patterns obtained with M2 and
M3 for Poland and Zimbabwe, respectively, in different years. We see how,
specially in the case for Zimbabwe, as the population gets older, the values
of the matrix below the diagonal (contacts toward young individuals) fade
in favor of contacts toward older individuals as those age-groups gain more
representation.
As for the mean connectivity (Figure 2.2C), considering the evolution of
37
CHAPTER 2. PROJECTING CONTACT PATTERNS
Figure 2.2: Analysis of methods M2 and M3. A-B: Contact patterns
Ma,a′(t) for five different years with methods M2 (blue) and M3 (green) for
Poland and Zimbabwe, respectively. C: Evolution of Mean Connectivity for
M2 (blue), M3 (green) and M0 and M1 (black, both methods give the same
mean connectivity).
contact patterns in M2 or considering them constant (M0) leads to the same
qualitatively behaviour, although variances are higher with M2. These trends
are decreasing in Europe and increasing in Africa. M0 and M1 have the same
mean connectivity, as M1 consists basically of a rewiring of those connections
that exist in M0 in order to correct for reciprocity. M3 is a normalization of
M2 so the connectivity is constant in this case.
2.3.4 Overview of different methods
We have shown up to four different methods of use heterogeneous contact
patterns when demography evolves in time (being the first one of them to sim-
ply use them without any further consideration regarding the demographic
structure). In table 2.2 we summarize their properties.
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Method Reciprocity? Preserves Intrinsic Connectivity? Constant average connectivity?
M0: Unadapted contact patterns No No No
M1: Pair-wise correction Yes No No
M2: Density correction Yes Yes No
M3: Density correction + Normalization Yes Yes (with a global factor) Yes
Table 2.2: Overview of different methods. Summary of the different
methods to deal with contact patterns and their properties.
2.3.5 Geographical Comparisons
The intrinsic connectivity matrices Γa,a′ that we obtain for every country
allow us to compare the contact patterns of different settings once the influ-
ence of demography has been accounted for, and removed. In Figure 2.3A
we represent these matrices for the 16 countries analyzed in this work. Just
by visual inspection we can identify some distinctive features: European ma-
trices are more assortative and present higher interaction intensities among
young individuals than African ones. To formalize this observation, in Fig-
ure 2.3B, we place the different matrices in a two dimensional plot defined
by the proportion of overall connectivity produced by young individuals (Y )


































African and European countries cluster around different values of these
two magnitudes: specifically, in African countries we found less assortativ-
ity and the contacts are less dominated by young individuals than in the
European countries. As for the Asia region we see that Japan and China
have significantly higher assortativity and fraction of contacts among young
individuals than either African or European countries. In turn, Hong Kong,
with its particular geographic idiosyncrasy –a small country, predominantly
urban, with one of the highest population densities in the world–, presents
an intrinsic connectivity matrix that is more similar to one from a European
country than from China or Japan.
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Figure 2.3: Geographical comparison of empirical contact matrices.
A: Γa,a′ matrices for the 16 countries considered in this work. B: Proportion
of the overall connectivity that comes from individual with less than 20 years
(Y ) vs the assortativity coefficient (r) for the 16 countries.
2.3.6 Short cycle SEIR dynamics
Up to now, we have shown that there are several ways to deal with de-
mographic change and evolving populations regarding the structure of the
contact patterns for a given population. We next address how these different
methods impact disease modeling. To this end, we implement a Short cycle
SEIR model. We choose a short-cycle disease so that we can assume that the
population structure is constant during each simulation. To parameterize
the model we will use the values of an influenza outbreak that took place in
Belgium in the season 2008/2009.113
The disease is described using a SEIR model. Susceptible individuals can
catch the disease with a transmissibility rate β per-contact with an infective
individual. Once infected, individuals remain on a latency state for ε−1 = 1.1
days on average. Then, they become infectious for µ−1 = 3 days on average,
period when they can transmit the infection to susceptible individuals. After
that, they recover and become immune to the disease. We use a discrete
and stochastic model where the population is divided into 15 age classes.
Social mixing is quantified by the contact matrices extracted from the data,
normalized accordingly. Time is discretized with a time step of ∆t = 1 day
and the results are averaged over 104 runs.
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Finally, we consider the reproductive number to be R = 2.12, the same
at all times and countries. With this value, we obtain the appropiate β for
















in the case of the method M2 is equal to the reproductive number, R. Note
that as we are adjusting β in each case to obtain the desired value of the
reproductive number, the mean connectivity of the matrix will not play a
role. Thus, we would obtain exactly the same results using M2 and M3, as
their only difference is the global contact rate and it will be incorporated in β.
These simulations allow us to study a situation where a short-cycle,
influenza-like pathogen appears in a given location, at different possible
times, associated to the same reproductive numbers. Under this hypothetical
scenario, we would like to know how different would be the forecasted size
of the epidemic as a result of considering different contact matrices coming
from the different projection methods proposed in this work. In particular,
this scenario is instrumental to distinguish the outcomes from models M0,
M1 and M2. However, the requirement of the outbreaks to have the same re-
productive numbers implies the assumption that the infectiousness β can be
estimated independently in each event. As a consequence, since the matrices
derived from M2 and M3 only differ by a global scaling factor, this operation
absorb the differences between M2 and M3, making them indistinguisable.
The results of this exercise are presented in Figure 2.4. In Figure 2.4A
we can see that, while methods M0 and M1 predict lower age-aggregated
incidences in European countries in 2050 with respect to 2000, M2 reduces
these differences and the incidences are comparable for both years or even
positive. A different situation occurs in Africa, where M0 and M1 predict an
increase in incidence in the future while using M2 would lead to a decrease,
though differences remain small (less than 5% of variation).
In panel 2.4B we represent, for two examples of Europe and Africa (Poland
in blue and Zimbabwe in orange), the temporal evolution of the incidence
observed with the different methods. Furthermore, we represent the age-
specific incidence for both countries in three different years: 2010, 2030 and
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Figure 2.4: SEIR dynamics with different methods. A: Median age
at 2000 and 2050 (black line, beginning with the value at 2000 and ending
with a bullet point with the value at 2050) for the 16 countries considered
and relative variation in incidence over the same period (colored bars), for
M0, M1 and M2. B: Incidence (over all ages) vs Year for Poland (blue)
and Zimbabwe (orange) using M0, M1 and M2. C: Incidence by age group
for Poland and Zimbabwe in 2010, 2030 and 2050 using M2. D: Relative






2050 (Panel 2.4C). The age-distribution of the incidence evidences the dif-
ferences in connectivity patterns between Poland and Zimbabwe. While the
incidence in elderly people drops in Poland (as the contact rates for those
age-groups also drop), it remains high in Zimbabwe for the same age-groups.
The different methods of implementing contact rates also affect the age-
specific incidence. In panel 2.4D we represent the relative variation in age-
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specific incidence obtained with methods M0 and M1 with respect to M2 for
Poland and Zimbabwe. In Poland we see that M0 and M1 tend to under-
estimate the incidence specially among the elder age-groups. In Zimbabwe
M0 tends to overestimate the incidence among young individuals, while with
M1 we encounter both effects: and overestimation among the youngest and
a underrepresentation among the eldest.
The reshaping of the age-specific incidence between models is coherent
with the changes in topology already studied. For the case of M0, i.e., main-
taining the contact patterns constant in time, we have that in the future,
as the demographic structure shifts to older populations, contacts toward
children will be overrepresented and contacts toward adults will be under-
represented. At first order we can obviate the contacts that are far from the
diagonal, and establish that M0 mainly underrepresents contacts between
adults and overrepresents contacts between young individuals (in the con-
text of aging populations). Thus, we will obtain an underrepresentation of
the incidence in adults, and the opposite in children. However, as the eldest
age-groups increase their population in Europe, they dominate the dynam-
ics and cause and underestimation of the global incidence that eventually
affects all age-groups. In African countries, where the contact patterns are
less assortative than European countries, this effect is smaller. Besides, as
African populations are still young even in 2050, the overestimation of young
contacts dominates the dynamics, and the differences in incidence are mainly
positive. The situation is similar for M1. As represented in Figure 2.1D-E,
for M1 we also have an underrepresentation of contacts between adults and
an overestimation between young individuals, yielding to similar results than
M0.
Altogether, these results illustrate how an ill adaptation of the contact
patterns observed in the past in a given country to a later time point can
translate into epidemiological forecasts that are highly biased. Regarding the
dynamic equivalence of methods M2 and M3, we have to emphasize that it
emanates only from the assumption that reproductive numbers can be mea-
sured at the early stages of any of the epidemics being simulated in each year,
which is a conservative -often optimistic- assumption. Alternatively, we could
think of an scenario where the reproductive number of a given pathogen was
estimated in a given year, and that information used to infer the probability
of transmission per contact (the infectiousness β) of the pathogen, with the
aim of producing a-priori forecasts for posterior re-apparences of the same
pathogen. In such alternative scenario, the usage of different contact ma-
trices projections would be even more relevant, for it would impact directly
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the reproductive number of the forecasted outbreaks, now characterized by
a common β. In such an scenario, (which is conceptually similar to the task
of producing long term forecasts of persistent diseases,129 based on epidemi-
ological parameters calibrated on an initial time-window, as we will do in
the next chapter), the dynamic equivalence of models M2 and M3 is broken,
since running M2 or M3 with the same infectiousness parameter and different
average connectivities yields different reproductive numbers.
2.3.7 Comparison with Prem et al.
In a recent work by Prem et al.,142 the contact pattern from the Polymod
project25 (averaged over the 8 European countries) is exported to different
countries. However, the approach proposed in Prem et al. 142 to complete that
task implies the integration of a series of data of disparate nature: house-
hold structures, pupil-to-teacher ratios, school enrollment rates, and also age
distributions. In this sense, although this work also allows to perform a sim-
ilar analysis and project an averaged Polymod matrix (for example) to other
non-Polymod countries, in this case, this is done using demographic data on
populations’ age distributions alone without including further data. As a
means to evaluate the accuracy of the more economic approach introduced
here compared to that proposed in Prem et al. 142 , we have focused on the
eight non-Polymod countries for which we have independent empiric data
(France, Russia, China, Hong Kong, Japan, Kenya, Uganda and Zimbabwe),
and compared, for each of them, three different contact matrices: A) the em-
piric ones, B) the projections obtained starting from the Polymod data, and
applying the transformations proposed in Prem et al. 142 and C) an equiva-
lent projection of the Polymod pattern using either M2 or M3 as proposed
in this work.
In order to obtain the projections based on this method, we first need
to produce an average of the Polymod contact matrices. To do so, we first
select the Polymod matrices, correct for reciprocity in each of them (assuming

















where the superindex c indicates the specific country of the Polymod
study, and n(c)a is the number of participants of age a in country c. Then, we
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extract Γ(Polymod)a,a′ assuming as demography the sum over all Polymod coun-
tries. Using this matrix, we obtain projections for the other non-Polymod
countries (using either M2 or M3, which are equivalent for the sake of these
analyses).
Once we obtained the trans-national projections of the Polymod data, we
can compare them against the matrices proposed in Prem et al. 142 as well as
against the empirical data reported in the different surveys conducted in the
eight countries listed in table 2.3.
Conuntry This work vs. Prem et al. Prem et al. vs. Surveys This work vs. Surveys
France 0.932 0.827 0.849
Russia 0.878 0.800 0.909
China 0.962 0.235 0.315
Japan 0.933 0.675 0.770
Hong Kong 0.909 0.661 0.856
Kenya 0.971 0.566 0.563
Uganda 0.948 0.649 0.670
Zimbabwe 0.964 0.573 0.609
Table 2.3: Comparison with the method proposed by Prem et al.
Correlation index of the comparison of different contact patterns. For the 8
non-Polymod countries considered in this work, we make three comparisons:
(1) projections of the Polymod matrix based on this work vs. the projections
made by Prem et al., (2) the projections made by Prem et al. vs the empirical
data measured in those countries and (3) projection based on this work vs
the same empirical data.
Importantly, the projections based on this method, which are based on the
age-distributions of the countries analyzed alone, correlate very strongly with
the projections proposed in Prem et al. 142 (r>0.9 everywhere but in Russia),
even though these precise a considerably larger amount of detailed data to be
built. Even more surprisingly, we see how our projections correlate slightly
better to the actual contact patterns observed in empirical studies conducted
in these different countries, pointing to the fact that, among all sources of
heterogeneity in social mixing, age is arguably more important than other
considerations that seemingly play secondary roles. However, correlations
between projections and empiric data are not always consistent, but, per-
haps unsurprisingly, only high enough when Polymod data is projected into
other European settings (Russia and France). This warns once again against
the indiscriminate extrapolation of contact structures measured in specific
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geographical areas to settings belonging to other continents or characterized
by profound cultural or demographic differences.
2.4 Conclussion
Summarizing, empirical contact patterns belong to a specific time and
place. If we want to integrate the heterogeneity of social mixing into more
realistic models, we need to address how (and in what cases) to export con-
tact patterns from empirical studies to the populations we want to study. In
this work, we have studied and quantified the significant bias incurred when
a specific contact pattern is blindly extrapolated to the future (or the past),
even if we remained inside the same country where those contacts were mea-
sured. In fact, only a couple of years after the measurement of these contact
patterns, the changes in the age structure of the population make them vary
significantly. Thus, for any meaningful epidemic forecast based on a model
containing age-mixing contact matrices, we would need to adapt them taking
into account the evolution of the demographic structures. Moreover, as we
have shown, even for cases that do not expand into long periods of time and
a constant demography could be assumed, it is necessary to make an initial
adaptation of whatever empirical contact structure we want to implement,
into the specific demographic structure of our system. We have also seen how
these relevant differences in the topology of contacts yield to significant con-
sequences for the spreading of a disease. Applying different methods to deal
with contact patterns leads to important differences not only in the global
incidence for a SEIR model, but also on age-specific incidences. Having such
an important impact for the spreading of a disease, the insights provided by
this work should be taken into consideration by modelers and also by public
health decision-makers.
In a similar way, we have explored the differences between the contact
patterns of different countries. Thus, we have found the existence of some
specific characteristics beyond the underlying demographic pyramid, which
warns against exporting contact patterns across different geographic areas
(i.e. continents). As there exists different intrinsic connectivity patterns
(i.e., once demography effects have been subtracted) between countries, it
is also likely that there exists a time-evolution of the intrinsic connectivity
inside the same setting. Although it is impossible to predict how society will
change in the future, we should always take this into account as a limitation
in any forecast for which the heterogeneity in social mixing is a key element.
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Finally, we note that there are some limitations that could affect quan-
titatively the results shown in this work. First of all, we have derived the
contact patterns of the different studies according to the demographic struc-
tures of the specific country for the year the survey took place. Thus, we
are implicitly assuming that the setting where the different surveys were per-
formed are comparable with the national data in terms of their demographic
pyramids. In other words, we assume that the surveys are representative of
the population at large. This is likely true for most of the countries analyzed,
but there are certain cases in which this might not be the case, either because
of small study size or putatively biased recruitment of participants. Besides,
as we have already discussed in section 2.2.3, the different granularity (i.e.,
definition of the age-groups) used throughout the bibliography studied also
imposes some limitations when comparing the data. It is also worth pointing
out that, although in this work we have focused on age-structured systems
(which has had its relevance in recent history of epidemiology), the problem
studied here can be extrapolated to other models that might categorize their
individuals based on other different traits that determine their social behav-
ior.
The results reported here and their implications open several paths for
future research. One is related to the social mixing patterns themselves. In
order to predict the large-scale spreading of a disease, multiple scales need
to be integrated and coupled together. This implies that when integrat-
ing different spatial scales, we need to deal with different contact matrices
and local demographies. For instance, in developed countries, it is known
that the structure of the population is not the same in the most central or
most populated cities as compared to smaller ones or the countryside. Thus,
nation-wide demographies and surveys to infer contact matrices might need
to be disaggregated. What is the right spatial scale to measure both quan-
tities is an interesting and unsolved question. In this sense, here we have
limited the simulated disease scenario to the case of isolated populations
−a country−, but it remains to be seen what are the effects over a meta-
population framework, in which we have mobility between subpopulations of
potentially very different demographic structures.
The insights provided by this work will be essential for the development
of a TB spreading model with heterogenous age-dependent contact patterns
and an evolving demographic structure, as related in the next chapter. We
have already seen the biases that different methods of projecting contact
matrices have over a simple SEIR model. Moving to a model with a more
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accused age dependency and a continuously evolving demography can be a
risky action if the warnings that we have given in this chapter go unnoticed.
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Throughout the next chapter we will develop a model for the assessment
of TB transmission. As the ultimate goal is the evaluation and comparison
of age-focused interventions, such as newborns or adolescents-focused vacci-
nation campaigns, that could help policy making, we are specially interested
in achieving a proper description of the multiple ways whereby TB dynamics
couples with populations’ age structure, a limitation that has been pointed
out as one of the most critical.67,144 For example, patients’ age is strongly
correlated to the type of disease that they tend to develop more often, as
well as to the probability of developing active TB immediately after infec-
tion (usually called “fast progression” 55). This way, while a larger fraction of
children younger than 15 years of age develop non-infectious forms of extra-
pulmonary TB with respect to adults (25% vs 10%55,93,145), the risk of fast
progression is larger in infants (50% in the first year of life), then decays (20-
30% for ages 1-2; 5% for 2-5 and 2% for 5-10), and raises up again in adults
(10-20% for individuals older than 10).53 Additionally, transmission routes
of TB, being this a paradigmatic air-borne disease, are expected to show
significant variations in intensity across age.25,146 The empirical characteri-
zation of these contact structures constitutes an intense focus of research in
data-driven epidemiology of air-borne diseases,123 and their influence on the
transmission dynamics of diseases like influenza has been recently explored
with relevant implications.147,148
49
CHAPTER 3. MODELLING TB TRANSMISSION
Thus, if subjects’ age modifies the disease-associated risks at the level
of single individuals, it is likely to expect that changes in the demographic
age-structure at the population level will impact TB burden projections.
This is mainly due to the slow dynamics that is characteristic to TB, which
forces modelers to describe the evolution of the disease during long periods
of time, typically spanning several decades. These time-scales are rather in-
compatible with the assumption of constant demographic structures, at least
nowadays, since world-wide human populations are presumed to age from
the current median of 30 years old to 37 in 2050.138 And yet, achieving a
sensible description of TB transmission able to capture the effects of time-
evolving demographic structures remains an elusive goal in TB modeling.
Demographic dynamics are traditionally neglected in TB transmission mod-
els, the same way that contact structures are assumed to be homogeneous
across age-groups.55,101,108
In this model we incorporate empirical data on demographic dynamics
and contact patterns around classical formulations of TB spreading models,
thus unlocking less biased descriptions of the spreading dynamics of the dis-
ease. To this end, we present a TB spreading model (Figure 3.1A) whereby we
provide a data-driven description of TB transmission that presents two main
novel ingredients with respect to previous approaches. First, the model incor-
porates demographic forecasts by the United Nations (UN) population divi-
sion138 (Figure 3.1B) in order to describe the coupling between demographic
evolution and TB dynamics. Secondly, the model integrates region-wise em-
pirical data about age-dependent mixing patterns adapted from survey-based
studies conducted in Africa and Asia130,133,134,136,137 (Figure 3.1C), following
the methodology developed in the previous chapter of this thesis, instead of
assuming that all the individuals in a population interact homogeneously, as
traditionally considered in the literature.55,101,108
Upon model calibration in some of the countries most affected by the
disease in 2015 and subsequent simulation of TB transmission dynamics up
to 2050 (Figure 3.1D), we scrutinize the implications derived from integrating
these pieces of empirical data within the model, and discuss their impact
on the forecasts produced, both at the level of aggregated incidence and
mortality rates and on their distributions across age-strata. Specifically, we
quantify the effects of populations’ aging on prospected incidence rates until
2050, as well as the impact on the age distribution of the disease burden that
emanate from introducing empiric contact data in the models. Furthermore,































































































































Figure 3.1: Model description. (A): Natural History scheme of the TB
spreading model. Description of the different classes is given through section
3.2.1 (B): Scheme of the coupling between TB dynamics and demographic
evolution. The transmission model summarized in panel A describes the evo-
lution of the disease in each age group, including the removal of individuals
due to TB-mortality (curved arrows). The evolution of the total volume
of each age-strata is corrected (bi-directional arrows: TB unrelated popu-
lation variations) to make the demographic pyramid evolve according UN
prospects. (C): Empirical contact patterns used for African and Asian coun-
tries. (D): Data flow scheme. Epidemiological parameters, contact matrices,
and demographic prospects are used to calibrate the model, with the goal of
reproducing observed TB incidence and mortality trends during the period
2000-2015. As a result of model calibration, scaled infectiousness, diagnosis
rates and initial conditions of the system in 2000 are inferred. These ele-
ments are then used (along with epidemiological parameters, contacts and
demographic data) to extend model forecasts up to 2050.
assess their statistical significance and robustness under a series of alternative
modeling scenarios. To do so, alongside the construction of a full model
that incorporates demographic evolution and empiric contact patterns, we
will also build two reduced models that will serve as baseline comparison:
reduced model 1 (RM1) that presents constant demographic structure (but
has empiric contact patterns) and reduced model 2 (RM2) that assumes
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homogeneity of contacts (but includes demographic evolution).
3.2 Model
3.2.1 Natural history of the disease
The model of Tuberculosis (TB) spreading is essentially based on pre-
vious models by C. Dye and colleagues,55,108 on which new ingredients –
heterogeneous contact patterns25 and demographical evolution– have been
incorporated. The natural history scheme has also been refined so as to
render it more suited to the definitions by the World Health Organization
(WHO), mostly in what regards to treatment outcomes.
Summarizing, we deal with an ordinary differential-equations based, age
structured model of TB in which we consider a class of unexposed individuals
–susceptible–, two different latency paths to disease –fast and slow– and six
different kinds of disease, depending on its aetiology: -non pulmonary, pul-
monary smear positive and pulmonary smear negative–, and depending on
whether it is untreated or treated. After the disease phase, we explicitly con-
sider the main treatment outcomes contemplated by the WHO data schemes:
treatment completion (or success), default, failure and death.71,149 We also
consider natural recovery without treatment, smear progression (from smear
negative to smear positive) and mother-child infection.
The model is structured in 15 age groups, 14 of them covering 5 years
of age up to 70 years old, and a last group including all individuals older
than 70 years old. When specifying the population of a certain state at a
specific age-group and time we will use the notation X(a, t), where X is the
concrete state (see list of disease states in table 3.6), t represents the time,
and a ∈ [0, 14] is the index representing any of the fifteen age groups.
In the following, we detail the natural history ingredients and transitions
between states that we have considered to build up this model; whose natural
history is schematized in figure 3.1A.
3.2.1.1 Primary Tuberculosis infection
We call primary the infection of an individual who was not previously ex-
posed to the bacterium: i.e. individuals of class S. If we denote the force of
infection λ(a, t) as the probability per unit time of any unexposed individual
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of age group a of being infected, then the total number of susceptible indi-
viduals getting infected per unit time will be approximated by λ(a, t)S(a, t).
We will address the explicit form of λ(a, t) in section 3.2.2.
Of these newly infected individuals, a fraction p(a) ∈ [0, 1] will experience
a quick development of the disease after a short course latency period –fast la-
tency Lf in what follows– characterized by the inability of the host’s immune
system to restrain mycobacterial growth. In the rest of cases, newly infected
individuals’ immune system succeeds at containing bacterial proliferation so
establishing a host-pathogen dynamic equilibrium that is characterized by
an asymptomatic latency state –known as Latent TB Infection, LTBI, that
corresponds to the class of slow latency Ls in the model– that can last for the
rest of the host’s life, or be broken even decades after the infection, typically
after an episode of immunosuppression. In conclusion, the primary infection
is described as follows:
• Primary infection (to fast latency): transition from S(a, t) to Lf (a, t):
p(a)λ(a, t)S(a, t) individuals/unit time.
• Primary infection (to slow latency): transition from S(a, t) to Ls(a, t):
(1− p(a))λ(a, t)S(a, t) individuals/unit time.
It is worth remarking that, within this modeling framework, individuals
in latency classes do not have TB disease: they do not develop any disease
symptom and they are not infectious at all. Besides, as we will describe in
the following sections, they can suffer ulterior re-infections.
Most of the disease parameters that regulate the fluxes of the Natural
History are taken from different bibliographic sources. Most of them are
taken directly from the works by Dye et al.108 and Abu-Raddad et al.55, that
form the base of this work. A list with the values of the different disease
parameters can be found in section 3.2.9. However, the values of p(a) used
in this model deserve further explanation.
The risk of fast progression to disease after infection is highly variable,
and strongly depends on the age of the individual. In the most recent and
complete work on this matter, by Marais et al.53, a complex outlook regarding
this parameter is reported, according to which fast-progression risk is higher
in newborns, then decreases in children and increases again during adoles-
cence. This pattern, which is largely accepted in the current literature,150–154
is summarized in Table 3.1.
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Age Risk of disease(%) p(a)
<1 year 50± 10
p(0) = 0.1870 (0.1474− 0.2333)1-2 years 18.50± 5.22
2-5 years 5.5
5-10 years 2.25± 0.25 p(1) = 0.0225± 0.0025
>10 years 15± 5 p(a) = 0.15± 0.05 ∀a > 1
Table 3.1: Values for p(a). p(a) values obtained after adapting the values
on the risk of developing disease after infection from Marais et al.53
The values of Table 3.1 have been obtained from Marais et al.53 after
summing up pulmonary and non-pulmonary disease risks, and propagating
their uncertainties assuming independence. We assign these values as the
parameters p(a). For the case of a = 0, which corresponds to ages from 0
to 5 years, we have three different values. We construct p(0) as a weighted
average:
p(0) = α<1p<1 + α1−2p1−2 + α2−5p2−5 (3.1)
The actual values of αi would depend on the demographic pyramid up to
5 years of age. However that information is not available with the precision
required here. Therefore we assume two extreme scenarios: a rectangular
pyramid, and a triangular pyramid in which the population of newborns
(less than 1 year) doubles that of 4 years old. The former will give us the
lower estimate while the latter provides the upper estimate, and the center
value is estimated as the average, yielding the final value of p(0) = 0.1870
(0.1474− 0.2333).
3.2.1.2 Progression from latency to (untreated) disease
Either from fast or slow latency, infected individuals can fall sick, pro-
gressing to one of the three different active forms of the disease. In the first
of these forms, the non-pulmonary disease Dnp, the pathogen can grow in
disparate parts of the host body, including the nervous system, bones, kid-
neys and other organs foreign to lungs. The main characteristic of this kind
of TB is that, since the bacilli can not reach the respiratory tract, the in-
dividuals are considered, for the purposes of this model, unable to transmit
the disease. However, if the pathogens proliferate in the lungs, they can
eventually reach the upper respiratory tract making its host able to transmit
the disease. According to the presence of viable bacilli in the sputum, we
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have the other variants of TB: pulmonary disease, smear negative Dp−, or
pulmonary disease smear positive Dp+; being the latter more infectious than
the former.
This scheme allows six different transitions from the two latency classes
to the three untreated TB disease classes:
• Progression from Lf (a, t) toDnp(a, t): ωfρnp(a)Lf (a, t) individuals/unit
time.
• Progression from Lf (a, t) toDp−(a, t): ωf (1− ρp+(a)− ρnp(a))Lf (a, t)
individuals/unit time.
• Progression from Lf (a, t) toDp+(a, t): ωfρp+(a)Lf (a, t) individuals/unit
time.
• Progression from Ls(a, t) to Dnp(a, t): ωsρnp(a)Ls(a, t) individuals/unit
time.
• Progression from Ls(a, t) to Dp−(a, t): ωs (1− ρp+(a)− ρnp(a))Ls(a, t)
individuals/unit time.
• Progression from Ls(a, t) toDp+(a, t): ωsρp+(a)Ls(a, t) individuals/unit
time.
where ωf and ωs represent the rates at which fast and slow progression
occur, and ρp+(a),ρp−(a) and ρnp(a) represent the probability to develop each
of the three different forms of TB previously described: pulmonary smear-
positive, pulmonary smear-negative and non-pulmonary, respectively. We are
using the closure relation ρp+(a) + ρp−(a) + ρnp(a) = 1, so we have only two
independent parameters –i.e., ρp+(a) and ρnp(a)–. These three probabilities,
as the fast progression probability, are age-dependent –children are known
to develop more often non-pulmonary forms of TB–.155
3.2.1.3 Tuberculosis related deaths
Individuals in D states suffer the effects of the disease in three ways:
1) they develop disease symptoms; 2) they –except the individuals in Dnp–
infect other individuals and 3) some of them die because of the disease. In
the model, we consider that each of the three kinds of disease has a specific
mortality rate, so deaths of D individuals are modeled by introducing three
independent fluxes:
55
CHAPTER 3. MODELLING TB TRANSMISSION
• Deaths of untreated non pulmonary disease: µnpDnp(a, t) individu-
als/unit time.
• Deaths of untreated smear negative pulmonary disease:
µp−Dp−(a, t) individuals/unit time.
• Deaths of untreated smear positive pulmonary disease:
µp+Dp+(a, t) individuals/unit time.
where µnp, µp− and µp+ are the TB-related death rates of Dnp, Dp− and
Dp+ individuals, respectively.
Finally, individuals who were treated in the past that did not respond to
treatment will ultimately die of the disease, at the larger rate µp+ regardless
of their initial type of disease. Class F is detailed later on in this section, in
the subsection regarding treatment outcomes.
• Deaths of failed recovery individuals: µp+F (a, t) individuals/unit time.
3.2.1.4 TB diagnosis and treatment
We consider that an individual belongs to D classes until she receives her
diagnosis, moment in which she joins the corresponding treated TB class T .
This corresponds to the following set of three transitions:
• Diagnosis of non pulmonar TB: transition from Dnp(a, t) to Tnp(a, t):
ηd(t)Dnp(a, t) individuals/unit time
• Diagnosis of smear negative pulmonar TB: transition from Dp−(a, t) to
Tp−(a, t):
ηd(t)Dp−(a, t) individuals/unit time
• Diagnosis of smear positive pulmonar TB: transition from Dp+(a, t) to
Tp+(a, t):
d(t)Dp+(a, t) individuals/unit time
Thus, te diagnosis rate d(t) defines the pace at which undetected individ-
uals in D classes get diagnosed. These diagnosis rates are country specific,
as they depend, among other factors, on the capabilities of Public Health
systems. Furthermore, the average time needed for TB diagnosis is known to
vary depending on the type of disease, partly because the diagnosis criteria
used in each type are different too. Here η represents the variation for the
diagnosis rate that is observed for the detection and diagnosis of non smear
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positive types of disease.
The estimations for the parameter η are based upon the case detection
ratios χ for each type of disease (Dp+, Dp− and Dnp) reported by Abu-
Raddad and colleagues.55 The case detection ratio is commonly defined as
the ratio of the number of notified cases of TB to the number of incident
TB cases in a given year. In Abu-Raddad et al.55, estimations for the case
detection ratios are provided for each type of disease and WHO region: χp+,
χp− and χnp; and it turns out that according to that source χnp ' χp− in
all regions. Therefore, if we compare the case detection ratios of non smear
positive and smear positive types of the disease we can obtain an estimation









The errors have been estimated by considering a 15% as the typical un-
certainty of both χp+ and χp−, as was done in Abu-Raddad et al.55 for several
parameters of the Natural History. We obtain the Confidence Interval for η
by propagating errors.
In the table 3.2 the values of η calculated are listed for the different re-
gions defined by the WHO. We have studied 5 countries from the AFRH
region (Nigeria, South Africa, Democratic Republic of the Congo, Ethiopia
and Tanzania), 1 from EMR (Pakistan), 4 from SEAR (India, Indonesia,
Bangladesh and Myanmar) and 2 from WPR (China and Philippines).
Regions χp+ χp− η
AFRH 0.51 0.43 0.843 (0.664-1.022)
EMR 0.45 0.53 1.178 (0.928-1.428)
SEAR 0.64 0.51 0.797 (0.628-0.966)
WPR 0.78 0.50 0.641 (0.505-0.777)
Table 3.2: Values of η. Values of χp+ and χp− considered in Abu-Raddad
et al.55 and the values of η for each region.
The diagnosis rate is allowed to vary in time, as it has been done in other
previous models (see section 3.2.8 for details).
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3.2.1.5 Treatment outcomes
Right after diagnosis, and supposing that antibiotic treatments are avail-
able immediately, sick individuals start their treatment. In terms of the
model, individuals under current treatment lie into Tnp, Tp− or Tp+, depend-
ing on the type of disease they receive treatment to be cured from. During
their stage at T classes, either by the effect of treatment or by the common
isolation measures that use to follow a TB diagnosis, individuals are not con-
sidered to be able to spread the disease.
Typical antibiotic series last six months; let Ψ be the rate associated to
the inverse of that treatment time. Once the treatment is completed, different
results are possible, and the WHO classifies these treatment outcomes into
four main groups:
• Success: the treatment has been completed and bacilli are not present
in the sputum.
• Default: the treatment has been abandoned before completion.
• Death.
• Failure: bacilli persist -or appear- in the sputum at the end of the
treatment (month five or later).
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µ ) so as to work just with these three fractions of unsuccessful
treatment outcomes. For pulmonary smear negative and non pulmonary TB
cases, the WHO database does not differentiate the fractions of treatment
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µ ). The values of the fractions of non successful
outcomes have been averaged during the fitting time window and their val-
ues are provided in table 3.9, where confidence intervals correspond to two
typical deviations of a multinomial distribution.
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Thus, we can enumerate all the possible treatment outcomes from all the
different kinds of patients to get:
• Early treatment abandon (default) of smear positive TB: transition
from Tp+(a, t) to Rp+D(a, t):
Ψfp+D Tp+(a, t) individuals/unit time.
• Failed treatment completion of smear positive TB: transition from
Tp+(a, t) to F (a, t):
Ψfp+F Tp+(a, t) individuals/unit time.
• Death during treatment of smear positive TB:
Ψfp+µ Tp+(a, t) individuals/unit time.
• Successful treatment completion of smear positive TB: transition from
Tp+(a, t) to Rp+S(a, t):
Ψ(1− fp+D − f
p+
F − fp+µ )Tp+(a, t) individuals/unit time.
• Early treatment abandon (default) of smear negative TB: transition
from Tp−(a, t) to Rp−D(a, t):
Ψfp−D Tp−(a, t) individuals/unit time.
• Failed treatment completion of smear negative TB: transition from
Tp−(a, t) to F (a, t):
Ψfp−F Tp−(a, t) individuals/unit time.
• Death during treatment of smear negative TB:
Ψfp−µ Tp−(a, t) individuals/unit time.
• Successful treatment completion of smear negative TB: transition from
Tp−(a, t) to Rp−S(a, t):
Ψ(1− fp−D − f
p−
F − fp−µ )Tp−(a, t) individuals/unit time.
• Early treatment abandon (default) of non pulmonary TB: transition
from Tnp(a, t) to RnpD(a, t):
Ψfp−D Tnp(a, t) individuals/unit time.
• Failed treatment completion of non pulmonary TB: transition from
Tnp(a, t) to F (a, t):
Ψfp−F Tnp(a, t) individuals/unit time.
• Death during treatment of non pulmonary TB:
Ψfp−µ Tnp(a, t) individuals/unit time.
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• Successful treatment completion of non pulmonary TB: transition from
Tnp(a, t) to RnpS(a, t):
Ψ(1− fp−D − f
p−
F − fp−µ )Tnp(a, t) individuals/unit time.
where the different Rxy variables stand for the groups of individuals that have
completed their treatment for disease of type x (pulmonary smear positive
p+ or negative, p−, or non-pulmonary np) with an outcome denoted by y
(Success, S, default D and fail F ). We have also used the subindex µ when
naming the fraction of deaths that occurs during treatment, but this outcome
does not have a recovery class associated –these individuals die and leave the
system–.
3.2.1.6 Natural recovery
In certain occasions, natural recovery from TB is possible without medical
intervention or treatment.55 This is modeled by introducing three new classes
of naturally recovered individuals in the first branch: RnpN(a, t), Rp−N(a, t)
and Rp+N(a, t). Undiagnosed and sick individuals of each type of TB join
these new classes after natural recovery as follows:
• Natural recovery of non pulmonary TB: transition from Dnp(a, t) to
RnpN(a, t):
νDnp(a, t) individuals/unit time.
• Natural recovery of smear negative pulmonary TB: transition from
Dp−(a, t) to Rp−N(a, t):
νDp−(a, t) individuals/unit time.
• Natural recovery of smear positive pulmonary TB: transition from
Dp+(a, t) to Rp+N(a, t):
νDp+(a, t) individuals/unit time.
where ν is the rate of natural recovery.
3.2.1.7 Endogenous reactivations after treatment or natural re-
covery
Nonetheless, naturally recovered individuals may experience an endoge-
nous reactivation of the disease, since generally speaking disease recovery
does not suppose the total elimination of the bacilli from the host organ-




• Endogenous reactivation of non pulmonary TB after natural recovery:
transition from RnpN(a, t) to Dnp(a, t): rNRnpN(a, t) individuals/unit
time.
• Endogenous reactivation of smear negative TB after natural recovery:
transition from Rp−N(a, t) to Dp−(a, t): rNRp−N(a, t) individuals/unit
time.
• Endogenous reactivation of smear positive TB after natural recovery:
transition from Rp+N(a, t) to Dp+(a, t): rNRp+N(a, t) individuals/unit
time.
Furthermore, endogenous relapse is also possible after antibiotic treat-
ment. Once the treatment has finished the probabilities of experiencing an
endogenous reactivation of the disease are related to the treatment outcome
of the initial disease episode.
Individuals who have experienced a failed treatment –F (a, t) class–, re-
gardless of the type of TB that they originally had, are considered as infec-
tious as smear positive untreated individuals (because they present bacilli in
the sputum at the end of the treatment) and their mortality risk due to TB
is also the same of a smear positive untreated individual.
Within this modeling framework, ulterior re-diagnosis, re-infections or
re-treatments for F (a, t) individuals are not considered, and so, once an indi-
vidual joins this class, her dynamics does not depend any more on the type of
disease she previously had. However, the fact that these individuals die at a
high rate (µp+) prevents this compartment of highly infectious individuals to
become a dead-end in the disease dynamics and a hidden driver of the results
obtained: in the simulations, the weight of this class among the totality of
infectious individuals never surpasses 10%.
Recovered individuals after successful completion of treatment are con-
sidered functionally cured –i.e. they neither present a specific mortality risk
due to TB nor they are infectious. However, they may undergo ulterior en-
dogenous reactivations of the disease, caused by the proliferation of the same
bacilli of the original episode, if these were not completely eliminated from
the host organism. In that case, we have the following transitions:
• Endogenous reactivation of non pulmonary TB after successful treat-
ment: transition from RnpS(a, t) to Dnp(a, t): rSRnpS(a, t) individu-
als/unit time.
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• Endogenous reactivation of smear negative TB after successful treat-
ment: transition from Rp−S(a, t) to Dp−(a, t): rSRp−S(a, t) individu-
als/unit time.
• Endogenous reactivation of smear positive TB after successful treat-
ment: transition from Rp+S(a, t) to Dp+(a, t): rSRp+S(a, t) individu-
als/unit time.
where rS is the endogenous relapse rate after successful treatment completion.
In what regards its estimation, there exist many epidemiological studies
based on the surveillance of cohorts of TB patients after treatment comple-
tion during defined follow-up periods, which are aimed at determining the
relapse rates, as well as the main risk factors associated to its increment. In
the exhaustive meta-analysis by Korenromp and colleagues,62 an ensemble of
such studies is considered. In that work, it is reported that, in all the works
re-analized, an average of 4.2% (3.1−5.3 c.i.) of HIV uninfected subjects have
a TB relapse episode during the follow-up period of the study, of which, 77%
(63 − 91 C.I.) is due to endogenous reactivation. This means that the frac-
tion of population that do not develop a relapse is the 96.77% (95.73−97.80).
Another relevant result of the meta-analysis is the finding that the risk for
TB relapse after treatment decreases with time. This can be seen from the
fact that the relapse rates calculated in the different studies considered tend
to be lower as the follow-up period of the trials is higher. This would imply
that most patients that experiment a relapse after treatment, do it within
the first years after the initial episode. This second result motivates the as-
sumption that the risk of developing a relapse during the follow-up period of
an epidemic surveillance study (100− 96.77 = 3.23% of the population) can
be associated to the total risk of developing such relapse during the entire life
of an individual. Hence, the task is to calculate an annual risk of relapse such
that, when applied over the whole period of life expectancy of a recovered
individual, it yields the same 3.23% of relapse cases. To this end, we estimate
that the average life expectancy of individuals within classes R is equal to 35
years, estimation that follows from assuming, as a first order approximation,
that infection and further recovery are events that occur uniformly in all ages.
Therefore, and since we are assuming that the relapse rate is constant in
age and time, we have an exponential decay describing the relapse of RxS
individuals (Rp+S, Rp−S or RnpS) of the form: RxS(t) ∼ e−rSt. Thus, after a
period t = 35 years assimilable to the average life expectancy of an individual
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that has already entered into class R, from an initial fraction of RxS = 1,
there remains RxS(t = 35) ∼ e−rS35 = 0.9677. This calculation yields the ac-
tual value of rS used in this work, rS = 9.4·10−4 1/year (6.4·10−4−1.3·10−3).
The confidence interval of rS has been obtained after the propagation of the
fraction of not relapsing population as the main source of uncertainty.
Finally, recovered individuals after treatment default are considered par-
tially infectious, although it is assumed that they do not have an explicit
mortality risk due to TB. However, their endogenous relapse risk is higher,
which can be modeled by introducing a parameter rD > rS as follows:
• Endogenous reactivation of non pulmonary TB after treatment default:
transition from RnpD(a, t) to Dnp(a, t): rDRnpD(a, t) individuals/unit
time.
• Endogenous reactivation of smear negative TB after treatment default:
transition from Rp−D(a, t) to Dp−(a, t): rDRp−D(a, t) individuals/unit
time.
• Endogenous reactivation of smear positive TB after treatment default:
transition from Rp+D(a, t) to Dp+(a, t): rDRp+D(a, t) individuals/unit
time.
rD stands for the endogenous relapse rate after treatment default, which
has been calculated as the product of rS and the relative risk factor for
endogenous relapse related to treatment non-compliance, 4.02 (1.79-9.01 c.i.),
taken from Picon et al.156, which yields the final value of rD = 3.8·10−3 1/year
(1.4 · 10−3 − 8.6 · 10−3).
3.2.1.8 Exogenous reinfection of infected individuals
Individuals belonging to classes Ls and R have been previously exposed
to TB bacilli, although they are not sick while remaining within those classes.
In addition, their rates of progression to disease due to eventual endogenous
reactivations are slower than the rate ωf of fast progression to disease from
Lf . For these reasons, an eventual exogenous re-infection of an individual
in classes Ls or R may cause a faster transition to disease, if fast progres-
sion takes place, than endogenous reactivation. This can be modeled by
introducing the following transitions:
• Exogenous re-infection of Ls(a, t) individuals yielding fast progression:
from Ls(a, t) to Lf (a, t):
p(a)qλ(a, t)Ls(a, t) individuals/unit time.
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• Exogenous re-infection of RnpN(a, t) individuals yielding fast progres-
sion: from RnpN(a, t) to Lf (a, t):
p(a)qλ(a, t)RnpN(a, t) individuals/unit time.
• Exogenous re-infection of Rp−N(a, t) individuals yielding fast progres-
sion: from Rp−N(a, t) to Lf (a, t):
p(a)qλ(a, t)Rp−N(a, t) individuals/unit time.
• Exogenous re-infection of Rp+N(a, t) individuals yielding fast progres-
sion: from Rp+N(a, t) to Lf (a, t):
p(a)qλ(a, t)Rp+N(a, t) individuals/unit time.
• Exogenous re-infection of RnpS(a, t) individuals yielding fast progres-
sion: from RnpS(a, t) to Lf (a, t):
p(a)qλ(a, t)RnpS(a, t) individuals/unit time.
• Exogenous re-infection of Rp−S(a, t) individuals yielding fast progres-
sion: from Rp−S(a, t) to Lf (a, t):
p(a)qλ(a, t)Rp−S(a, t) individuals/unit time.
• Exogenous re-infection of Rp+S(a, t) individuals yielding fast progres-
sion: from Rp+S(a, t) to Lf (a, t):
p(a)qλ(a, t)Rp+S(a, t) individuals/unit time.
• Exogenous re-infection of RnpD(a, t) individuals yielding fast progres-
sion: from RnpD(a, t) to Lf (a, t):
p(a)qλ(a, t)RnpD(a, t) individuals/unit time.
• Exogenous re-infection of Rp−D(a, t) individuals yielding fast progres-
sion: from Rp−D(a, t) to Lf (a, t):
p(a)qλ(a, t)Rp−D(a, t) individuals/unit time.
• Exogenous re-infection of Rp+D(a, t) individuals yielding fast progres-
sion: from Rp+D(a, t) to Lf (a, t):
p(a)qλ(a, t)Rp+D(a, t) individuals/unit time.
where q stands for the variation factor of the infection risk of individuals who
have been infected in a previous episode.
On the other hand, if fast progression after the secondary infection does
not take place, even if the initial state of the individual is one of the possible
R states, the rule is that no transition must be considered from these states
to Ls, because an endogenous reactivation from those initial states to disease
64
3.2. MODEL
is always more likely than from Ls, as either rN , rS or rD are greater than
the rate of transition from slow latency to disease ωs. However, we will count
these potential transitions when accounting for the number of infections that
occurred in the system.
In summary, re-infection has no effect on the model unless it is followed
by fast progression. Nevertheless, we note that the nature of TB infection
could be more complicated regarding the influence of repeated exposure. For
instance, in Lee et al.157 it is described how the progression to TB disease
increases with the number of exposures.
3.2.1.9 Smear progression
In certain cases, it is documented that patients of smear negative pul-
monary TB progress to smear positive ,108 even after being treated. In order
to describe this phenomenon, we introduce the smear progression by consid-
ering the following two transitions:
• Smear progression of untreated individuals: transition from Dp−(a, t)
to Dp+(a, t):
θDp−(a, t) individuals/unit time.
• Smear progression of individuals under treatment: transition from Tp−(a, t)
to Tp+(a, t):
θTp−(a, t) individuals/unit time.
where θ stands for the smear progression rate.
3.2.1.10 Mother-child infection transmission
We model the possibility of mother-child transmission right after birth
(peri-natal infection). While most of the newborns that enter the system at
each time step ∆N(a = 0, t) (see section 3.2.5 to see how we estimate it)
will enter the system as susceptible, a fraction of them will do it directly to
the latency classes. This reflects the known fact that a fraction mc of sick
women who are pregnant transmits the disease to the children within the first
weeks of their lives.158 The density of infected newborns depends then on the
fraction of mothers who have the disease and are able to transmit it at time
step t, which leads to the question of what is the relative risk of transmitting
the pathogen to the offspring for women in each of the infectious classes
included in the model. In this work we considered that the total number of
newborn infections is proportional to md(t):
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Rp+D(a, t) +Rp−D(a, t) +RnpD(a, t) + F (a, t)∑a=7
a=3N(a, t)
that represents the fraction of infected individuals present in the age groups
a ∈ [3, 7] associated to women fertility (between 15 and 40 years old), re-
gardless of their relative infectiousnesses. Therefore, this yields following the
distribution of the ∆N(a = 0, t) newborns among S and L classes:
• Birth of S(0, t) individuals (susceptible newborns): (1−mcmd(t))∆N(a =
0, t)
• Birth of Lf (0, t) individuals (infected after birth who develops fast pro-
gression): mcmd(t)p(0)∆N(a = 0, t)
• Birth of Ls(0, t) individuals (infected after birth who develops slow
progression):
mcmd(t)(1− p(0))∆N(a = 0, t)
3.2.2 Force of infection
The force of infection λ(a, t) is, as it has been said before in section
3.2.1.1, the rate at which infection occurs at time step t for a susceptible
individual in age-group a. This magnitude is calculated according to the
following expression:





being Υ(a′, t) the weighted density of all the infectious individuals within
age-group a′ at time step t:
Υ(a′, t) =
Dp+(a











where N(a, t) is the total population of age a, φp− ∈ [0, 1] is the coefficient
of infectiousness reduction of smear negative sick individuals with respect to
smear positive ones, and φD ∈ [0, 1] the infectiousness reduction of individ-
uals who have defaulted the treatment, (Rp+D individuals with respect to
smear positive, undiagnosed individuals Dp+). Diagnosed patients of smear
negative TB who failed their treatment, have an infectiousness reduction that
is the product of the two terms φp−φD.
On the other hand,M ca,a′(t) represents the relative contact frequency that
an individual of age a has with individuals of age a′ at time t, with respect
to the overall average of contacts that an individual has per unit time with
anyone else.
3.2.3 Contact patterns
One of the two principal novelties introduced in this work is the use of
empirical age-dependent matrices. It has been previously shown that aban-
doning the hypothesis of homogeneous age-mixing in favor of data-driven
approaches based on empiric data25,146 improves the descriptive capabili-
ties of epidemiological models of influenza-like diseases.147,148 Similarly, in a
study by Guzzetta and collaborators,114 the importance of considering het-
erogeneous contacts in the modeling of TB was assessed in the context of
Individual Based Modeling (IBM). Despite these first attempts, in mathe-
matical TB modeling at the level of broad populations (i.e. countries or
international macro-regions) the assumption of homogeneous mixing across
age-strata still constitutes one of the most pervasive simplifying hypothesis.
We have discussed thourughly in chapter 2 the implications of implement-
ing an empirical contact matrix in demographic settings that are different of
that where it was measured. In what concerns the development of this model,
there are two warnings we must consider: we should correct contact matri-
ces for reciprocity, and we shouldn’t export contact matrices across different
geographical areas if possible. With this in mind, we take two decisions: 1)
we will use method 3 (M3) (see equation 2.12) to adapt contact matrices
to the specific demographic structure at each time-step and 2) we will build
continental intrinsic connectivities that we then implement for each country
according to its geographical location.
For the computation of the contact matrices used here, we have collected
different survey studies from several countries: Kenya134, Zimbabwe137, Uganda136,
China130, Japan133 and Europe (8 countries)25. With the first three studies
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we build a contact matrix that will be adapted to be used in African coun-
tries (specifically for this work: Nigeria, South Africa, Democratic Republic
of the Congo, Ethiopia and Tanzania), while the next two are used to build an
Asian Contact Matrix (to be adapted to India, Indonesia, China, Pakistan,
Bangladesh, Philippines and Myanmar). Finally, the surveys performed in
the Polymod project, that corresponds to 8 European countries will be ag-
gregated into an European Contact Matrix that we will use to check the
robustness of the results against different contact structures (used only in
sections 3.3.5.5 and 3.3.7.1).
In order to construct continent-wise contact patterns, we begin by apply-
ing the same initial treatment described in chapter 2, section 2.2.3. Once
we have the normalized and reciprocal matrices for each study, we perform a
weighted sum per continent (using number of participants in each study as
weights) to obtain the correspondent regional matrices, that we will callM rega,a′
(for Africa, Asia and Europe, respectively, see figure 3.2, left column). We
then use the dispersion between studies to define the uncertainty associated
to the contact patterns (which we will be propagating to the final matrices
and finally, to model outcomes).
These regional matrices M rega,a′ only fulfill the symmetry of contacts in the
setting of reference where they have been obtained, defined as the union of
the countries being averaged in each case. In order to apply M3 to fulfill sym-
metry at every demographic setting (and at each time step), we extract the
correspondent intrinsic connectivity matrix (Γrega,a′) by using equation 2.10.
These regional connectivity matrix will be used to build at each time step
the contact patterns of the system using M3 (eq. 2.12)
We have decided to use M3 (that ensures a constant mean connectivity)
instead of the most natural M2 for two reasons. On the one hand, the main
objective that we pursue in this work regarding contact patterns is to quantify
the influence that they exert on model forecasts, by comparing the outcomes
of this model to a case where contacts are considered to be homogeneous.
Since, in the latter case, the mean contact intensity is trivially constant over
time, to use heterogeneous contact matrices that share this same property
constitutes a conservative choice that makes the comparison between the full
and the reduced model easier to interpret.
On the other hand, this procedure implies that the average contact in-
tensity in both cases is not just time-invariant, but equal to 1 in both cases.
This makes the scaled infectiousness parameter β(t) to be comparable be-
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Figure 3.2: Continent-wise empiric contact patterns. Empiric contact
patterns in evolving demographies, as number of contacts that an individ-
ual in age-group a (x-axis) has with individuals in age group a′ (y-axis).
(Left) Region-wise contact matrices M rega,a′ derived from weighted averages
from studies completed in each continent. (Middle) Intrinsic connectivity
matrices Γrega,a′ , (Normalized, in order to display 〈k〉 = 1) (Right): Country-
wise, time dependent contact matrices used in this study for the four countries
that have been studied in most depth. European contacts are showed when
applied to Ethiopia and India, to illustrate that the approach can be used to
test the effect of alien contact structures obtained in any setting (these are
only used in the analyses presented in figures 3.16 and 3.13)
tween the full and the reduced model, thus providing an overall scale for the
average capability of an infected individual to propagate the disease in both
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cases.
Besides, any possible evolution in the mean connectivity will be absorbed
by the infectious parameter β(t). Formally, this can be interpreted consider-
ing that β is the product of two indistinguishable nuisance parameters: the
average connectivity of the network of contacts (i.e. the average number of
epidemiologically relevant interactions that any individual has per unit time)
and the "intrinsic" infectiousness, (i.e. the probability of a contagion to occur
upon one of those contacts, if established between an infectious and a suscep-
tible individual). Among the alternative scenarios that we have studied to
assess the robustness of the results, we include different temporal evolutions
of β(t).
Under this formulation, the relative ratio between the contact intensities
of a group a towards two different groups a′ and a′′ is represented by the
fraction M ca,a′(t)/M ca,a′′(t), which measures how likely are individuals of age
a to interact with people of age a′ in comparison to age a′′. The temporal
evolution of this ratio only depends on the relative volumes of the target age













In the figure 3.2, we summarize this process, showing the contact pat-
terns obtained at each step, normalized to a common scale in each region.
As it can be observed, the corrections explained above designed to capture
the influence of the different demographic structures across countries and
time introduce slight variations when compared to the differences observed
between the three geographical areas.
We will compare the results with a reduced model in which we maintain
the classical hypothesis of contact homogeneity (reduced model 2, RM2).
This consists of assuming that the probability for two individuals to interact
is the same, which means that the contact frequency that an individual in
group a has with people in group a′ only depends on the frequency of the
target group in the population:
M c,RM2a,a′ (t) = N(a
′, t)/N(t) (3.7)
in such a way that the average number of contacts that an individual of
any age has per unit time is always and everywhere equal to 1. Thus, the




In the tables 3.3, 3.4 and 3.5, we specify the values of the intrinsic connec-
tivity matrices Γrega,a′ for the three macro-regions considered (Africa, Asia and
Europe). Notice that these are not directly the contact patterns considered,
but they have to be corrected by the demography of the individual setting
(equation 2.12).
0-5 5-10 10-15 15-20 20-25 25-30 30-35 35-40 40-45 45-50 50-55 55-60 60-65 65-70 +70
0-5 1.25 1.50 1.33 1.01 0.93 1.02 1.04 0.93 0.92 0.90 1.03 1.15 1.22 1.15 0.82
5-10 1.50 4.47 4.01 2.08 1.24 1.28 1.33 1.45 1.50 1.67 1.71 1.54 1.72 1.77 1.37
10-15 1.33 4.01 5.94 3.18 1.77 1.33 1.42 1.79 1.83 1.95 1.97 1.77 1.97 2.72 2.26
15-20 1.01 2.08 3.18 5.53 2.84 1.74 1.77 2.20 2.23 2.41 2.45 2.32 2.49 2.90 2.40
20-25 0.93 1.24 1.77 2.84 2.89 1.95 1.88 2.16 2.24 2.53 2.74 2.58 2.83 3.09 2.47
25-30 1.02 1.28 1.33 1.74 1.95 2.31 2.16 2.16 2.27 2.27 2.38 2.20 2.44 2.59 1.85
30-35 1.04 1.33 1.42 1.77 1.88 2.16 2.13 2.25 2.35 2.28 2.35 2.18 2.48 2.48 1.65
35-40 0.93 1.45 1.79 2.20 2.16 2.16 2.25 2.77 2.88 3.01 3.02 2.62 2.87 2.89 1.98
40-45 0.92 1.50 1.83 2.23 2.24 2.27 2.35 2.88 3.14 3.34 3.20 2.70 2.94 3.07 2.20
45-50 0.90 1.67 1.95 2.41 2.53 2.27 2.28 3.01 3.34 4.04 3.86 3.22 3.51 3.80 2.95
50-55 1.03 1.71 1.97 2.45 2.74 2.38 2.35 3.02 3.20 3.86 3.96 3.42 3.76 3.92 3.17
55-60 1.15 1.54 1.78 2.32 2.58 2.20 2.18 2.62 2.70 3.22 3.42 3.82 4.26 3.76 3.07
60-65 1.22 1.72 1.97 2.49 2.83 2.44 2.48 2.87 2.94 3.51 3.76 4.26 4.89 4.33 3.77
65-70 1.15 1.77 2.72 2.90 3.09 2.59 2.48 2.89 3.07 3.80 3.92 3.76 4.33 5.06 4.64
+70 0.82 1.37 2.26 2.40 2.47 1.85 1.65 1.98 2.20 2.95 3.17 3.07 3.77 4.64 3.55
Table 3.3: Intrinsic Connectivity Matrix Γrega,a′ for Africa
0-5 5-10 10-15 15-20 20-25 25-30 30-35 35-40 40-45 45-50 50-55 55-60 60-65 65-70 +70
0-5 13.89 0.87 0.34 0.31 1.41 1.19 1.88 1.99 1.11 1.18 0.94 0.90 0.97 0.70 0.90
5-10 0.87 13.36 4.60 4.17 0.75 0.62 1.23 1.31 1.35 1.44 0.78 0.76 0.68 0.50 0.50
10-15 0.34 4.60 25.52 5.70 0.77 0.68 1.07 1.09 1.61 1.72 0.90 0.90 0.80 0.59 0.64
15-20 0.31 4.17 5.70 13.23 1.08 1.04 0.90 0.89 1.24 1.32 1.25 1.29 0.86 0.65 1.41
20-25 1.41 0.75 0.77 1.08 3.26 3.18 2.17 2.19 2.20 2.30 2.65 2.67 2.36 1.81 2.13
25-30 1.19 0.62 0.68 1.04 3.18 2.49 1.52 1.63 1.78 1.90 2.14 2.01 1.76 1.29 1.40
30-35 1.88 1.23 1.07 0.90 2.17 1.52 1.92 2.14 1.98 2.13 1.74 1.56 1.46 0.98 0.88
35-40 1.99 1.31 1.09 0.89 2.19 1.63 2.14 2.31 2.06 2.20 1.82 1.67 1.56 1.05 0.98
40-45 1.11 1.35 1.61 1.24 2.20 1.78 1.98 2.06 2.52 2.70 2.16 2.07 1.77 1.25 1.53
45-50 1.18 1.44 1.72 1.32 2.30 1.90 2.13 2.20 2.70 2.87 2.30 2.23 1.88 1.38 1.69
50-55 0.94 0.78 0.90 1.25 2.65 2.14 1.74 1.82 2.16 2.30 2.99 2.87 2.29 1.82 3.04
55-60 0.90 0.76 0.90 1.29 2.67 2.01 1.56 1.67 2.07 2.23 2.87 2.68 2.09 1.61 2.57
60-65 0.97 0.68 0.80 0.86 2.36 1.76 1.46 1.56 1.77 1.88 2.29 2.09 5.99 5.60 3.13
65-70 0.70 0.50 0.59 0.65 1.81 1.29 0.98 1.05 1.25 1.38 1.82 1.61 5.60 6.07 3.48
+70 0.90 0.50 0.64 1.41 2.13 1.40 0.88 0.98 1.53 1.69 3.04 2.57 3.13 3.48 6.16
Table 3.4: Intrinsic Connectivity Matrix Γrega,a′ for Asia
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0-5 5-10 10-15 15-20 20-25 25-30 30-35 35-40 40-45 45-50 50-55 55-60 60-65 65-70 +70
0-5 13.85 7.09 2.32 1.29 1.56 3.18 4.64 3.66 2.26 1.62 1.71 1.54 1.94 1.12 0.65
5-10 7.09 32.05 5.93 1.86 0.98 2.14 3.42 4.35 3.30 1.65 1.57 1.27 1.50 1.03 0.73
10-15 2.32 5.93 39.26 6.06 1.08 0.75 1.67 3.02 4.12 2.48 1.38 0.81 0.88 0.81 0.99
15-20 1.29 1.86 6.06 32.18 4.67 1.47 0.91 1.42 2.78 3.23 1.60 0.94 0.51 0.43 0.73
20-25 1.56 0.98 1.08 4.67 9.04 3.78 1.84 1.07 1.31 1.79 1.58 0.97 0.51 0.33 0.36
25-30 3.18 2.14 0.75 1.47 3.78 5.44 2.59 1.41 1.14 1.38 1.80 1.33 0.98 0.42 0.41
30-35 4.64 3.42 1.67 0.91 1.84 2.59 3.64 2.51 1.60 1.46 1.26 1.30 1.28 0.56 0.40
35-40 3.66 4.35 3.02 1.42 1.07 1.41 2.51 3.74 2.16 1.43 1.12 0.96 1.17 0.81 0.55
40-45 2.26 3.30 4.12 2.78 1.31 1.14 1.60 2.16 3.35 2.46 1.52 0.93 1.15 0.77 0.74
45-50 1.62 1.65 2.48 3.23 1.79 1.38 1.46 1.43 2.46 3.13 2.10 1.30 0.86 0.59 0.90
50-55 1.71 1.57 1.38 1.60 1.58 1.80 1.26 1.12 1.52 2.10 3.22 2.26 1.29 0.63 0.81
55-60 1.54 1.27 0.81 0.94 0.97 1.33 1.30 0.96 0.93 1.30 2.26 3.46 2.00 0.99 0.65
60-65 1.94 1.50 0.88 0.51 0.51 0.98 1.28 1.17 1.15 0.86 1.29 2.00 3.67 1.85 1.04
65-70 1.12 1.03 0.81 0.43 0.33 0.42 0.56 0.81 0.77 0.59 0.63 0.99 1.85 1.84 1.13
+70 0.65 0.73 0.99 0.73 0.36 0.41 0.40 0.55 0.74 0.90 0.81 0.65 1.04 1.13 1.20
Table 3.5: Intrinsic Connectivity Matrix Γrega,a′ for Europe
3.2.4 Aging
The model considers 15 different age groups. Each of these groups com-
prises an age interval of ∆t = 5 years, except the last one that corresponds to
individuals older that 70 years old. The relevance of such an age structured
description of the system comes from the fact that some of the most relevant
dynamical parameters take distinct values for each age group. To account for
the aging of individuals as time goes by -and thus the evolution of their age
a- we introduce on the system of equations the following aging transitions,
that stands for the promotion of individuals within whatever dynamical class
of the model X(a, t) to the next age class X(a+ 1, t).
• Aging of individuals belonging to class X(a, t), transition from X(a, t)
to X(a+ 1, t): X(a, t)/∆t individuals/unit time.
Obviously, each class X(a, t) receives people from X(a − 1, t) and sends
out people to X(a + 1, t), except X(0, t), that only receives newborns and
X(14, t), for which no further aging occurs.
3.2.5 Demographic evolution
Once all the transitions among the different dynamical states of the sys-
tem have been described, as well as the aging fluxes, it is necessary to provide
a global description of the evolution of the demographic structure, given by
the evolution of the set of variables N(a, t), which are defined as the total
number of individuals within age group a in the population, no matter their
states regarding TB dynamics:
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N(a, t) = S(a, t) + Lf (a, t) + Ls(a, t) +Dp+(a, t) +Dp−(a, t) (3.8)
+Dnp(a, t) + F (a, t) + Tp+(a, t) + Tp−(a, t) + Tnp(a, t)
+Rp+N(a, t) +Rp−N(a, t) +RnpN(a, t) +Rp+S(a, t) +Rp−S(a, t)
+RnpS(a, t) +Rp+D(a, t) +Rp−D(a, t) +RnpD(a, t)
where the evolution of N(a, t) -in addition to aging and death by TB– is
subject to other driving forces related to aspects like vegetative variation
of population –births and non-TB deaths– as well as migration. In order to
provide a description of the temporal evolution of the demographic structure,
previous models have turned to different simplifying hypotheses to describe
the system.
One of them consists on forcing the system to preserve, at any time,
the total number of individuals N (t): N (t) =
∑
aN(a, t) by imposing
that N (t) = N (t = 0)∀(t).55 A more sophisticated alternative, adopted
in Dye et al.108, is based on imposing that the system preserves the ini-
tial age structure of the population by making that, in each age group:
N(a, t) = N(a, t = to)∀(t). This approach, however, is based on assuming
that the temporal evolution of the variables N(a, t) follows the predictions
of the United Nations Population Division, available at its on-line databases:
N(a, t) = NUN(a, t).138 Population aging is a common feature in virtually all
the countries under study.
In the following sub-sections, we detail these two different schemes (con-
stant versus evolving demographies, implemented in the reduced model 1 and
the full model, respectively), whose influence on model forecasts are analyzed
in this chapter.
Reduced model 1: Constant demographic structure
A first approach consists on imposing that the demographic structure of
the population has to remain constant during the dynamical process: i.e.
N(a, t) = N(a, to)∀t. As mentioned earlier, this is what is done in some
previous works,108 where the dynamical states indicate densities rather than
numbers of individuals. In this case, the force of infection is calculated as
an average of the densities of sick individuals in each age group, weighted by
the number of individuals within each age class of the demographic struc-
ture. In this way, Dye et al.108 provide a means for calculating infection and
mortality rates that takes into account the initial demographic structure of
73
CHAPTER 3. MODELLING TB TRANSMISSION
the population, and these rates can be eventually transformed into numbers
by using data about the evolution of the total population under consideration.
In order to provide an equivalent description in the context of the model –
where states represent number of individuals rather than densities–, we start
by calculating the variation of population due to TB and aging in each age
group:
Ṅo(a, t) = ((1− δ(a))N(a− 1, t)−N(a, t))/∆t (3.9)
−µp+(Dp+(a, t) + F (a, t))− µp−Dp−(a, t)− µnpDnp(a, t)
−Ψfp+µ Tp+(a, t)−Ψfp−µ (Tp−(a, t) + Tnp(a, t))
being δ(a) the Dirac delta function. In order to preserve the number of
individuals within each age group at any moment, we simply introduce a
term ∆N(a, t) that is intended to balance Ṅo(a, t) within each age group:
∆N(a, t) = −Ṅo(a, t), yielding:
Ṅ(a, t) = Ṅo(a, t) + ∆N(a, t) = 0 ∀(a, t) (3.10)
The key question is how to distribute these correction terms ∆N(a, t)
between the different dynamical states X(a, t) within age-class a. These
increments have to be distributed between X(a, t) dynamical states keeping
the relative volume of these states within the age group so as not to introduce
external, undesired biases on states’ densities. If we call ∆X(a, t) the fraction
of ∆N(a, t) that is introduced in state X(a, t), we have:









This scheme has the advantage, with respect to consider (as in Abu-
Raddad et al.55), that N (t) = N (t = 0)∀(t), that, at least, the structure of
the population is controlled. However, as in that case, population growth is
not explicitly considered, and further information about population volume
is required so as to scale rates into numbers, as done in Dye et al.108 Addition-
ally, the main problem with this approach comes from the fact that no vari-
ation of the age structure of the population can be considered by proceeding
this way, which might introduce significant biases from current demographic
74
3.2. MODEL
forecasts, specially when studying populations subjected to strong processes
of demographic aging.
Full model: Evolving demography according to an external con-
straint
Starting from the last scheme for modeling the demographic evolution, it
is easy to obtain a final approach that explicitly considers not only the influ-
ence of the age structure into the spreading, but also the population growth
and the variation of the age structure itself. To this end, it is necessary to
know the actual –or projected– evolution of the demographic structure of the
population during the period under analysis. In this case, we are modeling
TB dynamics from 2000 to 2050, and the official annual projections for the
population per age group of any country are available, up to 2100, at the
UN population division database.138 Thus, from the UN database we obtain
the actual annual population series expected by the UN for the populations
at each age group, which can be trivially fitted to a continuous function
NUN(a, t), from which we can derive an analytical derivative ṄUN(a, t) at
any moment. For the purpose of this work, a polynomial of degree 10 is
more than enough for building the continuous function NUN(a, t) from the
annual data series from UN Database during the period under study.138
So, if we recover the variation of population due to TB and aging in each
age group Ṅo(a, t), derived from equation 3.9, we can also introduce a term
∆N(a, t), aimed, this time, not at balancing Ṅo(a, t), but at forcing the total
temporal evolution of N(a, t) to follow precisely the function NUN(a, t). This
is achieved by defining, at each time step:
∆N(a, t) = ṄUN(a, t)− Ṅo(a, t) (3.13)
and introducing those ∆N(a, t) terms into the system dynamics, thus hav-
ing: Ṅ(a, t) = Ṅo(a, t) + ∆N(a, t) = ṄUN(a, t). Finally, provided that the
initial conditions have been properly set, N(a, t = 0) = NUN(a, t = 0) ∀a,
this yields the desired behavior for the demographic structure, i.e., N(a, t) =
NUN(a, t) ∀(a, t).
Again, the ∆N(a, t) forcing terms have to be introduced into the different
dynamical states within the same age class preserving their proportions, at
least in the age groups a > 0:
∆X(a, t) = ∆N(a, t)
X(a, t)
N(a, t)
∀a > 0 (3.14)
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and, under this assumption, the terms ∆N(a, t) for a > 0, represent the vari-
ations of volume of the age group a due to causes other than TB infection
and individuals aging. This would include all deaths not caused by TB, and
migration, assuming that these factors affect all the dynamical classes re-
gardless of their state with respect to TB infection.
The assumption that migration occurs independently of the disease state
is arguable, and, in principle, is hard to anticipate whether TB patients (or
latent TB carriers) are more or less prune to migrate than susceptible in-
dividuals. However, without specific data that could motivate an informed
alternative, we decided to take as the null hypothesis that all individuals are
equally prune to migrate regardless of their TB status. Nonetheless, migra-
tory fluxes do not represent the major cause of population variation in any
of the twelve countries studied, where the migratory balance (immigrants-
emigrants) supposes less than 25% of the vegetative growth (less than 10% in
8 over 12 countries, all but South Africa, China, Myanmar and Bangladesh)
during the period under study. Thus, if the actual reality is more complex
than this assumptions, and migrants and not migrants do present different
TB prevalence levels, the effects of these differences should be bound by the
reduced role of migration in the total variation of the populations under
study.
The situation is different for the first age class a = 0. In the first age
group, the birth of new individuals is the main cause of population variation.
For these reasons, and once observed that ∆N(a = 0, t) > 0 ∀t in all coun-
tries under consideration, for simplicity ∆N(a = 0, t) is directly associated
to the number of newborns and introduced in the S, Ls and Lf states, as
described in section 3.2.1.10.
The uncertainty of UN demographic projections is also reported at UN
Database,138 which allows us to reconstruct the demographic structures at
the extremes of the confidence interval (95%) N lowUN(a, t) and N
high
UN (a, t).
Therefore, its influence on the model forecasts is also measurable, as we will
discuss in the section devoted to uncertainty and sensitivity analysis (section
3.2.10).
3.2.6 Ordinary differential equations system
The following system of differential equations describes the evolution of
the different dynamical states of the model:
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Ṡ(a, t) = −λ(a, t)S(a, t)− (1− δ(a− 14))S(a, t)/∆t (3.15)
+ (1− δ(a))S(a− 1, t)/∆t + δ(a)(1−mcmd(t))∆N (a, t)
+ (1− δ(a))∆N (a, t)S(a, t)/N(a, t)
L̇s(a, t) = (1− p(a))λ(a, t)S(a, t)− p(a)qλ(a, t)Ls(a, t)− ωsLs(a, t) (3.16)
+ δ(a)mcmd(t)(1− p(0))∆N (a, t)− (1− δ(a− 14))Ls(a, t)/∆t
+ (1− δ(a))Ls(a− 1, t)/∆t + (1− δ(a))∆N (a, t)Ls(a, t)/N(a, t)
L̇f (a, t) = p(a)λ(a, t)S(a, t) + p(a)qλ(a, t)(Ls(a, t) +Rp+N (a, t)) (3.17)
+ p(a)qλ(a, t)(Rp−N (a, t) +RnpN (a, t) +Rp+S(a, t) +Rp−S(a, t))
+ p(a)qλ(a, t)(RnpS(a, t) +Rp+D(a, t) +Rp−D(a, t) +RnpD(a, t))
− ωfLf (a, t)− ((1− δ(a− 14))Lf (a, t)− (1− δ(a))Lf (a− 1, t))/∆t
+ δ(a)mcmd(t)p(0)∆N (a, t) + (1− δ(a))∆N (a, t)Lf (a, t)/N(a, t)
Ḋp+(a, t) = ωfρp+(a)Lf (a, t) + ωsρp+(a)Ls(a, t)− µp+Dp+(a, t) (3.18)
− d(t)Dp+(a, t)− νDp+(a, t) + rNRp+N (a, t) + rSRp+S(a, t)
+ rDRp+D(a, t) + θDp−(a, t)− (1− δ(a− 14))Dp+(a, t)/∆t
+ (1− δ(a))Dp+(a− 1, t)/∆t + (1− δ(a))∆N (a, t)Dp+(a, t)/N(a, t)
Ḋp−(a, t) = ωf (1− ρp+(a)− ρnp(a))Lf (a, t)− ρnp(a))Ls(a, t) (3.19)
+ ωs(1− ρp+(a)− ηd(t)Dp−(a, t) + rNRp−N (a, t)
+ rSRp−S(a, t) + rDRp−D(a, t)− (1− δ(a− 14))Dp−(a, t)/∆t
+ (1− δ(a))Dp−(a− 1, t)/∆t + (1− δ(a))∆N (a, t)Dp−(a, t)/N(a, t)
− µp−Dp−(a, t)− νDp−(a, t)− θDp−(a, t)
Ḋnp(a, t) = ωfρnp(a)Lf (a, t) + ωsρnp(a)Ls(a, t) (3.20)
− µnpDnp(a, t)− ηd(t)Dnp(a, t)− νDnp(a, t)
+ rNRnpN (a, t) + rSRnpS(a, t) + rDRnpD(a, t)
− ((1− δ(a− 14))Dnp(a, t)− (1− δ(a))Dnp(a− 1, t))/∆t
+ (1− δ(a))∆N (a, t)Dnp(a, t)/N(a, t)
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Ṫp+(a, t) = d(t)Dp+(a, t)−ΨTp+(a, t) + θTp−(a, t) (3.21)
− ((1− δ(a− 14))Tp+(a, t)− (1− δ(a))Tp+(a− 1, t))/∆t
+ (1− δ(a))∆N (a, t)Tp+(a, t)/N(a, t)
Ṫp−(a, t) = ηd(t)Dp−(a, t)−ΨTp−(a, t)− θTp−(a, t) (3.22)
− ((1− δ(a− 14))Tp−(a, t)− (1− δ(a))Tp−(a− 1, t))/∆t
+ (1− δ(a))∆N (a, t)Tp−(a, t)/N(a, t)
Ṫnp(a, t) = ηd(t)Dnp(a, t)−ΨTnp(a, t) (3.23)
− ((1− δ(a− 14))Tnp(a, t)− (1− δ(a))Tnp(a− 1, t))/∆t
+ (1− δ(a))∆N (a, t)Tnp(a, t)/N(a, t)
Ḟ (a, t) = Ψfp+F Tp+(a, t) + Ψf
p−
F (Tp−(a, t) + Tnp(a, t))− µp+F (a, t)(3.24)
− ((1− δ(a− 14))F (a, t)− (1− δ(a))F (a− 1, t))/∆t
+ (1− δ(a))∆N (a, t)F (a, t)/N(a, t)
Ṙp+N (a, t) = νDp+(a, t)− rNRp+N (a, t)− p(a)qλ(a, t)Rp+N (a, t) (3.25)
− ((1− δ(a− 14))Rp+N (a, t)− (1− δ(a))Rp+N (a− 1, t))/∆t
+ (1− δ(a))∆N (a, t)Rp+N (a, t)/N(a, t)
Ṙp−N (a, t) = νDp−(a, t)− rNRp−N (a, t)− p(a)qλ(a, t)Rp−N (a, t) (3.26)
− ((1− δ(a− 14))Rp−N (a, t)− (1− δ(a))Rp−N (a− 1, t))/∆t
+ (1− δ(a))∆N (a, t)Rp−N (a, t)/N(a, t)
ṘnpN (a, t) = νDnp(a, t)− rNRnpN (a, t)− p(a)qλ(a, t)RnpN (a, t) (3.27)
− ((1− δ(a− 14))RnpN (a, t)− (1− δ(a))RnpN (a− 1, t))/∆t
+ (1− δ(a))∆N (a, t)RnpN (a, t)/N(a, t)
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µ )Tp+(a, t) (3.28)
− rSRp+S(a, t)− p(a)qλ(a, t)Rp+S(a, t)
− ((1− δ(a− 14))Rp+S(a, t)− (1− δ(a))Rp+S(a− 1, t))/∆t
+ (1− δ(a))∆N (a, t)Rp+S(a, t)/N(a, t)




µ )Tp−(a, t) (3.29)
− rSRp−S(a, t)− p(a)qλ(a, t)Rp−S(a, t)
− ((1− δ(a− 14))Rp−S(a, t)− (1− δ(a))Rp−S(a− 1, t))/∆t
+ (1− δ(a))∆N (a, t)Rp−S(a, t)/N(a, t)




µ )Tnp(a, t) (3.30)
− rSRnpS(a, t)− p(a)qλ(a, t)RnpS(a, t)
− ((1− δ(a− 14))RnpS(a, t)− (1− δ(a))RnpS(a− 1, t))/∆t
+ (1− δ(a))∆N (a, t)RnpS(a, t)/N(a, t)
Ṙp+D(a, t) = Ψf
p+
D Tp+(a, t)− rDRp+D(a, t)− p(a)qλ(a, t)Rp+D(a, t) (3.31)
− ((1− δ(a− 14))Rp+D(a, t)− (1− δ(a))Rp+D(a− 1, t))/∆t
+ (1− δ(a))∆N (a, t)Rp+D(a, t)/N(a, t)
Ṙp−D(a, t) = Ψf
p−
D Tp−(a, t)− rDRp−D(a, t)− p(a)qλ(a, t)Rp−D(a, t) (3.32)
− ((1− δ(a− 14))Rp−D(a, t)− (1− δ(a))Rp−D(a− 1, t))/∆t
+ (1− δ(a))∆N (a, t)Rp−D(a, t)/N(a, t)
ṘnpD(a, t) = Ψf
p−
D Tnp(a, t)− rDRnpD(a, t)− p(a)qλ(a, t)RnpD(a, t) (3.33)
− ((1− δ(a− 14))RnpD(a, t)− (1− δ(a))RnpD(a− 1, t))/∆t
+ (1− δ(a))∆N (a, t)RnpD(a, t)/N(a, t)
where δ(a) stands for the Dirac delta function (δ(x = 0) = 1 and δ(x 6= 0) =
0). There are three quantities that depend on time: the force of infection
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λ(a, t), the diagnosis rate d(t) and the correction terms ∆N(a, t), standing
for any demographic variation in the population due to causes foreign to TB
and aging.
It is useful to define two additional variables, fully dependent on the dy-
namical state of the system, such as the accumulated number of TB incident
cases in each age group, from the beginning of the period under analysis
I(a, t), and the accumulated number of TB deaths equally defined M(a, t).
Their respective temporal evolution reads as follows:
İ(a, t) = ωfLf (a, t) + ωsLs(a, t) (3.34)
+rN (Rp+N(a, t) +Rp−N(a, t) +RnpN(a, t))
+rS (Rp+S(a, t) +Rp−S(a, t) +RnpS(a, t))
+rD (Rp+D(a, t) +Rp−D(a, t) +RnpD(a, t))
Ṁ(a, t) = µp+(Dp+(a, t) + F (a, t)) + µp−Dp−(a, t) (3.35)
+µnpDnp(a, t) + Ψf
p+
µ Tp+(a, t)
+Ψfp−µ (Tp−(a, t) + Tnp(a, t))
From these variables, once summed over all age groups, we explicitly
get the incidence rate as the number of new cases per year i(t), and the
annual mortality rate as the total number of TB deaths per year m(t), both




a (I(a, t+ 1)− I(a, t))





a (M(a, t+ 1)−M(a, t))
(N (t+ 1) +N (t))/2
(3.37)
The sums of I(a, t) and M(a, t) over all ages at the end of the period
under study provide the total number of cases and deaths due to the disease
during the whole period.
3.2.7 Initial conditions setup
Once we have detailed the forces driving the time evolution of state vari-
ables, it remains to be clarified how the initial conditions ~X(a, t = 0) for
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each possible state ~Xi are set. This problem is traditionally solved just by
considering that, at the beginning of the period analyzed, the system is at
a stationary state that is reached after fixing the temporal evolution of the
time dependent parameters to their values at the beginning of the period:
d(t = 0) = d0 and β(t = 0) = β0, as well as the demographic boundary con-
ditions N(a, t) = N(a, 0), where N(a, t) represents the populations at each
age group.55,108 We denote those stationary levels as ~X∗(a, d0, β0, N(a, 0)),
so we have Ẋ∗i = 0 ∀(i, t); provided that all the time-dependent parameters
and demographic forcing terms are frozen in their initial values at t = to.
Accordingly, the stationary vector ~X∗ is used to set up the initial conditions
of the system: ~X(a, 0) = ~X∗.
In this work, we do not impose that the system must be at station-
arity at t = 0. Instead, we calculate the stationary values of all states
~X∗(a, d0, β0, ~N(a, 0)), and we set up an initial state that can correspond ei-
ther to higher or lower levels of infection prevalence. In order to map these
possible variations on TB burden from the stationary vector of states ~X∗, we
distinguish the unexposed state, S(a, t), from the rest of the states joined by
individuals that have been infected with the bacillus at least once. Finally,
we define a parameter ς ∈ [−1, 1], such that, when ς < 0, the initial condi-
tions correspond to a state with lower TB burden than that in the stationary
state:
X(a, t = 0) = (1 + ς)X∗(a, d0, β0, ~N(a, 0)) ∀(X 6= S) (3.38)
S(a, t = 0) = S∗(a, d0, β0, ~N(a, 0))
1− ς ∑
X 6=S
X∗(a, d0, β0, ~N(a, 0))
 (3.39)
Instead, if ς > 0, the initial conditions are set to higher burden levels
from stationarity:
S(a, t = 0) = S∗(a, d0, β0, ~N(a, 0))(1− ς) (3.40)
X(a, t = 0) = X∗(a, d0, β0, ~N(a, 0))
(
1 +
ςS∗(a, d0, β0, ~N(a, 0))∑
X 6=S X
∗(a, d0, β0, ~N(a, 0))
)
(3.41)
Taking it to their extreme values, ς = −1 would mean that every indi-
vidual is at the susceptible state (pathogen-free situation) while ς = 1 would
mean that all the population is infected with the bacterium. ς = 0 would
imply that the initial conditions of the system are those from the stationary
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state. The previous definition ensures that, at any moment, the sum of indi-
viduals in all the states provides the desired population volumes regardless
of how far, or in which sense ς shifts the initial condition from the stationary
state defined by the vector ~X∗.
3.2.8 Model calibration procedure
The calibration procedure of the model implies the estimation, for each
country, of the initial conditions of the system, parameterized through the ς
coordinate, along with the diagnosis rate d(t) and the scaled infectiousness
β(t) that make the model reproduce the TB burden mortality and incidence
rates reported by the WHO from to = 2000 to tF = 2015. Both parameters
d(t) and β(t) are fitted to half-sigmoid-like curves, as follows:
d(t) =

d0 + (dsup − d0)t(t+ 1d1 )
−1 if d1 > 0
d0 if d1 = 0
d0 − d0t(t− 1d1 )


















Therefore, the diagnosis rate and the scaled infectiousness are, each of
them, parameterized by two quantities (d0, d1 and β0, β1). While d0 and β0
give the value of the diagnosis rate and scaled infectiousness at the beginning
of the temporal window (i.e. year 2000), d1 and β1 define their evolution,
either increasing or decreasing with time depending on the sign of d1 and
β1. In case of a decreasing evolution, both the diagnosis rate and the scaled
infectiousness are bounded to be greater than zero, while in the case of in-
creasing evolution the upper bounds are 2× β0 for the scaled infectiousness
and dsup = 12.17y−1 for the diagnosis rate. This latter upper bound cor-
responds to a minimum diagnosis period of one month. We consider this
minimum delay as reasonable, since the main symptom of TB is a continu-
ous cough during three weeks, and, after that, there is a diagnostic process
which is estimated to last, assuming a conservative lower boundary, at least
10 days.159
We have chosen this parameterization of the temporal evolution of the
diagnosis rate and the infectiousness because, unlike previous approaches
where the evolution of these parameters is assimilated to an exponential
curve,55,108 it provides a bounded growth for them, through a function that
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is still continuous and differentiable but does not introduce more parameters.
The goal of the calibration procedure is to minimize the overall error
H of the model outcome with respect to the input burden measurements














where ī(t) and m̄(t) stand for the annual incidence and mortality rates, cor-
responding to the national estimations available at the WHO database for
TB.149 These measurements of TB incidence and mortality have their corre-
spondent confidence intervals (̄ilow(t), īhigh(t)) and (m̄low(t), m̄high(t)), which
are not necessarily symmetrical with respect to the central values ī(t) and
m̄(t). Using these confidence intervals, and taking into consideration their
asymmetry, the corresponding terms ∆̄i(t) ∆̄m(t) are constructed as follows:
∆̄i(t) =
{
ī(t)− īlow(t) if i(t) ≤ ī(t)
īhigh(t)− ī(t) if i(t) > ī(t) (3.45)
∆̄m(t) =
{
m̄(t)− m̄low(t) if m(t) ≤ m̄(t)
m̄high(t)− m̄(t) if m(t) > m̄(t) (3.46)
In the case of China and Philippines the very small uncertainty on mor-
tality data (directly zero for some particular years) prevents us of using the















where 〈̄i(t)〉 and 〈m̄(t)〉 correspond to the averages of incidence and mor-
tality reported by the WHO for the entire period in each country, respectively.
The conceptual scheme for the fitting of these parameters essentially con-
sists in an iterative evaluation of the model across the parameter space
(ς, d0, β0, d1, β1), which is navigated according to a certain "routing" that
eventually guarantees the localization of a parameter set that yields an error
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H which constitutes a local minimum of the objective function H. We have
used a Levenberg-Marquardt algorithm to solve these multidimensional opti-
mization problem, implemented, as for the rest of the model, in programming
language C.160 See figure 3.3 for a graphic summary of the procedure.
First nested iteration (j=0)
Initial guess for...
(do, d1, bo, b1,z)(i=0, j=0)}initial conditionsdiagnosis rateinfectiousness
Calculate initial stationary state
X* (do, bo, N(a,0))
Set up initial conditions
X (to)=f (X*, z)
Run dinamics & evaluate error of 
aggregated burden levels
X (t)=f (X (to), do, bo, d1, b1,N(a,t))




(do, d1, bo, b1,z)(i’)
Is H small enough?
Model calibrated
YESNO
Figure 3.3: Schematic representation of the calibration algorithm.
3.2.9 Model states and parameters summary
In this section, we summarize all the dynamical states and parameters






S(a, t) Susceptible (not previously exposed to infection) individuals
Ls(a, t) Infected individuals (slow latency)
Lf (a, t) Infected individuals who will develop fast progression
Dp+(a, t) Untreated sick individuals: Smear positive pulmonar disease
Dp−(a, t) Untreated sick individuals: Smear negative pulmonar disease
Dnp(a, t) Untreated sick individuals: non pulmonar disease
Tp+(a, t) Sick individuals under treatment: Smear positive pulmonar
disease
Tp−(a, t) Sick individuals under treatment: Smear negative pulmonar
disease
Tnp(a, t) Sick individuals under treatment: non pulmonar disease
F (a, t) Patients who faultily finished their treatment.
Rp+S(a, t) Patients of smear positive pulmonary TB who successfully
finished their treatment.
Rp+D(a, t) Patients of smear positive pulmonary TB who defaulted their
treatment by two consecutive months or more.
Rp+N(a, t) Patients of smear positive pulmonary TB that naturally re-
covered –without treatment– from the disease.
Rp−S(a, t) Patients of smear negative pulmonary TB who successfully
finished their treatment.
Rp−D(a, t) Patients of smear negative pulmonary TB who defaulted their
treatment by two consecutive months or more.
Rp−N(a, t) Patients of smear negative pulmonary TB that naturally re-
covered –without treatment– from the disease.
RnpS(a, t) Patients of non pulmonary TB who successfully finished their
treatment.
RnpD(a, t) Patients of non pulmonary TB who defaulted their treatment
by two consecutive months or more.
RnpN(a, t) Patients of non pulmonary TB that naturally recovered –
without treatment– from the disease.
N(a, t) Total number of individuals in age group a
I(a, t) Accumulated number of TB cases in age group a from the
beginning of the period.
M(a, t) Accumulated number of TB deaths in age group a from the
beginning of the period.
Table 3.6: Description of the different dynamic states.
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3.2.9.2 Literature-based epidemiological parameters
Meaning Parameter Value C.I. Reference
Probability of fast
progression p(a)
(a = 0) 0.187 (0.1474,0.2333) Marais et
al.53, this
work
(a = 1) 0.0225 (0.0200,0.0250)
(a > 1) 0.15 (0.10,0.20)
Rate of fast progres-
sion (y−1)
ωf 0.900 (0.765,1.035) Abu-Raddad
et al.55
Rate of slow progres-
sion (y−1)




(a < 3) 0.100 (0.085,0.115) Abu-Raddad
et al.55(a ≥ 3) 0.500 (0.425,0.575)
Probability of non-
pulmonary disease ρnp(a)
(a < 3) 0.250 (0.2125,0.2875) Abu-Raddad














µnp 0.100 (0.085,0.115) Abu-Raddad
et al.55
Reduction of infec-
tion risk for previ-
ously infected indi-
viduals








θ 0.015 (0.007,0.020) Dye et al.108




rS 9.392×10−4 (6.364,12.450)×10−4 Korenromp
et al.62, this
work
Table 3.7: Bibliography-based epidemiological parameters (part I).
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Relapse rate for nat-
urally recovered indi-
viduals (y−1)
rN 0.030 (0.020,0.040) Dye et al.108
Natural recovery
rate (y−1)
ν 0.100 (0.085,0.115) Dye et al.108
Infectiousness reduc-
tion coefficient of
Dp− with respect to
Dp+






φD 0.500 (0.250,0.750) Dye et al.108
Proportion of moth-
ers that infect their
newborn children
mc 0.15 (0.10,0.20) Pillay et
al.158
Diagnosis rate reduction
of Dp− and Dnp with re-
spect to Dp+
η
Africa: 0.843 (0.664,1.022) Abu-Raddad
et al.55 , this
workAsia: 0.797 (0.628,0.966)
Table 3.8: Bibliography-based epidemiological parameters (part II).
In tables 3.7 and 3.8 we represent the 19 epidemiological parameters used
in the model, along with the eventual dependencies each of them show (to
age, geographic setting, or none), the bibliographic source and the section of
the appendix where the meaning of each parameter is explained.
3.2.9.3 Treatment outcomes probabilities
The probabilities of individuals to end their treatment according the four
categories defined by the WHO (success, default, failure or death), defined
as:




µ ): fraction of default, failure and death outcomes for
smear positive pulmonary TB.149
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µ ): fraction of default, failure and death outcomes for
smear negative pulmonary and non pulmonary TB.149
have been obtained from the WHO Treatment Outcomes database for
each country, and their values in Ethiopia, Nigeria, India e Indonesia are
presented in table 3.9:
Parameter Ethiopia Nigeria India Indonesia Reference Section
fp+D (%) 3.84 (3.74,3.94) 8.51 (8.36,8.66) 5.97 (5.95,6.00) 4.62 (4.58,4.66) WHO Database
149 3.2.1.5
fp+F (%) 1.04 (0.99,1.10) 1.23 (1.16,1.29) 2.07 (2.05,2.08) 0.62 (0.61,0.64) WHO Database
149 3.2.1.5
fp+µ (%) 3.97 (3.87,4.08) 5.64 (5.51,5.76) 4.48 (4.46,4.51) 2.31 (2.28,2.34) WHO Database149 3.2.1.5
fp−D (%) 3.28 (3.22,3.35) 6.58 (6.43,6.72) 6.11 (6.09,6.13) 7.18 (7.12,7.24) WHO Database
149 3.2.1.5
fp−F (%) 0.12 (0.11,0.13) 0.24 (0.21,0.27) 0.42 (0.41,0.43) 0.27 (0.26,0.28) WHO Database
149 3.2.1.5
fp−µ (%) 3.53 (3.46,3.59) 6.27 (6.13,6.41) 3.11 (3.09,3.13) 1.98 (1.94,2.01) WHO Database149 3.2.1.5
Table 3.9: Treatment outcomes probabilities in Ethiopia, Nigeria, India
and Indonesia.
3.2.9.4 Initial conditions and fitted parameters (Diagnosis rate,
and scaled infectiousness)
Once all the mentioned parameters are fixed, we obtain the time-evolving
parameterization of diagnosis rates and infectiousness as the result of the
calibration procedure explained in section 3.2.8, along with the initial con-
ditions of the system in each country. These temporal evolutions are de-
rived from equations 3.42 and 3.43, while the fitted values of the parameters
(do, d1, βo, β1) are reported in table 3.10 for Ethiopia, Nigeria, India and In-
donesia. Confidence Intervals are obtained through the procedure explained


















Ethiopia 0.19 (0.15,0.25) 4.75 (3.94,5.64) 7.10 (4.57,10.90) 73.84 (20.62,103.83) 0.16 (0.16,0.25)
Nigeria 0.045 (0.003,0.088) 0.36 (0.30,0.43) 5.30 (3.36,8.03) 3.71 (-3.93,11.15) -0.29 (-0.53,-0.02)
India 0.51 (0.12,1.06) 2.98 (1.80,4.26) 10.12 (5.10,16.99) -1.20 (-12.01,9.19) -0.30 (-0.44,-0.15)
Indonesia 1.53 (1.31,1.80) -7.60 (-20.99,-0.42) 16.25 (10.82,25.59) -12.73 (-17.73,-8.97) 0.05 (0.04,0.07)
Table 3.10: Fitted parameters for different countries.
In figure 3.4 we represent the evolution of d(t) in these countries, which
describes the average rate at which sick individuals receive their diagnosis
in each country and time. The scaled infectiousness β(t) has a less immedi-
ate epidemiological interpretation, for it is only directly proportional to the
88
3.2. MODEL
number of infections R̃0, that is caused, on average, by each infectious agent,
which also depends on the distribution of individuals among the different in-
fectious classes and age groups. This magnitude (which reduces to the basic
reproductive number R0 when evaluated on a fully susceptible population)
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Figure 3.4: Evolution of β(t) and R̃0(t). (Top) Diagnosis rates for smear-
positive individuals (in years−1). (Bottom) Average number of secondary
infections per infectious agent R̃0. The red curve shows the result given by
the central fit, while the shadowed area represents the uncertainty obtained
as described in section 3.2.10
We found very variable values of the diagnosis rates across the different
countries. This is not unexpected, as the diagnosis time depends mostly on
the quality of the Health System, for which we can find huge inequalities be-
tween countries. We will provide a more complete study of these inequalities
and how they are captured by the model in section 3.3.5.2.
The number of secondary infections per incident case does not show the
same variability. The values for R̃0 lie between 5 and 12 secondary cases
for the 4 countries analyzed during the entire window. These values are
compatible with previous studies.161
3.2.9.5 Fitted parameters in the reduced models
In table 3.11, we present the fitted parameters for the two reduced models
in India, Indonesia, Nigeria and Ethiopia, compared to the values from the
full model (already reported in 3.10).
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Complete Model 0.19 (0.15,0.25) 4.75 (3.94,5.64) 7.10 (4.57,10.90) 73.84 (20.62,103.83) 0.16 (0.16,0.25)
Constant Demography 0.22 (0.16,0.27) 4.40 (3.68,5.24) 7.22 (4.64,11.02) 70.97 (28.80,91.43) 0.21 (0.05,0.31)
Homogeneous Mixing 0.19 (0.15,0.25) 4.56 (3.80,5.36) 7.18 (5.12,10.73) 80.78 (36.04,110.66) 0.23 (0.09,0.34)
Nigeria
Complete Model 0.045 (0.003,0.088) 0.36 (0.30,0.43) 5.30 (3.36,8.03) 3.71 (-3.93,11.15) -0.29 (-0.53,-0.02)
Constant Demography 0.046 (0.004,0.090) 0.37 (0.31,0.43) 5.30 (3.35,8.04) 2.71 (-3.67,9.85) -0.27 (-0.52,-0.01)
Homogeneous Mixing 0.038 (0.003,0.080) 0.35 (0.14,0.40) 5.52 (3.81,8.15) 2.91 (0.33,10.50) -0.36 (-0.46,0.10)
India
Complete Model 0.51 (0.12,1.06) 2.98 (1.80,4.26) 10.12 (5.10,16.99) -1.20 (-12.01,9.19) -0.30 (-0.44,-0.15)
Constant Demography 0.51 (0.13,1.04) 2.66 (1.51,4.05) 10.07 (5.12,16.78) 6.16 (-0.39,12.97) -0.25 (-0.37,-0.10)
Homogeneous Mixing 0.51 (0.12,1.06) 2.94 (1.83,4.18) 9.12 (4.55,15.20) -1.04 (-11.38,11.52) -0.30 (-0.45,-0.15)
Indonesia
Complete Model 1.53 (1.31,1.80) -7.60 (-20.99,-0.42) 16.25 (10.82,25.59) -12.73 (-17.73,-8.97) 0.05 (0.04,0.07)
Constant Demography 1.53 (1.31,1.80) -8.71 (-22.14,-1.40) 16.14 (10.74,25.42) -7.51 (-11.74,-4.83) 0.08 (0.06,0.11)
Homogeneous Mixing 1.53 (1.31,1.80) -8.09 (-21.64,-0.84) 14.68 (9.63,23.38) -12.20 (-16.72,-9.07) 0.06 (0.05,0.08)
Table 3.11: Fitted parameters for different countries and models.
3.2.10 Model uncertainty and sensitivity analysis
All the input data sources mentioned in the previous section, and sum-
marized in Figure 3.1D, carry intrinsic uncertainties whose influence on both
fitted parameters and forecasts has to be evaluated. To this end, we have
performed exhaustive uncertainty and sensitivity analyses that allow us to
generate confidence intervals for model outcomes, produce significance esti-
mates (i.e. p-values) as well as to evaluate the part of this uncertainty that
is propagated from each of the model inputs.
3.2.10.1 Uncertainty sources analysis
We consider four main different types of inputs, which are associated
to independent uncertainty sources for the sake of sensitivity/uncertainty
analysis:
• Parameters associated with the Natural History of the disease: a total
amount of 19 parameters, listed in table 3.7, each of them conservatively
treated as totally independent uncertainty sources ui, i ∈ [1, 19].
• Burden and treatment outcomes estimations provided by WHO, listed
in table 3.9. Based upon a number of case notifications and treatment
outcomes of finite cohorts surveilled in each country, the World Health
Organization provides estimations for incidence and mortality rates ī(t)









µ ). For the purpose of the model, we have grouped these
estimations produced by the WHO TB division as mutually depen-




• Demographic structures N(a, t): which are also considered as a single
uncertainty source, labeled as u21.
• Contact matrix M ca,a′(t), whose uncertainty comes from the variability
between studies, is the last single uncertainty source u22.
By proceeding in this way, we have 22 uncertainty sources ui, i ∈ [1, 22]
that are considered independent, whose contributions to the uncertainty of
a certain model outcome x we want to evaluate. Here, a model outcome can
be any possible magnitude that derives from the entire calibration-simulation
procedure, as summarized in figure 3.1D. This includes, among others, in-
cidence and mortality rates evaluated at any time (or averaged during the
entire period), total accumulated number of incident cases or deaths, values
for the parameters fitted during the calibration step, and importantly, differ-
ences between the full and the reduced models, either absolute or relative, of
any of these primary outcomes. Future chapters will include other epidemio-
logical forecasts obtained with this model, such as different measurments of
the impact of a vaccine, that will follow the same uncertainty analysis.
The entire model-based calibration + simulation procedure, summarized
in figure 3.1D, can be expressed, for what regards the estimation of any
generic model outcome x, as a generic functional relationship x = f(~u),
where ~u represents the 22-dimensional vector of uncertainty sources (i.e., in-
put data).
Altogether, the computation of model sensitivity to singular input uncer-
tainty sources and its grouping into overall model uncertainty can be sum-
marized according to the following steps:
Estimation of singular sensitivities of model outcome x to individ-
ual variations in uncertainty source ui (Sensitivity analysis). First,
given a generic model outcome x, its sensitivity to a given uncertainty source
u(i) with a 95% confidence interval equal to (ulowi ,u
high
i ) is defined as its varia-
tion in response to a deviation in u(i) towards the lower limit of its confidence
interval:
dlowi (x) = x(u1, ..., u
low
i , ..., u21)− x(~u) (3.48)
or towards the upper limit:
dhighi (x) = x(u1, ..., u
high
i , ..., u21)− x(~u) (3.49)
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Importantly, since the variation in ui that precedes the estimation of
dlowi (x) and d
high
i (x) occurs before model calibration, we are capturing, through
this approach, the sensitivity of the entire procedure -calibration included- to
the uncertainty input ui, which implies that the signs of dlowi (x) and d
high
i (x)
cannot be trivially anticipated and can also coincide, as we see, in some
cases, in figure 3.14. In that figure, we use red (blue) bars to represent the
variations in the total number of TB cases/deaths that the model produces
in 2000-2050 as a consequence of increasing (decreasing) the value of each
uncertainty source to the upper (lower) limit of its respective confidence in-
tervals.
Furthermore, it is important to note that some uncertainty sources re-
port several parameters (not just one) whose confidence intervals plausibly
carry strong correlations. That is the case of the age dependent parame-
ters, multi-dimensional demographic structures and contact matrices, as well
as the WHO estimations, which comprise several measurements of different
nature (treatment outcomes fractions, mortalities and incidence rates). In
these cases, where single uncertainty sources ui consist of multi-dimensional
correlated data, the sensitivity terms dlowi (x) and d
high
i (x) are calculated upon
variation of all the components of ui to the limits of their confidence intervals
as a block.
Grouping individual sensitivities according type of input data. Gen-
eration of confidence intervals and significance levels (Uncertainty
analysis). Once the individual sensitivity of all the n=22 sources of uncer-
tainty are computed following the approach explained in the previous section,
for the case of the 19 bibliographical parameters we separate positive versus
negative sensitivities (i.e. sensitivity instances where the shift in the uncer-
tainty source translates into an increase or a decrease in the model outcome),
represented as red vs. blue bars in figure 3.14. Then, the square root of the
sum of the squares of each type (positive and negative sensitivities) are com-
puted. Denoted as ∆(x)highparam and ∆(x)lowparam, respectively, these quantities
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h(−dlowi (x)) · dlowi (x)2 + h(−d
high




where h stands for the Heaviside function (i.e. h(x) = 1 when x > 0
and 0 otherwise). The properties of this function ensure that only positive
di terms contribute to ∆(x)highparam (regardless of whether they come from an
increase dhighi or a decrease dlowi in the uncertainty source), and, at the same
time, that only negative di terms contribute to ∆(x)lowparam.
In a similar way, we can isolate the contribution to the model uncertainty
of the other uncertainty sources. For the uncertainty coming from WHO
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For the demographic prospects (u21):
∆(x)highdemo =
√
h(dlow21 (x)) · dlow21 (x)2 + h(d
high






h(−dlow21 (x)) · dlow21 (x)2 + h(−d
high




And, finally, for the contact matrices (u22):
∆(x)highcont. =
√
h(dlow22 (x)) · dlow22 (x)2 + h(d
high






h(−dlow22 (x)) · dlow22 (x)2 + h(−d
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Throughout this work, coloured areas around curves, error bars or any
Confidence Interval referred to an outcome of the model is calculated by
















In figure 3.5, and figure 3.9, in order to visualize the relative fraction of
the total uncertainty that is due to the different 4 main uncertainty sources,
we linearly weight the uncertainty error bar as follows:
























































The global uncertainty ranges so obtained (x−∆(x)low, x+∆(x)high), be-
ing propagated from 95% confidence intervals from the different uncertainty
sources, are subsequently interpreted as 95% confidence intervals for model
outcome x. When this outcome is a difference between the full and the re-
duced models, its significance level is estimated assuming that the outcome
follows a normal distribution centered in x, with the confidence interval width
∆(x)low (or ∆(x)high, should x be negative) defining the standard deviation
(∆(x)low = 1.96σ).
In this section we summarize the structure and origin of different pieces
of data used in this work. A scheme on how these data are included in the
model can be found in Figure 3.1D
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• Annual rates of incidence and mortality from 2000 to 2015 for the
different countries studied. WHO TB burden estimates database.149
These data are used to calibrate, for each country independently, the
scaled infectiousness (β0, β1), diagnosis rate (d0,d1) and initial distance
to stationarity ς.
• Treatment outcomes for the different countries. WHO TB treatment









µ (fraction of individuals experimenting the different
possible treatment outcomes)
• Population of each age group and country from 2000 to 2050. UN popu-
lation division database.138 From this data we extract the demographic
structures that populations are forced to follow as explained in section
3.2.5
• Age contact patterns from different experimental settings.25,130,133,134,137?
Used to construct the contact rates between age groups (see sections
3.2.2 and 3.2.3).
• Different bibliographical sources,55,62,108,154,156 from which we extract
values for 19 epidemiological parameters (see tables 3.7 and 3.8 ).
3.3 Results
3.3.1 Baseline forecasts of TB incidence and mortality
To illustrate the ability of the method to reproduce current epidemic
trends in different scenarios, the model was applied to describe the TB epi-
demics in India, Indonesia, Nigeria and Ethiopia (Figure 3.5). These coun-
tries, which accumulate as much as ∼40% of the total TB burden world-wide
in 2015, were selected because of their different temporal evolution trends,
current and prospected demographic profiles and geographic locations. Re-
markably, the model does not predict, in general, a sustained decrease in TB
burden for the decades to come in these cases, whose incidence rates (per mil-
lion habitants and year) range between 1246 (524-2124 95% C.I.) (Ethiopia)
and 3669 (2348-5247 95% C.I.) (Indonesia), in 2050.
Regarding confidence intervals, colored areas in Figure 3.5 quantify the
contribution to global uncertainty that stem from the different types of in-
put data processed by the model. This includes epidemiological parameters
(purple), demographic data (orange), contact patterns (green), and, most
95
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Figure 3.5: Fitting and prediction in Ethiopia, Nigeria, India and
Indonesia. Population structure at 2000 and 2050 (projection), and annual
incidence and mortality rates predicted by the model in 2000-2050. Coloured
areas represent 95% confidence intervals. The contribution to overall uncer-




importantly, WHO-burden estimations (blue). Complementarily, in section
3.3.6, the individual contribution of each epidemiological parameter is further
disclosed in an exhaustive sensitivity analysis. Of all the different individ-
ual sources of uncertainty that are susceptible to impact model’s forecasts,
current WHO estimates for TB burden levels is the only one that introduces
more than a 15% deviation with respect to central estimates (the uncertain-
ties in total number of TB cases prospected in 2000-2050 that are propagated
from WHO-data span from 36% (Ethiopia, lower limit) to 92% (Nigeria, up-
per limit) with respect to central expectations).
3.3.2 Effects of populations aging on aggregated TB
forecasts
All countries analyzed in this work are experiencing population aging to
some extent, consistent with the overall trend that is forecasted for global
human populations during the same period.138 The four countries selected in
Figure 3.5 lie at different points of the demographic transition by the begin-
ning of the period under analysis (year 2000), and are expected to evolve at
different paces into more or less aged populations by 2050.
In order to isolate the influence of populations aging on model outcomes,
we compared the model with a simplified version where demography evolu-
tion is neglected as done in previous approaches55,101,108 (reduced model 1,
RM1). In this reduced model the demographic structures are taken from
their initial configuration in 2000 and remain static until 2050. The results
shows that the demographic evolution leads to a systematic and significant
increase in the prospected incidence rates, which is variable in size across
countries (Figure 3.6A: relative increase in incidence in 2050: full vs reduced
model 1: India: 39.6% (13.9-63.6 95% C.I.), Indonesia 23.4% (7.9-36.5 95%
C.I.), Ethiopia 56.0% (29.2-62.1 95% C.I.), Nigeria 34.5 % (9.1-42.9 95%
C.I), see also Figure 3.9, 3.11 and table 3.13 for equivalent results in other
countries). Furthermore, the relative variation between incidence forecasts
obtained from the full and the reduced model by 2050 significantly correlates
with the intensity of the aging shift, as given by the change in the frac-
tion of adults (age>15 years) in 2000-2050 (Figure 3.6B, Pearson correlation
r=0.66, p=0.02). This is indeed a natural consequence, since adults are bur-
dened with higher incidence rates than children, and thus, populations’ aging
implies a relative increase of the demographic strata that is most affected by
the disease (adults), in detriment of children, among whom TB incidence is
lower (Figure 3.6C).
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Figure 3.6: Effects of demographic dynamics on model forecasts.
(A): Incidence rates from 2000 to 2050 obtained from the full model (red)
and reduced model 1 (constant demography, blue). (B): Relative variation of
aggregated incidence at 2050 for the top 12 countries with highest absolute
TB burden in 2015 versus variation in the fraction of adults in the population
during the period 2000-2050. In all countries but Tanzania and Philippines,
in grey in the figure, the variations in incidence are significant at a nom-
inal p=0.05. (C): Age specific average incidence rate of TB vs. variation
of age-strata population density in 2000-2050. (D): Incidence projections
for synthetic scenarios of demographic evolution. In each panel, the demo-
graphic evolution of each country is substituted by these synthetic scenarios:
demographic transitions that go from stage iii in 2000 to different ending
points in 2050. Colors in incidence series correspond to those in the arrows
below, indicating the respective demographic transitions. Model calibration
is repeated in each case.
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Next, we built a series of synthetic demographic evolutions to simulate
different scenarios (Figure 3.6D). To this end, we used three pivotal examples
extracted from actual cases of populations featuring young, triangular demo-
graphic pyramids (Figure 3.6D, stage i, extracted from Ethiopia in 2000),
aged, inverted-pyramids (stage v, extracted from China, 2050); as well as
intermediate situations (stage iii, extracted from Indonesia, 2000, and stages
ii and iv, built upon linear interpolation). Making use of these pivotal pop-
ulations, we built synthetic transitions among them occurring in the period
2000-2050, which we then integrate in the TB model, in the four countries
analyzed, instead of their own real demographic projections. As we can see
in Figure 3.6D, population aging appears associated to increased incidence
rates, while eventual transitions towards younger populations would cause
incidence forecasts to decline faster.
These results show that ignoring the populations aging within TB spread-
ing models generates forecasts of aggregated burden that are systematically
and significantly lower than those obtained when this ingredient is taken into
account.
3.3.3 Effects of aging on age-specific burden levels
Next, we interrogated whether the effect of aging on TB burden estimates
is only due to a relative increase of the age-strata more hit by the disease
(i.e. adults), or if, in turn, significant increases in the incidence rates within
age groups can be identified.
In Figure 3.7, we show, for one example per continent –India and Ethiopia–
, the infection matrices between age groups as described by each model, and
their difference. The entry (a, a′) of these matrices represents the prospected
number of infections (in 2050) from age-group a (infection source) to a′ (in-
fection target) per year per million people in group a′. For both countries, the
differences between full and reduced model 1 point to a systematic under-
estimation of the number of infection events caused by adults as a conse-
quence of ignoring demographic dynamics, as well as an over-estimation –
only appreciable in India–, of infections caused by children during the period
under analysis. Furthermore, once contagions are aggregated across infection
sources within each target age-group (Figure 3.7, age-specific infection rates
histograms, built as column-wise marginal sums of the infection matrices),
significant differences between age-specific infection rates arise in both coun-
tries, mainly in adult age strata, where the full model predicts systematically
larger incidence levels than the reduced model 1.
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Figure 3.7: Effect of demographic aging on age-specific TB burden.
Age-to-age infection rate matrices (number of infections from age group a to
age group a’ per year per million people in target age-group a’); and age-
specific infection and incidence rates forecasted in 2050 for India and Ethiopia
(number of contagions, or new active TB cases, respectively) per year and
million individuals in a give age-group) for full model and reduced model
1. In the left column, the forecasts derive from the full model, and, in the
central column, from reduced model 1 (constant demography). In the right
column we represent the difference (full - reduced model 1) of these three
observables: infection matrices, age-specific infection rates and age-specific
incidence rates. Differences in incidence and infection rates are shown in grey
when they are not statistically significant.
This ultimately translates into an increase in age-specific incidence rates
of active TB cases (Figure 3.7, age-specific incidence histograms), which can
be easily interpreted attending to the larger probabilities of developing the
most infectious forms of pulmonary TB that adults experiment with respect
to children55. Adults, whose proportion increases in the system as a result
of considering populations’ aging, not only constitute the part of the demo-
graphic pyramid most hit by the disease, but also the one that contributes
the most to overall spreading. Therefore, including populations’ aging on
model dynamics causes not just an increase in the aggregated burden levels
across all age-groups, but also within age-strata.
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3.3.4 Effect of contact patterns heterogeneities
After discussing the impact that demographic dynamics has on model
outcomes, we inspected what are the effects of including contact patterns
in the TB model forecasts, either at the level of aggregated rates or within
age-specific strata. To do so, we have built a second reduced model where
the empirical contact matrices estimated from survey studies conducted in
Africa and Asia130,133,134,136,137 are substituted by the classical hypothesis of
contacts homogeneity (reduced model 2).
In Figure 3.8, we represent the infection matrices that derive from the
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Full Model Difference (Full-Reduced)Reduced Model 2
Figure 3.8: Effect of heterogeneous contact patterns on age-specific
TB burden. Age-to-age infection rate matrices, and age-specific infection
and incidence rates forecasted in 2050 for India and Ethiopia, from full (left)
and reduced model 2 (center); with the difference (full - reduced model 2)
in the right column in each case. Differences in incidence and infection rates
are shown in grey when they are not statistically significant, otherwise they
have the color associated to the model for which the rate is higher.
Clearly, empirical contact patterns reshape the distribution of contagions
among age-groups, giving a larger importance to assortative infections that
take place among individuals of similar ages –specially between adolescents
and young adults–, while penalizing infections from children to adults, or
vice-versa. As a result, in this case, the infection and incidence rates of TB
among children are higher in the reduced model, while the full model pre-
dicts more infection and disease burden among adults, with slight variations
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between the two countries that are due to the different contact data used
in each case in the full model. In all the countries analyzed, the opposite
directions of the differences between full and reduced model that are found
in children versus adults tend to compensate each other. This results into
similar global incidence rates produced by both models (see section 3.3.5, fig
3.12).
Summarizing this part, and despite the reduced effect observed on aggre-
gated rates, we showed that including empirical contact structures on TB
model dynamics reshapes the transmission patterns among age groups, and
generates significant differences in age specific infection and incidence rates.
3.3.5 Complementary results and further analyses
3.3.5.1 Fit and forecast for the top 12 countries with highest ab-
solute TB burden
In previous sections we have performed the majority of the analyses in
India, Indonesia, Nigeria and Ethiopia, which were selected for their differ-
ent initial age-structures, TB burden trends and demographic shifts. Now
we extend the analyses to the 12 countries affected by highest absolute TB
burden levels in 2015 (values of fitting rest in table 3.12 and predictions of
incidence and mortality in figure 3.9).
In all these countries, except China and Philippines, the rest represents
the residual sum of squares normalized by the input data uncertainty of each
measure. In the last two examples, where confidence interval limits coincide
with central estimates in some cases, we normalized the squared residuals by
the average incidence and mortality rates, respectively (see section 3.2.8 for
further details). In Figure 3.9 we see that the model is able to reproduce
satisfactorily the observed trends in 2000-2015 in all cases.
For a better understanding of the quality of the fit we also show the av-
erage relative difference between the data points and the outcomes obtained
with the model once fitted during the fitting window. However, notice that
this is not the magnitude that we optimize during the calibration process, it
only gives an interpretation of the agreement with the data.
From Figure 3.9 we see that, in general, incidence and mortality forecasts
from the reduced model 1 are systematically lower than those obtained when
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Figure 3.9: Incidence and Mortality for top 12 countries with most
TB cases Demographic pyramids in 2000 and 2050, and incidence and mor-
tality projections (2000-2050) for the 12 countries with the largest number
of incident cases in 2015.
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South Africa 0.790 4.95
Bangladesh 0.201 3.65






Table 3.12: Values of fitting error H. Values of the rest H and relative
error for the fit (averaged in the fitting window) for the countries fitted in
this work. For the ten first countries, the rest is defined as the sum of the
squared deviations between model and data, normalized by the uncertainty
of input data in each case (see equation 3.44). In China and Philippines
(∗, see equation 3.47) the normalization factors are set up as the average
incidence and mortality during the training period, thus their H values are
not in the same scale of the rest of the countries. Further details are provided
in section 3.2.8
3.3.5.2 Case Notifications
The Case Notification Ratio (CNR), i.e., the fraction of all incident cases
that a particular Health System detects and notifies to the WHO-surveillance
systems each year, is a fundamental magnitude in the surveillance and con-
trol of TB. As a means of validating the model and its calibration procedure,
we interrogated whether CNR values reported by the WHO in each country
correlate to model-based Treatment coverage ratios, (defined as the fraction
of incident cases per year that get diagnosed) despite the fact that these
magnitudes are not considered or compared during the calibration step. In
figure 3.10 we represent the results of this comparison in 2015, where we see
that model-based treatment coverage fractions are strikingly correlated to
CNR values reported by WHO across countries (Pearson correlation exclud-
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Figure 3.10: Treatment coverage and Case Notification Rates. Treat-
ment coverage and associated uncertainty obtained with the model (red sym-
bols) and Case Notification Rates, with their correspondent Confidence In-
tervals, extracted from WHO data (grey) in 2015.
Importantly, we find that treatment coverage is slightly higher than the
CNR in every country, which can be interpreted in terms of under-reporting
of diagnosed cases. The CNR and model-based Treatment Coverage ratios
are closely related, but not fully equivalent, since a fraction of the total
TB cases that a country detects and treats each year goes undetected to the
WHO surveillance systems, despite TB notification being mandatory in most
of the countries analyzed. An exception is found in Indonesia, not included
in the figure, where the model predicts a Treatment coverage that is much
higher than the CNR (Treatment coverage: 81.5% (CI: 78.3-83.7), CNR: 33%
(CI: 23-50)). Precisely in Indonesia, previous studies have pointed out the
presence of significant levels of TB under-reporting to the WHO surveillance
systems162, partly related to the fact that in this country the notification of
TB cases is not mandatory.
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3.3.5.3 Relative Differences between Full Model and Reduced Model
1
We have compared the incidence and mortality rates predicted by the
full model, (i.e., considering demographic changes), and the reduced model
1 (for which the demographic pyramid is considered constant in time), but
it remains pendant to stablish whether the difference between forecasts from
the full and the reduced model are statistically significant or if, instead, their
uncertainty may be larger than its magnitude. To shed light on this ques-
tion, in figure 3.11 we represent, for the twelve countries analyzed, the time
evolution of the relative differences between the incidence rates that each
model produces, alongside the correspondent uncertainty intervals, obtained
as detailed in section 3.2.10.1.
As we can see in Figure 3.11, differences between the full model and the
reduced model 1 become significant in most countries, often right after the
end of the fitting window (2015). In Table 3.13 we register the relative differ-
ence between the incidence rates in 2050 as derived from each model, along-
side the corresponding 95% confidence intervals and the significance levels.
By 2050, differences between models become statistically significant (at 99%
significance level) for all countries except two: Philippines and Tanzania.
Country Relative Difference (%) Signifcance level
India 39.6 (13.9-63.6) ∗∗
Indonesia 23.4 (7.9-36.5) ∗∗
China 41.9 (14.7-81.1) ∗∗
Nigeria 34.5 (9.1-42.9) ∗∗
Pakistan 61.0 (36.4-71.8) ∗ ∗ ∗
South Africa 33.7 (13.5-40.8) ∗ ∗ ∗
Bangladesh 62.5 (51.1-71.4) ∗ ∗ ∗
Philippines 16.8 (-15.5-74.4) −
Dem. Rep. Congo 37.3 (16.0-47.5) ∗ ∗ ∗
Ethiopia 56.0 (29.2-62.1) ∗ ∗ ∗
Myanmar 50.3 (39.5-69.5) ∗ ∗ ∗
Tanzania 7.4 (-34.1-108.0) −
Table 3.13: Relative difference in the incidence rate in 2050 between
full and reduced model 1 for the 12 countries with more TB cases in 2015.























































































































































































Figure 3.11: Relative differences between the full model and the re-
duced model 1, in terms of the incidence rate in the 12 countries considered.
3.3.5.4 Effect of Contact Patterns at the aggregated level
Previously, we have shown that the assumption of homogeneous mixing
overestimates the burden of TB in children, and underestimates it among
adults. These opposite effects largely cancel each other, which makes the
total effect to shrink when considering the aggregated burden across ages. In
figure 3.12 we represent the forecasts of incidence and mortality for the mod-
els with heterogeneous and homogeneous mixing patterns (full vs. reduced
model 2).
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 2000  2010  2020  2030  2040  2050
Year
Ethiopia Nigeria India Indonesia
Reduced Model 2 (homogeneous contacts)Full Model
Figure 3.12: Effect of contact patterns at the aggregated level. Pre-
dictions of incidence and mortality rates for full (red) versus reduced model
2 (violet) in Ethiopia, Nigeria, India and Indonesia
As detailed in Table 3.14, the usage of empiric contact patterns translates
into slightly larger burden rates (relative differences around 10% between the
full and the reduced model 2 in 2050). These modest differences are still sig-
nificant in Ethiopia, India and Indonesia, despite their relatively small values
when compared to the magnitude of forecasts’ uncertainty. This is not an
anomalous behavior, since outcomes from the full and the reduced model are
strongly dependent variables, and the uncertainty is propagated to them in
a paired fashion (i.e., the same sources of uncertainty affect both models si-
multaneously), which is considered when comparing results from model pairs.
This allows us to detect significance differences between model behaviors of
lower effect sizes than the characteristic uncertainty of each independent
model alone.
Country Relative Difference in incidence (2050) (%) Significance level
Ethiopia 11.1 (7.8-16.6) ∗ ∗ ∗
Nigeria 10.5 (-136-11.7) −
India 11.1 (2.0-16.6) ∗
Indonesia 9.1 (2.6 - 15.1) ∗∗
Table 3.14: Relative difference in the incidence rate in 2050 between
full and reduced model 2 in Ethiopia, Nigeria, India and Indonesia. Sig-
nificance levels: −: not significant, ∗:95%, ∗∗:99%, ∗ ∗ ∗:99.9%.
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3.3.5.5 Effect of Contact Patterns on TB burden distribution across
age
We have discussed how the usage of empiric contact patterns (in opposi-
tion to the assumption of homogeneous mixing) can change the distribution
of TB burden among the different age groups. Regarding this result, it is
relevant to note that the contact structures tested in Asian and African coun-
tries differ, and thus, a subsequent question is whether or not these empiric














































































































































































































































































































































































































































































































































































Higher in AfricaHigher in Asia
Higher in AsiaHigher in Europe


























































Figure 3.13: Effect of contact patterns switching on TB burden dis-
tribution across age (A): Matrix of infection rates, and age-specific rates of
infection and incidence (averaged during the period 2000-2050) correspond-
ing to the use of different contact patterns (African, Asian and European) in
Ethiopia. (B): Pairwise differences. Non-significant differences in infection
and incidence rates are represented in grey, otherwise they are coloured as
the predominant contact pattern.
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To answer this question in one particular example, we have chosen one
of the countries analyzed, and generated forecasts based on simulations per-
formed using contacts derived from African surveys data (i.e. the default),
as well as Asian, and European contact structures.
The results of these tests, where the average incidence rate during the
period (2000-2050) is reported for each case, are represented in figure 3.13.
In the figure, upon pair-wise comparison between the forecasts associated
to each contact matrix, we see that African contacts lead to higher burden
among the eldest age-groups, while the European contact patterns tend to
induce more infections and TB cases among younger individuals and the
matrix used in Asian countries represents an intermediate situation.
3.3.6 Sensitivity analysis
In figure 3.5, as in figure 3.9, the contribution to overall uncertainty of
each type of input data is disclosed: epidemiological parameters (purple),
contact matrices (green), demographic prospects (orange) and WHO burden
estimates (blue). In figure 3.14, the contribution of the uncertainty derived
from each single epidemiological parameter is further shown.
We see that WHO burden estimates are responsible for most of the un-
certainty holding relative differences with the mean value when the limits of
the confidence intervals are considered almost reaching 100% in some par-
ticular settings (Nigeria, upper bound). The second source of uncertainty
that produces more variability in these forecasts corresponds to the demo-
graphic projections, with a relative difference with the mean value between
5-10% when the upper or lower limits of the demographic projections are
considered. This result is coherent with what we have discussed earlier: the
inclusion of demographic evolution significantly changes the predicted inci-
dence and mortality rates. As for the rest of uncertainty sources (epidemio-
logical parameters and contact matrices), their influence in the uncertainty
are significantly smaller. Only in some exceptional cases we find parameters
producing a relative difference with the mean value surpassing 5%, and in
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Figure 3.14: Sensitivity Analysis in India, Indonesia, Nigeria and Ethiopia.
Red (blue) bars represent the variations in total number of TB cases/deaths
that the model produces in 2000-2050 after increasing (decreasing) the value
of each uncertainty source to the upper (lower) limit of its respective confi-
dence intervals, prior to model calibration. The bottom panels contain the
sensitivities associated to the WHO burden estimates and the demographic
projections.
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3.3.7 Robustness tests
3.3.7.1 Effect of demographic evolution
During the next section we will study how the main result of the work (i.e.,
the higher TB burden predicted as a consequence of considering demography
evolution in the model), is robust under a series of alternative modeling
scenarios
Different burden levels. All the forecasts produced in this work are based
on estimates of incidence and mortality reported by the World Health Or-
ganization. These estimates are based on a combination of epidemiological
observations and empiric criteria that are known to be affected by high levels
of uncertainty, as reflected by the large confidence intervals that these data
present in many countries, which has been taken into account and incorpo-
rated to model forecasts. However, the broad nature of these estimates often
leads to re-evaluation of methods and values reported by the WHO in their
periodic TB reports, with the result that, in some cases, the burden estimates
vary beyond the range of uncertainty initially assumed as a result of these
methodological updates. For example, the burden estimates that we use for
India turned out to be underestimated in previous publications.71
Taking it into account, the question of whether the effects of demographic
evolution are robust under wide variations in the input burden data consti-
tutes a valid concern. To show that those effects are indeed robust under a
wide range of initial burden levels, in figure 3.15 we have repeated the sim-
ulations for the full and reduced model 1 under alternative scenarios where
initial burden levels have been doubled/halved. Checking the relative dif-
ference between models in the incidence rate at 2050 (table 3.15), we see
that it remains statistically significant (p<0.05) in every case. Thus, even if
the data of incidence and mortality are not extremely reliable, and could be
proven to be biased in the future, the need to improve current models and
incorporate the evolution of demography holds as a general conclusion valid
for a wide range of initial burden levels.
Different Contact Patterns. During this work, we have implemented two
different contact matrices: one adapted from statistical surveys conducted in
Africa, and another one from Asian studies. This supposes an arguable im-
provement with respect to the assumption of contacts homogeneity, and even
with respect to using the same contact structure in all countries. However,
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Country Bias Relative Difference (%) Significance level
Ethiopia Double 52.6 (25.6-59.2) ∗ ∗ ∗Half 57.9 (31.3-63.8) ∗ ∗ ∗
Nigeria Double 31.1 (9.9-39.1) ∗∗Half 37.3 (12.8-63.4) ∗∗
India Double 39.0 (13.4-61.2) ∗∗Half 40.2 (6.5-61.0) ∗
Indonesia Double 21.1 (6.6-33.8) ∗∗Half 27.9 (11.2-41.8) ∗ ∗ ∗
Table 3.15: Relative differences for incidence rates in 2050 between
full and reduced model 1, as obtained from biased TB burden esti-
mations (WHO estimates doubled/halved with respect to reported values).























































































 2000  2010  2020  2030  2040  2050
Double
Half
Ethiopia Nigeria India Indonesia
Reduced Model 1 (constant demography)Full Model
Figure 3.15: Robustness against biased input burden estimates. Inci-
dence rate forecasts from full (red) and reduced model 1 (blue) under biased
input burden estimates (WHO estimates doubled/halved with respect to re-
ported values).
the available bibliography on empiric contact patterns is still reduced, and
we are far away from an ideal situation where empiric data of comparable
quality standards is at hand at a country-specific level. In this sense, the
question of whether the effects of demography evolution might be dependent
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or not of the specific contact structure that we use in each country is perti-
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Reduced Model 1 (constant demography)Full Model
Figure 3.16: Robustness against different contact patterns. Incidence
Rates forecasted from full (red) vs reduced model 1 (blue), for three different
contact patterns (African, Asian and European).
To this end, in figure 3.16, we show epidemic forecasts derived from the
full and the reduced model 1, under scenarios where the contact structure of
each country has been substituted by the other matrices considered across the
paper, including a contact matrix built from the European Polymod study.
Once again, we have obtained the same result: considering the evolu-
tion of demography leads to higher burden prospects, independently of the
contact pattern used in the simulations. In table 3.16 we show the relative




Contacts Country Relative difference (%) Significance level
African
Ethiopia 56 (29-62) ∗ ∗ ∗
Nigeria 35 (9-43) ∗∗
India 26 (3-53) ∗
Indonesia 15 (5-24) ∗∗
Asian
Ethiopia 65 (56-76) ∗ ∗ ∗
Nigeria 47 (33-64) ∗ ∗ ∗
India 40 (14-64) ∗∗
Indonesia 23 (8-37) ∗∗
European
Ethiopia 67 (57-77) ∗∗
Nigeria 57 (41-75) ∗ ∗ ∗
India 42 (14-61) ∗∗
Indonesia 28 (12-47) ∗ ∗ ∗
Table 3.16: Relative differences for incidence rates in 2050 between
full and reduced model 1, evaluated using different contact matri-
ces. Significance levels: −: not significant, ∗:95%, ∗∗:99%, ∗ ∗ ∗:99.9%.
Different evolution of fitted parameters. The model forecasts pre-
sented in this work are produced under the hypothesis that, after the training
period (2000-2015), the time evolution of scaled infectiousness and diagnoses
rates will still be governed by the sigmoid curves described by equations 3.42
and 3.43. However, if the pace of variation of these parameters slows down
in future years from the expected trends, the TB burden rates will increase
from the forecasts reported. To explore the behavior of the model in that
situation, and re-evaluate the difference between full and reduced model 1,
we have repeated the comparison in alternative scenarios where the pace of
variation in the fitted parameters is slowed down from 2015 a 50% and a
100% from its expected trend.
The underestimation of TB burden that stems from ignoring demographic
evolution is also robust against variations in the time-evolution of fitted pa-
rameters after 2015. In table 3.17 we show the relative difference of the
incidence rates in 2050, and we check again that these differences are signif-
icant for all alternative scenarios.
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Reduced Model 1 (constant demography)Full Model
Figure 3.17: Robustness against alternative variation rates of the
fitted parameters. Incidence Rates obtained from the full and the reduced
model 1, for 2 alternative scenarios where variation rates of the fitted param-
eters is reduced a 50% and a 100% from their expected behaviour from 2015
on.
Country Variation rate reduction Relative difference (%) Significance level
Ethiopia 50% 56.3 (28.9-62.6) ∗ ∗ ∗100% 57.1 (28.1-64.2) ∗ ∗ ∗
Nigeria 50% 32.5 (10.0-41.1) ∗∗100% 30.0 (10.6-38.7) ∗∗
India 50% 45.5 (27.5-62.7) ∗ ∗ ∗100% 51.7 (37.4-64.1) ∗ ∗ ∗
Indonesia 50% 31.3 (16.8-43.6) ∗ ∗ ∗100% 37.3 (23.6-49.0) ∗ ∗ ∗
Table 3.17: Relative differences for incidence rates in 2050 between
full and reduced model 1, evaluated applying different reductions
on the variation rate of the fitted parameters after 2015. Significance
levels: −: not significant, ∗:95%, ∗∗:99%, ∗ ∗ ∗:99.9%.
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Effect of Demographic Evolution without re-fitting parameters.
Comparisons between the full and -for example- the reduced model 1 across
the text are performed upon independent calibration of each model, to ensure
that both reproduce the initial burden trends independently. However, this
procedure does not guarantee that the differences between models arise from
the demographic dynamics itself, since they might be a consequence of the
different parameters and initial conditions that are estimated in each case.
To rule out this possibility, we present here a series of simulations where we
use the values for fitted parameters and initial conditions that were estimated















































 2000  2010  2020  2030  2040  2050
Year
Ethiopia Nigeria India Indonesia
Reduced Model 1 Full Model Reduced Model 1 (calibration from Full Model)
Figure 3.18: Effect of Demographic Evolution without re-fitting pa-
rameters. Incidence rate series produced by the full model (red), the re-
duced model 1 (blue, continuous), and a non-calibrated version of the reduced
model 1 which makes use of the same parameters and initial conditions fitted
for the full model (blue, dashed line).
Country Relative Difference in incidence (2050) (%) Signifcance level
Ethiopia 59.7 (31.7-65.5) ∗ ∗ ∗
Nigeria 23.7 (7.4-33.0) ∗∗
India 68.6 (59.4-75.7) ∗ ∗ ∗
Indonesia 50.8 (37.8 - 61.3) ∗ ∗ ∗
Table 3.18: Relative difference in the incidence rate in 2050 between
full and reduced model 1 without re-fitting the model The reduced
model 1 is executed using the same initial conditions and fitted parameters
inferred upon full model calibration (red minus dashed blue lines in figure
3.18). Significance levels: −: not significant, ∗:95%, ∗∗:99%, ∗ ∗ ∗:99.9%.
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In Figure 3.18 and Table 3.18, we see that the reduced model 1 still repro-
duces significantly lower burden projections than the full model even though
it is not calibrated to reproduce the data before 2015. Note that the differ-
ence with respect to the full model is in many cases amplified.
3.3.7.2 Effects of contact patterns
We also checked the robustness of considering contacts heterogeneity on
the age distribution of TB burden in a wide spectrum of different modeling


























































































































































































































































































































































































































Figure 3.19: Robustness tests for contact heterogeneity. Age specific
incidence rates (2050, Ethiopia), for the complete model, the reduced model
2 and the difference between them for different scenarios (same as in sec-
tion 3.3.7.1). Non-significant differences in infection and incidence rates are
represented in grey, otherwise they are colored as the predominant model.
In figure 3.19 we show the age distribution of incidence in 2050 for
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Ethiopia in 6 scenarios: (A) the base scenario, (B) the case where the reduced
model is not recalibrated; (C) a scenario where TB burden data is doubled,
(D) a scenario where TB burden data is halved; (E) a scenario where time
evolution of fitted parameters is reduced a 50% from 2015, and (F) a sce-
nario where these variation rates are totally arrested from 2015 on. In all
these different settings, the assumption of homogeneous mixing between age
groups implies the emergence of significant differences between age-specific
incidence rates with respect to the hypothesis of homogeneous mixing.
3.4 Conclussions
The model presented here was specifically designed to provide a suitable
description of TB transmission dynamics in situations where demography
is evolving at the same time that the epidemics unfolds. Importantly, we
showed that considering current populations’ aging trends in TB transmission
models is followed by a systematic increase in burden forecasts. This worri-
some result can be understood in terms of the known mechanisms whereby
age affects the transmission dynamics of the disease. In TB, adults are af-
fected by higher age-specific burden levels than children, and, at the same
time, they are more efficient spreaders, given their increased tendency to
develop infectious forms of pulmonary TB.55 As a consequence, considering
populations’ aging translates in higher burden forecasts, simply by increasing
the fraction of older individuals with respect to children.
These results suggest that the decay in TB burden levels that has been
observed in most countries during the last decades might be harder to sustain
than previously anticipated. Under this view, the socio-economic and Public
Health improvements that made possible the recent decline of TB world-wide
would need to be intensified in many countries if the goal of TB eradication
is to be pursued before 2050, at the same time that global aging of human
populations unfolds.
Furthermore, the model incorporates a data-driven description of the de-
pendency of TB transmission routes with age, which, we have showed, exerts
a significant influence on the forecasted age-distribution of the disease bur-
den, by reshaping infection routes. These results will impact the evaluation
and comparison of novel epidemiological interventions, mostly if they are con-
ceived to target specific age-strata, as is the case of new preventive vaccines.
In this context, previous works have concluded that a quick immunization
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of young adults through vaccination campaigns focused on adolescents is ex-
pected to produce a faster decline in TB incidence than an alternative strat-
egy based on newborns’ vaccination.101 These results would further reinforce
this hypothesis, to the extent that empirical contact patterns are followed by
a relative increase of TB among adults with respect to children. It has to be
noted, though, that in the decision of what is the optimal age-group to tar-
get in a hypothetical immunization campaign for a new vaccine, at least two
additional aspects have to be considered, namely, whether the new vaccine
is conceived to boost or substitute BCG, and whether previous exposure to
environmental antigens are expected to compromise vaccine performance, as
we will explore in next chapter. BCG substitutes, and/or vaccines suscep-
tible to lose immunogenicity due to exposure to mycobacterial antigens of
individuals before vaccination might not be eligible for adolescent immuniza-
tion anyways.
Despite all the improvements introduced here, this approach is not ex-
empt from the strong limitations that affect all TB transmission models
operating at this level of resolution. The outcomes of the model depend on
a series of epidemiological parameters and initial burden estimates that are
subject to strong sources of uncertainty. Even though we have registered
these uncertainties and propagated them to the final model outcomes, future
improvements and reassessment of these pieces of input data are generally
expected to impact the quantitative outcomes of the model, and to further
delimitate the uncertainty ranges here reported. As a first example, interna-
tional Health Authorities come insisting on the importance of implementing
systematic surveys of TB prevalence in many countries, as a means towards
more accurate TB burden evaluations. Accordingly, they revise and update
their burden estimates on a regular basis, as new data become available,
which obviously impacts model calibration and results. Furthermore, the
demand of epidemiological studies aimed at obtaining updated estimates of
key epidemiological parameters in current epidemiological settings has been
pointed out as a primary need for the development of more reliable TB
models.163 Similarly, we have seen here the importance of obtaining data of
contact patterns specific for each setting, by showing that different contact
structures inferred from studies conducted in different parts of the world
yield to significantly different distributions of TB burden across age (Figure
3.19). Importantly, the interpretation of these burden distributions of TB
across age is hindered by the limited quality of the data available regard-
ing TB distribution across age; which makes adventurous any comparison
between model and data. For example, current WHO data-structure only
splits TB incidence into two major age groups (0-14 vs 15+), with alleged,
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heavy under-reporting biases among children.
All these considerations, taken together, evidence the need of further
studies, spanning from the implementation of systematic surveys that could
unlock more accurate burden estimations (either aggregated or, very impor-
tantly, age-specific), to the re-estimation of key epidemiological parameters
and contact patterns in specific epidemic settings.
Despite those limitations, in this chapter we have showed that abandon-
ing the simplifications of constant demography and homogeneous contacts
shared by previous models of TB transmission is not just technically feasi-
ble, but it has significant effects on model outcomes. Remarkably enough,
TB is not the only disease where long characteristic time-scales and strong
age-dependencies concur,164,165 which, despite the specific details of the trans-
mission dynamics of each case, implies that similar corrections to what we
have proposed here for the case of TB might be pertinent to correct bias of
current epidemic models of other diseases too.
The ultimate goal is the evaluation of new interventions for TB, specif-
ically new vaccines. This model, as has been described in this chapter is
not able yet to produce impact evaluation of new vaccines as we have not
implement interventions. However, this model will constitute the foundation
on which we will build impact evaluations for new vaccines by the end of
this thesis. But before we incorporate new vaccines to this model, we should
analyze carefully the different effects that vaccines can trigger in order to
construct a faithfull characterization. The next chapters will focus on this
precise issue.
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Chapter 4
Quantifying the Masking and
Blocking effects on BCG
4.1 Introduction
There is still a lot to be known about the immunology of MTB, and clini-
cal work and development of new vaccines is hurdled by these limitations.115
Even the current vaccine BCG, that has been around for the last century,
constitutes a mistery for immunologists due to its very variable efficacy.76
The efficacy of BCG is consistent in protecting infants, especially from the
most severe forms of meningeal and miliary TB76 but is limited against pul-
monary forms of the disease responsible for transmission fueling the growing
epidemic worldwide. Accordingly, nowadays there exist tens of different re-
search teams worldwide developing as many novel experimental vaccine can-
didates designed as revaccination (boosting) strategies in BCG vaccinated
individuals (adolescents or adults) or as a BCG replacement strategies at
birth.82
BCG fails to provide consistent protection to the pulmonary forms of
the disease, especially in adults,74 who are the main contributors of overall
disease spreading as shown previously. Consequently, an accurate evalua-
tion of the BCG impact under different conditions –population susceptibil-
ity, geography, environmental exposure, etc.– is essential. Such an evaluation
will allow the assessing of the efficiency of BCG as a reference vaccine and,
at the same time, will provide new guidelines and methodological tools to
better evaluate the potential efficacy of the newly developed TB vaccines.
The highly variable and apparently inconsistent results obtained in BCG’s
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efficacy tests and meta-analysis have been subject of intense scientific con-
troversy,76,166 and the use of BCG during the 20th century has been largely
argued.167,168
The hypothesized causes underlying the observed variability of BCG effi-
cacy in different settings include differences between the BCG strains,169 ge-
netic, epi-genetic or socio-economical differences between populations, study
quality, parasitic co-infections, etc.82 In addition, multi-variate meta-analysis
of BCG efficacy determination studies consistently determine that latitude is
a variable showing a most prominent correlation with the performance offered
by BCG,72,167,170,171 pointing to the existence of latitude-driven mechanisms
influencing it, rather than other possible explanations related, for example, to
the ethnicity of the tested populations.172 Among these possible mechanisms,
the hypothesis that agglutinates a greater consensus points to the existence
of a complex, latitude-dependent immunological process of environmental
sensitization (ES) to mycobacterial antigens which might interfere with the
observed action of BCG vaccine in different ways. The hypothesis of ES
being the source of BCG efficacy variability has been backed up by different
epidemiological observations.76,173–175
ES is thought to have its origin in the exposure of individuals either to non
tuberculous mycobacteriae (NTM) –whose antigenic similarity to MTB176,177
is able to cause cross reactivity in the human immune system178,179– or to
the reservoir of latent infection of MTB itself (and other closely related bac-
teria within the MTB-complex). Additional sources of sensitization have
been postulated, like certain parasitic infections.180 The diversity among the
different putative sources of ES is notorious, the relationship between their
prevalence and latitude is not homogeneous, and their levels of cross reac-
tivity are variable as well. This situation portraits a complex landscape that
makes specially ventured to attribute the geographical patterns of BCG ef-
ficacy variation to a single factor, as it could be a global increase in NTM
prevalence levels next to the equator,178,179,181 which has been demonstrated
to be inaccurate for some species.182 Even though, it seems clear that overall
levels of ES increase both with closeness to equator and subjects’ age at the
time of vaccination.
Two different mechanisms have been theorized on how this exposition to
environmental antigens would affect the response of the host to a vaccine
like BCG.121 The masking hypothesis postulates that ES confers a signif-
icant protection against TB in such a way that a vaccine can barely offer
an additional level of protection.121,183 As an alternative hypothesis, it has
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been suggested that ES prior to vaccination may trigger an immune response
capable of blocking the assimilation of the vaccine by the host, either if it’s
a live-attenuated vaccine or if it’s a booster. This is known as the block-
ing hypothesis.121,184 These two effects have the potential to explain, to a
large extent, the variability observed in the trials performed, that is, both
the dependence of BCG efficacy on age at the time of vaccination—as an
individual gets older its exposition to mycobacteriae increases—and its ge-
ographical variations. Finally, it is worth highlighting that masking and
blocking do not exclude each other: in a scenario in which both mechanisms
take place, ES would contribute at the same time to reduce disease risk of
non-vaccinated individuals, and to impair vaccine assimilation of immunized
ones.
Several studies have tackled the problem of evaluating ES impact on
BCG vaccine efficacy from different angles. Researches in animal models
have shown that environmental mycobacteria strains can interfere with BCG
vaccination and with susceptibility to M. tuberculosis infection.185–187 The
influence of the effects of Masking and Blocking on measurements of efficacy
has been also studied from a theoretical point of view,172,188 even though
none of these works allows a quantification of masking and blocking effects
on vaccine’s efficacy levels measured on clinical trials performed on humans.
BCG-REVAC trials were designed to discriminate these two effects on
BCG performance when applied on individuals of dissimilar ages in the
Brazilian cities of Salvador and Manaus.166,189,190 In particular, three types
of trials were conducted in the study, measuring the efficacy of as many vac-
cination strategies in each city: newborn vaccination, school-age vaccination
and school-age revaccination. The rationale behind the election of such a
design is twofold. On the one hand, replicating the experiment design in
two cities of the same country located at considerably different latitudes,
renders reasonable the assumption that the main source of variability at the
efficacies observed is due to different levels of ES, since virtually any other
plausible source of variation (i.e., vaccine preparation, strain or application
protocol, ethnic diversity etc.) are absent or controlled for across the study.
On the other hand, the trials design allows discriminating between blocking
and masking effects, since the differences across cities of the efficacies ob-
served for each type of trial are expected to vary depending on what of the
two effects is dominant.
After the analysis of BCG-REVAC trials, Barreto et al. observed that the
efficacy of the vaccine, when applied to newborns and measured later in life
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did not show a strong geographic variation, which suggests that spontaneous
protection related to masking should play a residual role, if any. On the
contrary, when BCG was applied at school age,166 either the first time, or as
a second dose, vaccine efficacy observed was in both cases lower in Manaus
than in Salvador; which in principle would be compatible with the blocking
hypothesis if vaccine assimilation were more efficient in Salvador as a con-
sequence of lower levels of ES bound to its larger distance to the equator.
However, even if the design of BCG-REVAC trials allowed to qualitatively
asses the greater relevance of the blocking mechanism as compared to mask-
ing, no actual quantification of these two effects and their relative role has
been provided up to now. In this sense, after the work by the BCG-REVAC
consortium, several questions remain unanswered, as we do not know (1)
what is the relative likelihood of both hypothetical mechanisms when trying
to explain the observed results of the trial, (2) how much predictive power
would a full model containing both effects gain with respect to single effects
scenarios (masking or blocking alone) (3) whether significantly different com-
binations of masking and blocking strengths could be similarly compatible
with the observations derived from the trials, and very relevantly, (4) what
are the intensities of blocking and masking effects, and their confidence in-
tervals, yielding a most significant agreement with the data.
In this chapter, we introduce a family of mathematical models to in-
terpret the results from BCG-REVAC trial under the light of masking and
blocking effects, in order to contribute to answering the aforementioned ques-
tions within the limitations imposed by the reduced statistical power derived
from the reduced number of trials studied. By confronting the model against
the results of the BCG-REVAC studies, we are able to measure extent to
which these effects are sufficient to explain the efficacies measured.166 Fur-
thermore, we quantify the specific masking, blocking and immunity waning
effects yielding best-fitted estimates for the efficacies measured. To this end,
we compared the likelihoods of three different modeling scenarios: a first
model in which both effects concurrently take place, a second model only
considering blocking and a third one containing only masking. Translat-
ing the trial results into quantitative estimations of blocking and masking
strengths constitutes a relevant step towards a deeper knowledge on how
BCG efficacy depends on individuals’ age and geographical areas.
Similarly, it would provide a quantitative reference for the plausible ranges
of blocking and masking levels that other TB vaccines might eventually suffer
as well, which could be especially relevant in the context of impact evaluation
of novel vaccines. Up to our knowledge, the BCG-REVAC studies are the only
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set of trials specifically designed to discriminate the effects of Masking and
Blocking. Even though this chapter is restricted to this particular setting,
the framework here proposed could also be extended to the interpretation of
future trials and impact evaluation of future vaccines.
4.2 Methods
4.2.1 Data analyzed: the Brazilian BCG-REVAC clini-
cal trials
BCG-REVAC consisted of a set of cluster-randomized trials involving
more than 200,000 school-aged children in the Brazilian cities of Manaus
and Salvador, whose principal aim was evaluating the effectiveness of BCG
under different vaccination protocols. The enrolled population of the study
consisted of non-infected school children between 7 and 14 years old at the
moment of randomization. Within this population, individuals presenting
a positive BCG scar are separated from the rest, distinguishing, this way,
the enrolled individuals who were vaccinated at birth from those who were
not. Each group is then split into an intervention and a control group;
individuals in the intervention group were vaccinated within the context of
the trial. Summing up, there are 4 cohorts in each city: non-vaccinated (1),
vaccinated after birth (2), firstly vaccinated at school age during the trial (3),
and revaccinated, after a first dose applied after birth, in the trial too (4).
Upon such classification of enrolled individuals in cohorts, the effectiveness
of BCG vaccination strategies was measured by comparing the TB incidence
rate within an end-point associated to active disease in the four cohorts,
according to three different types of trials: Trial I: BCG at birth vs. no
intervention (cohort 2 vs.1). Trial II: BCG first dose at school age vs. no
intervention (cohort 3 vs. 1). Trial III: revaccination at school age vs. first
dose at birth only (cohort 4 vs. 2).
4.2.2 A model to describe BCG efficacy variation: mask-
ing, blocking and immunity waning
The six clinical trials conducted within the framework of BCG-REVAC
study-three types of trials per two cities- output efficacies that span from
1% to 40% protection (see Table 4.1 and Fig. 4.1, red continuous lines).
In order to explain this variability, we propose a model according to which
the different protection levels found in each of the four cohorts in the study,
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schematically shown in Fig. 4.2, result from the interplay between the in-
trinsic vaccine efficacy, its temporal waning patterns, masking and blocking
effects. These three mechanisms of vaccine protection shifts are ultimately
responsible for vaccine’s performance variation, either in space or in time.
Trial Efficacy in Salvador Efficacy in Manaus
Vaccination at birth vs No vaccination 40% (22-54%) 36% (11-53%)
Vaccination at school age vs No vaccination 34% (7-53%) 8% (-39-40%)
2nd dose at school age vs Vaccination at birth 19% (3-33%) 1% (-27-23%)
Table 4.1: Vaccine efficacies (95% CI) obtained from the BCG-
REVAC trials.
Figure 4.1: Best fit estimates for each trial by models 1, 2 and 3
(yellow, blue and green dots, respectively) for the trials conducted in the
BCG-REVAC study. The colormap represents the probability of obtaining a
less extreme value of the efficacy, according to the distributions considered.
The probability of zero marks the central estimate (red, continuous line)
while the dashed red lines mark the 95% CI reported by Barreto et al.166
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Figure 4.2: Scheme of the different contributions to the disease risk
for each cohort.
First of all, in absence of masking or blocking, a naive vaccinated indi-
vidual will receive a protection level, right after vaccination, that we call
e(0). As time after vaccination goes by, this protection level will wane up
to e(t) < e(0), generally speaking. This implies that, if we deal with a pop-
ulation in which the incidence rate of new TB cases per unit time is equal
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to x; t years after vaccination, this rate is modified to (1 − e(t))x, provided
that no additional effects take place. Taking that into account, a protective
vaccine will have positive efficacy values e(t) ∈ (0, 1], being also possible
for a (failed) vaccine to have a negative efficacy if it augments the disease
risk among vaccinated individuals instead of reducing it. In this model, the
time waning patterns of the intrinsic vaccine efficacy do not depend on the
geographical area, but just on time since vaccination, which approximately
is, in average, 4.5 years for school age vaccination (cohort 3) and 16 years
for newborn vaccination (cohort 2), which implies the consideration of two
intrinsic efficacy parameters: e(4.5) and e(16).
Besides vaccination, ES can also support protection against disease through
the masking mechanism. The masking level, denoted by m, is a protection
parameter formally equivalent to the intrinsic vaccine efficacy (thus verifying
m ∈ (0, 1] for a protective effect, and negative otherwise), whose effects are
suffered by initially naive, non-vaccinated individuals subject to ES. Thus,
in principle, the longer the time an individual has been exposed to ES—i.e.,
the older the individual is at the moment of observation—the higher is the
masking-related protection she might show. Masking is also a geography-
dependent effect, since it depends on ES, which forces us to consider two
masking parameters: mM for Manaus and mS for Salvador. The dependence
of these parameters on age cannot be resolved, since all the cohorts analyzed
in the study have approximately the same age.
Additionally, if e(t) describes the protection provided by the vaccine to
a naive individual in absence of masking or blocking t years after vaccina-
tion, we also need to describe how this protection is modified if the vaccine
is applied to non-naive subjects. If an individual’s immune system has been
stimulated prior to vaccination (either by masking like in cohort 3, or by a
previous vaccine, like in cohort 4 before the second dose), and consequently
she is partially protected against the disease, it is unrealistic to assume that
the full effect of the new dose is additive.121
Instead of that, the model considers that a vaccine dose applied on a
previously protected individual will contribute, at most, up to resetting the
initial protection levels e(0), provided that no blocking of the vaccine takes
place. In cohort 3, this implies that, right after the school age vaccination, if
the vaccine is not blocked (b = 0, see below), it will have a protective effect
e′ that will be concurrent with the masking protection m so as to reduce the
disease risk from [1 − m]x to [1 − e′][1 − m]x. The estimation of e′ comes
from assuming that such disease risk must equate what we would observe if
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a vaccine of full efficacy were applied on naive individuals, and observed 4.5
years later:
[1− e′][1−m]x = [1− e(4.5)]x =⇒ e′ = e(4.5)−m
1−m
(4.1)
Similarly, the school-age dose at cohort 4, will add to the protection
provided by the newborn dose e(16), diminishing the disease risk from [1 −
e(16)]x to [1− e′′][1− e(16)]x. To estimate e′′ , we assume that, if the second
vaccine is not blocked, the disease risk achieved by both vaccines together
[1 − e(16)][1 − e′′]x is equivalent to the disease risk reached by the same
vaccine, if applied on unprotected individuals, 4.5 years after vaccination:
[1− e′′]x = [1− e(4.5)]x −→ e′′ = e(4.5)− e(16)
1− e(16)
(4.2)
Finally, vaccine intrinsic efficacy can be blocked by prior ES; an effect
that we model through the blocking probability b ∈ [0, 1], where b = 0 means
that no blocking appears, while b = 1 stands for a totally blocked vaccine,
meaning that vaccinated individuals would only have the protection level that
they already had before vaccination. Blocking is also a geography-dependent
factor, since it is considered a consequence of ES as well, which forces us to
distinguish bM and bS for Manaus and Salvador, respectively. Unlike mask-
ing, blocking does not depend on the age of the individuals at the moment of
observation, but on their age at the moment of vaccination. In this case we
study cohorts vaccinated at two moments in life—at birth and at the begin-
ning of the trials—being the first of these cases (the newborn vaccination)
considered blocking-free, as it is assumed that when the vaccine is applied
shortly after birth, there is no place for prior ES.
Taking all these effects into account, we are left with a set of six in-
dependent parameters ~P = {e(4.5), e(16),mM , bM ,mS, bS} to describe the
variability observed in the trials, either temporal or geographical, under the
light of blocking and masking effects, concurrently. The temporal trends of
the level of protection of each cohort are schematically shown in Fig. 4.3. For
Trial I the control group is cohort one that corresponds to non-vaccinated
individuals. In this cohort, a level of protection above zero can only be due
to masking, which is an increasing function with age. In turn, the interven-
tion group corresponds to cohort 2 that is the newborn vaccination group:
individuals are vaccinated right after birth, which provides a protection that
overcomes any possible masking effect, cannot be blocked by ES and wanes
with time. In the case of Trial II the vaccinated cohort is cohort 3, firstly
immunized at school age. In this cohort individuals might be protected by
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masking before the vaccine is applied. Then, at the moment of vaccination,
if not blocked, the vaccine will overcome masking protection up to the ini-
tial value e(0), which then will wane. Finally, if blocking takes place the
protection provided by the vaccine will be reduced. The control cohort in
this case is cohort 1 again. Finally, for Trial III the intervention group cor-
responds to cohort 4, joined by individuals firstly vaccinated at birth, and
revaccinated at school age. At variance to the first dose, which cannot be
blocked, the second dose might be blocked by ES or not, in which it will reset
the initial protection levels provided by the vaccine. The control group for
this trial is cohort 2, that corresponds to individuals only vaccinated at birth.
Figure 4.3: Scheme for the temporal evolution of the level of pro-
tection for the cohorts of the three types of trials considered, ac-
cording to the different vaccination strategies and ES mechanisms.
The grey shaded area represents the age window of the individuals enrolled
in the study.
In the following, we will refer to this full model as model 1. In Fig. 4.2,
we represent the variations on the disease rates provoked by each effect that
takes place in each cohort according to model 1. Summing all the possible
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contributions to the development of active disease for each cohort, we derive
the general disease rates characterizing each cohort of one city as follows:
dl1 = (1−ml)x (4.3)
dl2 = [1− e(16)]x (4.4)
dl3 = (1− bl)[1− e(4.5)]x+ bl(1−ml)x (4.5)
dl4 = (1− bl)[1− e(4.5)]x+ bl[1− e(16)]x (4.6)
where the superscript indicates location, and x the incidence rate ob-
served in the population.
From equations 4.3-4.6, it is immediate to derive the expressions for the























The system of Eq. 4.7 represents a full model for the vaccine effica-
cies observed during BCG-REVAC trials, which is based on the assumption
that the sources of geographical variability for BCG’s performance are both
masking and blocking effects. From the full model, two reduced versions
can be conceived: a masking-free model (model 2 in the following) in which
mM = mS = 0, and a blocking free model in which bM = bS = 0 (model 3).























By considering these three models, this approach allows quantifying and
comparing the plausibility of blocking and masking hypotheses to potentially
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explain the variation in BCG efficacy trials observed in the controlled setup
conceived in the BCG-REVAC trials, taking into account the non-linearities
associated to each mechanism, which play a central role in the derivation of
Eqs. 4.7-4.9.
4.2.3 Models solution: parameters estimation and con-
fidence intervals
In order to identify the set or sets of parameters yielding a best fit for the
efficacies observed in BCG-REVAC trials, we compare the model prediction
associated to any parameter set ~P to a set of empirical probability distribu-
tions derived from BCG-REVAC data. From each of the confidence intervals
reported in Barreto et al., (2014) we build a two-piece normal distribution191
for each trial reported, centered in the reported values [ēli]BCG-REVAC (for loca-
tion l ∈ {Manaus,Salvador} and trial i ∈ {I, II, III}), and with asymmetric
variances [σli]
±
BCG-REVAC equal to one half the radius of the confidence inter-
vals reported in Barreto et al., (2014), so preserving the confidence levels of
the intervals reported (see Fig. 4.1).
Once the empirical distributions have been defined, for each possible set
of parameters and for each of the six trials we define the Z -score associated
to the model prediction as:








BCG-REVAC will take each of its two possible values depending on
the sign of [ēli]mod−[ēli]BCG-REVAC. From Z li(~P ), we define the corresponding p-
values pli[Z li(~P )] as the probability of the empirical distributions reproducing
BCG-REVAC data to have a Z-score Z̃ so that |Z̃| > |Z li(~P )|. This allows







to maximize so as to identify the model’s parameters ~P ∗ more likely to
yield the BCG-REVAC results. The global landscape of L(~P ) is explored
using a hill-climbing algorithm designed to identify all possible local maxima
in the space of parameters. Finally, a Levemberg-Marquardt algorithm160 is




In order to estimate the confidence interval associated to model estima-
tion, the following numerical procedure is performed. First, and starting
from the maximum likelihood estimate ~P ∗ , we move on each parameters’
axis until a value of L = 0.05 is reached in each case. We call this increment
Aj(j ∈ [1, 6]) (see Fig. 4.4). These values are not symmetrical, again, and
so we distinguish between A+j and A
−
j . Using these asymmetric widths, we
construct a two-piece normal distribution for every parameter, centered in
~Po and having an asymmetric variance given by σ±j = cA
±
j , where c is a
common modulation coefficient. Besides, the distribution is truncated at 1.
Finally, we numerically estimate c by generating sets of points in the param-
eter space whose coordinates in each axis are obtained from the split normal
distributions mentioned for an initial guess of c. Through an iterative process
we search the value c = c∗ for which a 95% of the points generated in the
parameters space, yield efficacy estimations verifying L(~P ) > 0.05. Once we
have found the optimal value of the scaling coefficient, the reported uncer-
tainty of the j-th parameter corresponds to 95% CI given the distributions
we have used.
Figure 4.4: Confidence intervals estimation scheme. Degraded shades
represent the joint probability density associated to the estimation of con-
fidence intervals around the model best fit. The modulation coefficient c is
determined so as to make the brown area within the black line of L(~P ) = 0.05
to precisely accumulate the 95% of the total joint probability distribution.
4.3 Results
In order to find the sets of parameters yielding best estimates of BCG
efficacies according to these models, we have performed a series of numerical
optimization procedures seeking for likelihood maximization. First, we are
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interested in addressing whether a unique likelihood maximum exists across
the parameter space of each model or whether, on the contrary, there exist
multiple parameter combinations associated to comparable values of L(~P )
close to the maximum. This is an important point to address, since the exis-
tence of different maxima in a model would indicate the inability of the model
to univocally quantify the effects causing the efficacy variations observed. To
tackle this question, we performed an iterative hill-climbing algorithm start-
ing from 20,000 random points across the parameter space for each model.
The algorithm works by proposing at each step a random displacement fol-
lowing a uniform distribution in the parameter space within a hyper-cube of
size d = 0.001, and accepted only if it corresponds to an increasing of the
likelihood function L(~P ). The algorithm stops when no further move is ac-
cepted after N = 107 rejected displacements (i.e., the function L(~P ) reaches
a maximum) . As it can be seen in Fig. 4.5, while model 2 presents a unique
likelihood maximum (L(~P ∗) = 0.53), models 1 and 3, which contemplates
masking, fails at providing a univocal vaccine’s description associated to a
unique solution from likelihood optimization.
Instead of that, as we can see in Figs. 4.5A, 4.5C, 4.5D and 4.5E models
1 and 3 present a parameters cliff across which, model’s likelihood is near
to its maximum, and largely comparable (L(~P ∗) = 0.79 for model 1, and
L(~P ∗) = 0.002 for model 2). Furthermore, a relative likelihood test compar-
ing models 2 and 3 (that is, comparing blocking vs. masking as exclusive





= 3.8 × 10−3. This
result, considering that both models share the same amount of parameters,
highlights again the inability of masking to provide a picture for vaccine ef-
ficacy variation as accurate as blocking does, as we can also see in Fig. 4.1,
where the best fit provided by each model is presented as well.
If the analysis of model 3 and its comparison against model 2 allows us
to discard masking as an autonomous mechanism able to explain the vac-
cine efficacy measured in the trials, it remains to be elucidated whether its
consideration in addition blocking in model 1 might still be able to signifi-
cantly improve the fitting of the observed data. To answer this question, we
conduct a simple likelihood ratio test in which the null and full models are,
respectively models 2 and 1. From such test, we obtain that the statistic:





= 0.80, is a chi-square distributed variable with 2 de-
grees of freedom (difference between number of parameters of models 1 and
2) under the null model. The obtained value does not allow to discard it
even with a 50% confidence (χ2(p = 0.5, df = 2) = 1.39), which indicates
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Figure 4.5: Distribution of the parameters which yield a maximum
in the likelihood function. (a-c) Hill climbing algorithm distributions for
models 1, 2 and 3, respectively. Random initial points in red. In green, we see
the peaked distribution of the end points of the algorithm around the solution
of the models. (d and e) parameters cliff yielding quasi-constant values of
maximum likelihood L(~P ∗) = 0.79 (d) for model 1 and L(~P ∗) = 0.002 for
model 3 (e). Model 2 is the only model capable of provide an univocal
description yielding maximum likelihood.
that masking is not just unable to provide an acceptable description of the
observed data by itself but also makes no significant contribution to explain
the variations in vaccine efficacies observed in the trials under study, when
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considered in addition to blocking. This is also reflected in the close esti-
mates that are found for blocking parameters in models 1 and 2 (see Table
4.2 and Fig. 4.5).





Table 4.2: Optimal parameters of model 2. Models 1 and 3 are unable
to provide a unique parameter set yielding maximum likelihood.
Besides, if we analyze the combination of parameters that formed the
cliff of maximum likelihood in model 1, we see that it consists in very similar
levels of masking for the two different cities, which enters into conflict with
the mentioned correlation between ES effects and closeness to equator.
In summary, these results point at blocking as the only plausible source of
vaccine efficacy variation between the two mechanisms considered, validating
the qualitative interpretation of the BCG-REVAC outcomes by Barreto et
al.166 The best fit of model 2 yields a likelihood L(~P ∗) = 0.53, which corre-
sponds to moderate blocking levels in Salvador (bS = 0.41 c.i.[0.14, 0.68]) and
to almost total blocking in Manaus (bM = 0.96 c.i.[0.52, 1.00]). These results
are consistent with the assumed correlation between ES action strength and
closeness to equator.
4.4 Discussion
Understanding the mechanisms driving ES effects on BCG performance
is a crucial task in the agenda towards the development of new tuberculosis
vaccines. In this work, we have proposed a mathematical model that allows
the quantitative evaluation of these two effects based on the BCG-REVAC
trials performed in Brazil.166 We have seen that the divergence in the mea-
sured efficacies of the trials is explained with high values of blocking, which
concur with the qualitative discussion made in Barreto et al.166 Furthermore,
we have also observed for the first time that no alternative behavior of BCG
is compatible with the observed data within the context of a model in which
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BCG’s variability is entirely attributed to ES sensitization.
Admittedly, the range of applications of the results here exposed must be
restricted to the provision of a plausible explanation for the efficacy varia-
tion patterns observed within a controlled context such as the BCG-REVAC
studies, in which the equivalent design of the trials in both cities makes
reasonable to assume that ES is the only mechanism responsible for the
variations observed. In that sense, the quantitative conclusions reached in
this work should be interpreted as a mean to discriminate between the two
mechanisms studied when it is reasonable to neglect any source of vaccine
variation foreign to ES. Nonetheless, it is worth remarking that this approach
cannot provide any insight on the relevance of ES itself when compared to
other plausible sources of variability that could also affect vaccine’s efficacy,
such as diversity in production, administration, and type of BCG vaccine
strain used, as well as the TB strain that circulates in a particular popula-
tion, among others. In that sense, the analysis of new, hypothetical trials
similarly structured, conducted in other geographical areas, could certainly
yield different results, if additional sources of variation not considered in this
work were playing a relevant role.
The model here proposed could however be generalized so as to address
some additional questions that go beyond a simple comparison between mask-
ing and blocking, which would involve a more detailed description of the
blocking effect itself.
On the one hand, it is pertinent to ask whether prior vaccination with
BCG might trigger a blocking effect comparable in magnitude to that caused
by ES; a question that could be tackled by an extension of the model here
proposed in which two blocking parameters –one associated to each source–
are considered instead of one. Remarkably enough, distinguishing between
BCG vaccine and ES as possibly different causes of blocking might lead to rel-
evant quantitative consequences in what regards impact evaluation of novel
vaccines, mostly because the old vaccine is still used in the vast majority
of countries, also in geographical areas in which low levels of ES would be
expected.
On the other hand, an additional limitation of this study, inherited from
the BCG-REVAC studies design, is due to the restriction of trials’ endpoints
to diseased and not diseased individuals, without measuring infection as a
third relevant outcome. This limitation prevents us to address the impor-
tant question of whether the vaccine is blocked in its protective role against
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infection, or if, instead, blocking interferes more intensely with the vaccine’s
performance at reducing the progression rates from latency to active dis-
ease.75,192
If infection was registered as an additional endpoint in the clinical trials
–something, in general, feasible193– this approach could then be extended so
as to estimate two different blocking components associated to the impair-
ment of vaccine’s protection against infection and active disease indepen-
dently. Once again, such hypothetical study could bring important insights
for future vaccine development, and in particular could contribute strongly to
the debate of what should be the primary goal of TB vaccines.107 Generally
speaking, more studies are needed to evaluate how general are the patterns
found by BCG-REVAC trials, with the ultimate goal of assessing a positive
explanation to the long lasting problem of BCG efficacy variation patterns.
4.5 Conclussions
The crucial implications of discriminating and quantifying masking and
blocking effects for TB vaccine development are twofold. On one hand, un-
derstanding the range, and causes behind variations of BCG efficacy is es-
sential,194 since the efficacy of any novel vaccine will be measured against
BCG. On the other hand, depending on where a new vaccine is applied and
how old are the target populations, masking or –more likely– blocking effects
would affect new vaccines too.
These issues affect different stages of the vaccine development pipeline,
as sketched in Fig. 4.6. In the first place, during the process of vaccine eval-
uation in the context of clinical trials, studies of new tuberculosis vaccines
should account for the possibility that prior sensitization may compromise
their effects.76 In this sense, and even if a new vaccine targeting TB in ado-
lescents and adults rather than any other age group is expected to have the
quickest impact on disease transmission and control, before we address the
question of impact of novel vaccines, it is essential to know if the vaccine
is more effective than BCG. The most reliable way of knowing whether a
new vaccine works better than BCG is by conducting an efficacy trial in a
naive population without previous ES (e.g., previous BCG vaccination, my-
cobacterial infection and/or TB contact) in order to avoid possible effects of
masking or blocking.74,121,166
Furthermore, and once the efficacy estimation is complete, in order to
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Figure 4.6: Scheme of the basis for evaluation of anti tuberculosis
vaccines in absence of universally reliable protection correlates.
First stage: design of vaccine efficacy determination clinical trials: the age
of the cohorts must be elected taking into account that prior exposure to
mycobacteria –either environmental, M. tuberculosis after exposure or even
prior TST or also BCG– may corrupt the observed vaccine efficacies. Second
stage: vaccine impact evaluations: bulk, short-term and long-term impact
forecasts should be equally considered, as well as age-distributed impacts in
terms of cases, infections and casualties prevented.
produce any reliable vaccine impact and cost-effectiveness forecast, modeling
scenarios contemplating ES deleterious effects on TB vaccines are manda-
tory. The fact that, according to this analysis, blocking emerges as the
driving effect behind BCG variability poses a potential pitfall to any vaccina-
tion strategy focused on individuals older than those analyzed here, including
most strategies conceived so far for booster vaccines. This is especially worth
noticing because blocking, unlike masking, is not supposed to degrade the
vaccine-induced protection obtained further during life by individuals immu-
nized promptly after birth. Again, even if immunizing adolescents is thought
to provide better impacts than vaccination strategies focused on younger
age-segments, if such a novel vaccine is affected by blocking just as BCG is,
then its impact will decrease in a way that, given the high blocking levels
here identified, might even revert the comparison. As suggested by Helen
McShane “we should optimize deployment of BCG to administration as close
to birth as possible”.194 This should be the case for new priming live vaccines
candidates based on BCG replacement strategies as well.82
Taken altogether, the results highlight the need for measuring ES effects
on novel vaccines performance, as well as of diversifying vaccination strate-
gies. As this chapter proves, the execution of clinical trials is essential in
the case of TB, and more information can be extracted from them than the
classical assessment of efficacy. In the next chapter, we will study the design
of efficacy clinical trials and propose a new analysis that could improve our
knowledge of the new vaccines being tested, which in the long term could
provide more accurate impact evaluations and less biased decisions by policy-
makers.
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Chapter 5
Design principles for TB vaccines’
clinical trials
5.1 Introduction
As it has been explained throughout this thesis, nowadays a very active
research community is engaged in the development of disparate candidates
for a new TB vaccine, several of them being tested in clinical trials.82,195,196
Since the resources available for this collective endeavor are limited, the de-
velopment of rational approaches for filtering vaccine candidates represents
a first order priority for Public Health Organizations and funding agencies.
Accordingly, a well-defined stage-and-gate system has been defined and im-
plemented, to which the different candidates must adhere in order to ad-
vance through the subsequent phases of the vaccine development pipeline.197
By providing a transparent framework for the evaluation and comparison of
candidates at all stages, the system allows prioritizing the investment on the
vaccines showing better performances regarding safety, immunogenicity and
protection at each step, with the ultimate objective of maximizing the like-
lihood of success for the final finding of a new, safe and impactful TB vaccine.
Gathering the information needed to guarantee the eventual success of a
vaccine poses a number of conceptual challenges that manifest at different
stages of the clinical pipeline, making the evaluation and comparison of the
different candidates under consideration an arduous task. The lack of protec-
tion correlates for TB198,199 hinders early efficacy evaluations, affecting our
ability to identify the very presence of any protective effects from a given vac-
cine at the early stages of its development. That major limitation factually
forces researches to rely new vaccines efficacy estimates to large randomized
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phase II and II-b clinical trials, which require the recruitment of thousands
of individuals in high prevalence epidemiological settings during years to be
completed. In this regard, the recent results from the nearly designed phase
IIb trials of the novel vaccines MVA85A,200 and H4:IC31201 even though it
fails at providing evidence of significant protection, represents a solid frame-
work for such studies.
However, even once the task of measuring the vaccine’s efficacy at reduc-
ing risk of disease (V Edis) is achieved upon completion of a phase IIb clinical
trial, the interpretations of these results are not always immediate and can
be due to different mechanisms of action of the vaccine. On the one hand,
a vaccine can contribute to reduce disease risk by decreasing the fraction
of fast progressors, increasing the probability that newly infected individu-
als are able to contain immediate bacterial proliferation developing latent
TB infection (LTBI). Alternatively, the vaccine can delay the onset of active
TB, slowing down the dynamics of fast progression instead of preventing it.
These two possible mechanisms have different dynamical interpretations in
terms of epidemiological transmission models, and might appear, in princi-
ple, independently and not necessarily correlated. The question of whether
an individual will progress to active disease rapidly after infection or not
depends on the ability to induce an initial strong innate immune response
to the pathogen along with a later T-cell mediated adaptive response both
of which are needed, if not to prevent infection by completely eliminating
the bacteria, at least to arrest bacterial growth and confine the pathogen
within granuloma.44 If such complex response fails, fast transition to disease
will take place, as a consequence of the host’s inability to both eliminate or
confine bacteria around closed granuloma, yielding to rapid pathogen prolif-
eration. Factors affecting the probability of individuals to join fast or slow
paths to disease upon infection are both environmental and genetic, but lit-
tle is known about how they impact, if they do it at all, the delay observed
between infection and onset of symptoms in recent transmission TB cases
(i.e. fast progressors).44
The main focus of this chapter is the analysis of this apparently innocent
mechanistic degeneracy problem, in virtue of which, it is hard to distin-
guish, in the context of a clinical trial designed to estimate vaccine efficacy
against disease, a vaccine that prevents from fast-progression from a vaccine
that simply delays it. After a formal description of the question, we use
Monte-Carlo methods to simulate synthetic clinical trials,202 along with a
compartmental transmission model to produce impact forecasts (an upgrade
of the model described in Chapter 3)129 of vaccines that, yet compatible with
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single trial-derived lectures of V Edis, have different effects on fast-progression
dynamics. Upon such an exercise, we find that vaccines reducing the proba-
bility of fast progression are expected to offer, for the same observed levels
of V Edis, significantly larger long-term impacts than vaccines that delay it.
This situation translates into an excruciating level of uncertainty in what re-
gards model-based impact evaluation of vaccines protecting against disease,
unless a method for telling apart which of the two mechanisms constitutes
a more plausible model under the light of the trial data is provided. Fi-
nally, we develop such a method for analysing raw results of clinical trials,
which allows to isolate and measure what are the mechanisms of action of
the vaccine that prevent or delay fast-progression to disease. This translates
into more accurate impact forecasts and more faithful characterizations and
comparisons of different types of vaccines, in a fraction of cases that depends
on trials’ specifications (cohort sizes and follow-up periods duration).
5.2 Methods
5.2.1 Vaccine protection mechanisms against disease:
reducing fast-progression probability vs. reduc-
ing fast transition rates to active TB
The essential goal of this work is to provide a means to interpret the
results of a generic phase II clinical trial of vaccine efficacy in terms of
compartmental models used downstream to evaluate vaccines’ impact and
cost-effectiveness. In the more elementary version of these models (figure
5.1A),55,97,101,102,108,203,204 susceptible individuals get infected at a rate β de-
fined by the interplay of their intrinsic susceptibility to infection and the fre-
quency of contacts with infectious individuals that they experiment. Upon
infection, they can develop fast-progression to disease (F) with a probabil-
ity p, or slow-progression (latent infection L) with the remaining probability
1−p. Finally, while fast progressors develop disease (D) at a rate r associated
to typical transition times lower than one year, latent individuals can remain
so for decades, only eventually falling sick, at a rate rL << r. When we are
talking about vaccinated individuals, parameters β, p and r get reduced to
(1− εβ)β, (1− εp)p and (1− εr)r, respectively.
From this general picture, a series of assumptions are necessary to in-
terpret the dynamics observed in a trial in terms of such minimal trans-
mission model. A typical randomized, placebo controlled clinical trial of
vaccine efficacy consists of two cohorts of initially susceptible individuals,
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Figure 5.1: Assessment of the degeneracy problem in efficacy evalu-
ation. A: Transmission model. B: Scheme of times of transition to infection,
and associated survival curves. C: Scheme of times of transition to disease
(after infection) and associated survival curves (of non-disease states). D:
Curve of values of (εp,εr) compatible with a measurement of V Edis = 0.5 af-
ter 4 years of follow-up (assuming εβ = 0). We have marked 5 different points
in this curve, with very different balance between the two mechanisms that
cause the degeneration, to be used in next examples. E: Forecasted impacts
(thousands prevented cases) obtaining after introducing the 5 highlighted
vaccines in a TB spreading model129 in Ethiopia for the period 2025-2050.
F: Evolution of measured V Edis for the 5 highlighted vaccines as a function
of the follow-up period.
(i.e. QuantiFERON-TB (QFT) negative200). At the beginning of the study,
the vaccine is supplied to one of these cohorts, while a placebo is given to
the other. Then, individuals will be periodically tested for infection (QFT)
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or disease (standard TB diagnosis criteria), during a given follow-up period
short enough (i.e. less than 10 years) for us to assume that all the transi-
tions to active disease observed were due to fast progressors in the first place.
Finally, analyzing transition times to infection and disease end-points, two
independent vaccine efficacy parameters can be measured: efficacy against
infection V Einf and against disease V Edis, (figure 5.1, panels B,C). Under
the light of this elementary transmission model, such efficacy observations
can arise from the three putatively independent mechanisms: reduction of
susceptibility to infection (via εβ > 0, see figure 5.1A), reduction of the frac-
tion of fast-progressors (εp > 0) and reduction of the rate of fast progression
to disease (εr > 0).
All that said, the nature of the question under analysis turns evident:
how to estimate three independent mechanisms of action of the vaccine from
two measurements of vaccine efficacy? Regarding vaccine protection against
infection, that question is easy to answer, since the only way for a vaccine to
protect immunized individuals against infection is to reduce their probability
of getting infected upon a contact with an infectious individual, which simply
implies that V Einf = εβ. Instead, vaccine’s protection against disease offers
a more complex outlook, because different vaccines, showing different com-
binations of effects on fast progression probabilities and transition rates to
disease (εp vs εr) are compatible with a single lecture of V Edis (figure 5.1D).
This implies that, from a trial-derived lecture of V Edis it is not possible to
say whether the vaccine decreases individuals’ risk to develop disease by re-
ducing the probability for them to become fast progressors upon infection or,
alternatively, by slowing down the rate at which they develop TB.
Once the problem is identified, a direct way to quantify its relevance is to
interrogate whether vaccines acting through different combinations of (εp, εr)
that are still compatible with a common value of V Edis might produce dif-
ferent impacts when applied on large populations. To answer this question,
we capitalized on the epidemiological model from Chapter 3, with a small
modification to incorporate vaccines. Using such a model, we simulated the
introduction of vaccines in Ethiopia, and obtained vaccines’ impact estima-
tions in terms of TB cases prevented from 2025 to 2050, upon a newborn-
focused vaccination campaign implemented at the beginning of that period
(figure 5.1E, vaccines compatible with V Edis = 50% in a 4 year-trial). For
this particular case, we found a difference of 256 thousand cases prevented
(104-466 95% CI) between the first vaccine (εp = 0.00, εr = 0.74) and the last
one (εp = 0.50, εr = 0.00), even though both vaccines provide an efficacy of
V Edis = 50% in a 4 year-trial. This supposes a relative difference of 51% (45-
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59 95% CI)–, evidence the critical relevance of this degeneracy, which would
compromise the reliability of any comparison between any disease-preventing
vaccine candidates solely based on their observed efficacy levels V Edis.
These results have a straightforward interpretation: slowing down tran-
sition rates to disease of fast progressors will always be less effective, in the
long term, than removing them from the fast-transition branch. A comple-
mentary way to illustrate this is to evaluate the time evolution of the efficacy
V Edis that would be observed, for a single vaccine, in trials of different du-
ration depending on its mechanisms of action (figure 5.1F), which can be
derived analytically (see section 5.2.2). In this sense, a vaccine that reduces
the intrinsic risk of developing fast progression (εp > 0) provides a reduction
in the risk of disease that is almost independent of the observation time. In-
stead, for a vaccine that only slows down the rate at which fast-progressors
develop active disease, the observed efficacy is a rapidly decreasing function
of time: the longer the trial, the less efficient the vaccine would appear to
be. This situation, which is intrinsically bound to the lower impacts fore-
casted from εr-based vaccines, translates into a violation of the hypothesis
of constant proportional risks underlying standard survival analysis (Cox
regression) typically used to estimate V Edis for those vaccines, a question
whose implications are discussed in detail in section 5.2.3.
5.2.2 Analytical solution of the transition model
According to the scheme of transitions that we are using to model a
clinical trial (see panel A of figure 5.1), the evolution of the four states (S:
Susceptible, F : Fast-progressors, L: Slow-progressors, latent infection and






= βpSc(t)− rFc(t) (5.2)
dLc(t)
dt
= β(1− p)Sc(t)− rLLc(t) (5.3)
dDc(t)
dt
= rFc(t) + rLLc(t) (5.4)
For the vaccinated cohort (subindex v), parameters β, p and r are modi-





= −(1− εβ)βSv(t) (5.5)
dFv(t)
dt
= (1− εβ)β(1− εp)pSv(t)− (1− εr)rFv(t) (5.6)
dLv(t)
dt
= (1− εβ)β(1− (1− εp)p)Sv(t)− rLLv(t) (5.7)
dDv(t)
dt
= (1− εr)rFv(t) + rLLv(t) (5.8)
In this model we implicitly assume that the individuals in the cohorts
correspond to a small fraction of the total population in the site, and thus,
their contribution to overall transmission once sick can be neglected. Solving
the system of differential equations, we obtain the proportion for every state
at each cohort. Initial conditions are Sx = 1 and Lx = Fx = Dx = 0 for
x = c, v, i.e. all individuals are susceptible at the beginning of the trial.
Sc(t) = exp(−βt) (5.9)






(1− εβ)βp (exp(−(1− εr)rt)− exp(−(1− εβ)βt))
(1− εβ)β − (1− εr)r
(5.12)
Lc(t) =




(1− εβ)β (1− (1− εp)p) (exp(−rLt)− exp(−(1− εβ)βt))
(1− εβ)β − rL
(5.14)




−β (1− p) (exp(−rLt)− exp(−βt))
β − rL
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Dv(t) = 1− exp(−(1− εβ)βt) (5.16)
−(1− εβ)β(1− εp)p (exp(−(1− εr)rt)− exp(−(1− εβ)βt))
(1− εβ)β − (1− εr)r
−(1− εβ)β (1− (1− εp)p) (exp(−rLt)− exp(−(1− εβ)βt))
(1− εβ)β − rL





p(Bv − Cv)εp + Av − pBv − (1− p)Cv
A− pB − (1− p)C
(5.17)
where:
A = 1− exp(−βT ) (5.18)
Av = 1− exp(−(1− εβ)βT ) (5.19)
B =




(1− εβ)β(exp(−(1− εr)rT )− exp(−(1− εβ)βT ))
(1− εβ)β − (1− εr)r
(5.21)
C =




(1− εβ)β(exp(−rLT )− exp(−(1− εβ)βT ))
(1− εβ)β − rL
(5.23)
5.2.3 Methods for the estimation of V Einf and V Edis
In order to obtain efficacy at infection, which corresponds to the parame-
ter εβ in the model, we implement the Cox Regression Model,205 since mod-
eling of infection is trivially compatible with the premises of Cox Regression
Model (i.e. Proportional Hazards). However, that is not the case for efficacy
at disease. According to the modeling that we propose for post-infection
processes, the applicability of Cox Regression Model is not guaranteed, since
the hypothesis of proportional hazards might not be correct depending on
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the features of the vaccine considered. To illustrate this situation, we have
conducted Schoenfeld’s Residual tests206 for different vaccines, characterized
by different values of εp and εr. The results of such a test are represented
in Figure 5.2 panel B, where we show the proportion of tests with a False
Discovery Rate (FDR) below 5% (Benjamini-Hochberg correction for Mul-
tiple Testing207). As a conclusion, we see how vaccines that delay the fast
progression rates violate more often the hypothesis of Hazards Proportion-
ality, which is coherent with the observation shown in figure 5.1C, where we
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Figure 5.2: Schoenfeld’s Residual tests. A. Coefficients of variation.
Simulations have been performed with a Cohort Size of 3000 individuals and
a follow-up period of 4 years. B. Proportion of tests with a FDR below 5%
as a function of εp and εr. Simulations have been performed with a Cohort
Size of 3000 individuals, a follow-up period of 4 years, and 500 iterations.
Motivated by that limitation of classical survival analysis regarding V Edis
we decided to make use of a more elementary, proportion-based estimate
for measuring the efficacy of a vaccine against disease, namely V Edis(T ) =
1− ρ(T ), where ρ(T ) is the disease ratio evaluated at the end of the trial, as
defined in equation 5.17.
This alternative way to estimate V Edis (or, equivalently, ρ) enables a
tractable analytical relationship between ρ, εr and εp, which will be useful in
order to determine εp once εr is independently estimated. Additionally, even
though the proportional hazards hypothesis is not perfectly met for all vac-
cines, it is worth noticing that the differences observed between proportion-
based and Cox-regression measures of V Edis(T ) are small.
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In Figure 5.2 we compare the results obtained with both measurements
of efficacy at disease for different vaccines. We see in panel A, representing
the Coefficient of Variation (CV) of such the two different measures, that
differences are bound below 8% of the mean of the efficacies estimated from
both methods.
5.2.4 Estimation of Vaccine Impact using a TB trans-
mission model
To estimate the impacts of different vaccines (in Ethiopia during the pe-
riod 2025-2050), we use the model developed in Chapter 3. The first stages
of the Natural History considered in this model are equivalent to those con-
sidered for the simulation of Clinical Trials, with a first class of susceptible
individuals from which individuals access two possible latency states (fast or
slow) when an infection occurs.
The model, as it was described, can not be used to evaluate the im-
pact of vaccines. Thus we need to extend the model by adding a second
branch for vaccinated individuals. This second branch follows qualitatively
the same Natural History, already explained in Chapter 3, but quantitatively
the disease parameters that regulate all the transitions between states can
be modified by the epidemiological intervention considered (in this case vac-
cines). Thus, for every parameter x in the unvaccinated branch, we have
x′ = (1− εx)x in the vaccinated branch, where εx represents the effect of the
vaccine over the parameter x.
In this work, we study vaccines that act over three different parameters:
the force of infection (εβ), the probability of fast progression (εp) and the
rate of fast progression (εr). We assume εx = 0 for every other parameter
(i.e., the vaccine has no other effect). Individuals in the vaccinated branch
contributes to the force of infection with the same weight than no vaccinated
individuals (i.e., a reduction in infectiousness or contact rate as a result of
vaccination is not considered).
For this study, we are considering newborn vaccination. Newborns enter
the system only in the vaccinated branch starting in 2025 (which we consid-
ered as the year that, in the best case scenario, a new massive vaccination
campaign could begin), while they enter the unvaccinated branch exclusively
(following an unmodified Natural History) before that year. In other works,














































Figure 5.3: Natural History scheme of the TB spreading model with
a vaccinated branch. To the control branch (i.e. non-vaccinated), a par-
allel branch where individuals have received a vaccine (i.e. red arrow transi-
tions) is added. In the vaccinated branch, the disease transmission dynamics
is the same with the exception of that, depending on the vaccine type, the in-
fectiousness, probabilities of fast transmission and/or rates of fast-progression
to disease are reduced, as dictated by the vaccine descriptors εβ, εp and εr,
respectively.
newborn coverage, for instance BCG coverage in Ethiopia reached a 92% in
2016.208
The impact results that are reported in what follows correspond to the
difference of incidence cases in the period 2025-2050 between the scenario in
which no vaccine is introduced and the scenario where we introduce a vac-
cine with its corresponding specifications. Further technical specifications on
model parameters, bibliographical sources, methods used to estimate uncer-
tainty in model-based estimates, etc., can be found in Chapter 3.
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5.2.5 Interaction between impact evaluation time win-
dow and vaccine mechanism
The impact of a vaccine will strongly depend on the period of time consid-
ered. While vaccines that are focused on the delay of fast-progression might
work well in short-term, its effectiveness is compromised in the long-term
as we have discussed previously. In figure 5.4, we further explore that phe-
nomenology representing the impact, measured over different durations, for
different vaccines that give the same disease efficacy in 4-year trials relaying
either to different extents on εr or εp. As we can see, in the short term (when
the evaluation of impact is performed over a period that is smaller or of
the same order than the period of the clinical trial itself) vaccines designed
to delaying fast-progression are associated to quicker short term impacts.
However, as the evaluation time window is enlarged, vaccines that prevent













































































Figure 5.4: Impact measured over different time windows, for vac-
cines that provides the same disease efficacy in 4 year trials. The
x-axis shows the value of εr of the vaccines, as the parameter relevant of the
curve εp − εr. εβ = 0 in this case.
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In principle, it is expected that the intrinsic efficacies of the vaccine are
comprised between 0 and 1, where 1 would mean a perfect efficacy and 0 no
effect at all. However, it is possible for a vaccine to have a negative effect. In
the case of efficacies affecting rates (i.e. εβ and εr) there is no formal lower
limit and a rate equals to ∞ (associated to ε = −∞) would mean an instan-
taneous process, although a conservative enough limit of -300 is implemented
to avoid numerical instabilities. On the contrary, εp works as a modifier of
a probability, which implies that (1 − εp)p has to be comprised between 0
and 1, introducing a lower limit for εp that is εp,min = 1 − 1p . Furthermore,
the existence of such lower bound in εp generates in turn an upper bound for
εr, since these two parameters are analytically bounded through a common
value of the disease-ratio ρ = Dv/Dc.
Based on this result, when evaluating the state-of-the-art complete un-
certainty in the evaluation of impacts, we will assign as the minimum impact
that corresponding to the vaccine with the maximum possible value of εr
(and therefore minimum value of εp, given the analytical expression that links
those parameters for a given V Edis). For the maximum impact in principle
there exists no bound as already mentioned. However, given the saturation
of the impact that is produced for decreasing values of εr, the limit that we
have imposed of εr = −300 provides a good proxy for the upper bound of
impact.
5.2.6 Breaking the degeneracy: a method for estimating
εr and εp
Even though violation of the proportional-hazard hypothesis in trials’
data constitutes a first signature suggesting delay in progression rates rather
than fast progression prevention, its potential to tell apart quantitatively the
possible mechanisms of action of a vaccine (see figure 5.2) is limited. Thus,
we propose a different approach to provide an independent estimation of εr
and εp.
5.2.6.1 Estimation of εr: truncated fit of transition rates from
uncensored sub-cohorts
The method consists of adding, to the custom estimation of V Einf and
V Edis, a third statistical analysis aimed at directly estimating εr from the
transition times between infection and disease (figure 5.5, panel A). To do so,
unlike classical survival analysis, we only make use of data associated to not-
censored times: that is, individuals that have completed their transition to
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disease within the follow-up period of the trial. By doing so, we can assume
that all these cases correspond exclusively to fast progressors (for rL << r),
and obtain an analytical expression for the expected distribution of transition
times observed between infection and disease t = tdis − tinf (i.e., the time
difference between the moment individuals first produce QFT positive results
and when they fall sick), conditioned to the moment the infection took place.
Furthermore, if we assume that the transition from active disease upon infec-
tion is a Poisson process, –as it is done customarily in compartmental models
in mathematical epidemiology55,108,209–, the theoretical probability distribu-
tion function (PDF) of the time t = tdis.−tinf. between infection and disease in
the control cohort would correspond to an exponential curve f(t|r) = re−rt,
from which the average transition time 〈t〉 = 1/r and its associated variance
σt = 〈t2〉 − 〈t〉2 = 1/r2 can be easily obtained by integrating the moments of
the PDF.
However, in the practical context of a clinical trial, the period of measure
cannot be arbitrarily extended, which implies that the maximum transition
time that can be observed for a subject who was initially infected at tinf is
truncated at tmax = T − tinf , where T stands for the follow-up period of the
trial. This situation implies that the integrals needed to obtain the expected
value of the transition time need to be truncated as well, which ultimately











−r(T−tinf ) (T − tinf )
1− e−r(T−tinf )
(5.24)
Similarly, by truncating the integrals of the second moment of the distri-
bution we can obtain its dependence with the time at infection, 〈t2〉(tinf )),
and ultimately derive the corresponding expression for the variance of ob-
served transition times as a function of tinf :
σ2t (tinf ) =
− exp(−r(T − tinf))
(
1 + (r(T − tinf) + 1)2
)
+ 2 (1 + r(T − tinf) exp(−r(T − tinf)))





(T − tinf)2 exp(−2r(T − tinf))
(1− exp(−r(T − tinf)))2
(5.25)
Equations 5.24 and 5.25 describe how observed transition times from
infection to disease and their variance are expected to be biased towards
lower values as the infections occur later during the trial; simply because the
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Figure 5.5: Method for estimating εr and εp A. Scheme of the Method for
characterizing vaccine’s efficacies. B. Schematic representation of the process
of this work. C. Transition times of control cohort (top) and two different
vaccinated cohorts (center and bottom). Expectation values in blue for vac-
cinated cohorts and grey for controls. Analytical predictions in dashed lines.
D. Probability density of the inferred parameters of the vaccines (εβ, εr, εp),
alongside the inferred parameters (with their respective CIs) for two differ-
ent vaccines. E: Fraction of correct realizations of a trial as a function of
the follow-up period, for three different cohort sizes and 5 different vaccines
(same 5 as in Figure 5.1)
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to disease is left. These expressions allow us to isolate the effect of that bias,
and to infer, using only data from individuals developing active TB during
the trial, the transition rate r within the control cohort, via a Maximum
Likelihood approach (R package bbmle210) along with its confidence intervals
(95% reported). Then, the exercise is repeated in the vaccine cohort, whose
transition rate rv, in terms of the transmission model would be expressed as
the product r(1 − εr), which yields the following expression for the vaccine





Finally, we obtain an estimation of the CI for εr by propagating the
independent uncertainties of rv and r.
5.2.6.2 Estimation of εβ and εp
The effect of the vaccine on the infection rate, codified in the model as εβ,
coincides, by construction, with the vaccine efficacy against infection V Einf ,
and, as such, is inferred using Cox-regression (R package OIsurv211).
The third vaccine effect –reduction of fast-progression probability εp–
can be trivially deduced once the other effects are known. First, we need to
calculate the disease-ratio at the end of the trial (see equation 5.17). The
ratio will depend only on the parameters of the vaccine (εβ, εp and εr) and
on the natural parameters of the disease (β, p, r and rL) and on the trial
follow-up period T . From equation 5.17 we finally obtain εp as follows:
εp =
ρ(T ) (A− pB − (1− p)C)− Av + pBv + (1− p)Cv
p (Bv − Cv)
(5.27)
Finally, in order to estimate εp uncertainty, we propagate standard error
from εβ (Cox regression), εr (from Maximum likelihood-based inference of
fast-progression rates at control cohort and at vaccine cohort, as explained
before) and ρ. Regarding the latter source of uncertainty, we obtain the








which yields the following confidence interval:














where Dc(T ) and Dv(T ) are the fraction of cases observed at both cohorts
during the follow-up period, and z1−α
2
is the standard score for the chosen
level of significance α (we will use 95%).
5.2.6.3 Testing the method: Synthetic clinical trials simulations
To test the performance of this approach, we used Monte Carlo methods
to simulate synthetic clinical trials of different lengths and sizes, for vaccines
acting through different mechanisms and showing disparate levels of protec-
tion (Figure 5.5, panel B). To these produce synthetic simulations of clinical
trials, we first calibrated the baseline parameters of the transmission model
to reflect the current epidemic situation in Worcester, South Africa, where
the MVA85A study took place.200 First, the transition rate from LTBI to
disease is assumed to be rL = 7.5 × 10−4y−1, in accordance with previous
bibliographical estimations.55 The probability of fast-progression has been
fixed to p = 0.375 which is compatible with previous observations about the
remarkably high probability of developing fast-progression during the first
months of life. The value used in this work is a reference to simulate trials
conducted in newborns.
Second, the baseline transmission rate was estimated to be β = 0.069y−1
to reproduce the proportion of infections in the control cohort of the MVA85A
trial (12.8% after 2 years). Finally, the transition rate from fast latency to
disease r = 0.97y−1 was calibrated to reproduce the same proportion of cases
than in the control cohort of MVA85A trial (2.3% after 2 years), once all
the other parameters are fixed. The fast-progression rate is also compati-
ble with previous observations.55 Thus, this approach is specific both to the
site and age-strata of individuals joining the trial, which means that the in-
ferred baseline parameters cannot be automatically used to simulate trials
conducted in other sites, or age-cohorts, although similar re-calibrations are
possible upon availability of reference data. Similarly, since BCG vaccination
is mandatory in South Africa, the baseline parameters have embedded the
eventual protective effects provided by the old vaccine.
Next, we arbitrarily define a vaccine by providing the triad of vaccine
efficacies (εβ, εr, εp), describing its effects on the infection rate, the transition
rate to disease, and the probability of fast progression, respectively. While
a value of, for example, εβ = 0 means no protection against infection, and
εβ = 1 means perfect protection, it is worth stressing that, in principle, vac-
cines where any of the three ε parameters is lower than zero are possible,
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as it is possible to observe a failed vaccine that indeed increases the risk of
infection or disease with respect to the control cohort, as occurred in the
MVA85A trial (although not significantly).200
Once all the dynamical parameters governing TB transmission dynamics
in both cohorts are set up, we use an agent-based approach to simulate the
evolution of N individuals per cohort during a follow-up period T . We use a
discrete time step of 3 months to reproduce the temporal resolution between
consecutive analyses (QFT for infection and/or TB diagnosis tests for active
TB) in the MVA85A trial.
Thus, we generate a set of vectors of transition times to infection and
active TB that summarizes the realization of the trial. Since the model is
probabilistic by construction, we iterate to obtain a set of simulated trials
describing a distribution of most-likely outcomes associated to such a trial
set-up as a function of the a-priori known vaccine behavior. From a given
vaccine (εβ, εr, εp) and trial design (N, T ) we simulate 500 equivalent trials
that we characterize using the method developed. From the inferred param-
eters we obtain a global estimation of the parameters and their CIs that we
will use to evaluate their impact and their respective uncertainty.
In order to obtain global estimates and confidence intervals for vaccine
descriptors we follow a three steps approach. First, we generate a set of 500
synthetic clinical trials for each vaccine analyzed. Second, for each of these
simulated trials, we infer the values of the vaccine descriptors εβ, εp and εr
along with their confidence intervals: that of εβ from Cox-regression, that
of εr, as explained before, and, finally, that of εp propagated from the other
two, and from the CI of the disease ratio ρ. Finally, we assume that the
true values of these parameters come from an unweighted mixture of normal
distributions each of which is associated to the log transform of one minus
the outcome of each simulated trial. The final value and CI of each of the
three vaccine descriptors is associated to the median and 95% CI of such
distribution mixture, back in the linear scale. Through this approach we get
a global estimation of the accuracy and precision of the method as a func-
tion on the predefined vaccine’s characteristics and trial dimensions, which
we have introduced in the TB spreading model for the forecasts of vaccine
impacts (and their correspondent Confidence Interval).
Then, for each clinical trial realization, we use the method to infer the
vaccine descriptors (εβ, εr, εp). In figure 5.5, panel C we represent three ex-
amples of how the transition times associated to a single realization of a
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synthetic trial can be used to infer the transmission rates at the control co-
hort (upper panel) or at the vaccine cohort used, which are compared to infer
εr. Here, two types of vaccines are considered: an example of a vaccine that
prevents fast progression (center, where the inferred transition rates are not
significantly different from the controls), and another example where the vac-
cine reduces transmission times to disease within the fast progression branch
(lower panel). Then, once εr is estimated from the analysis of the transi-
tion times, we infer the other two parameters as described above to retrieve
estimates for the three vaccine descriptors (εβ, εr, εp). As it can be seen in
Figure 5.5D, this closely reproduce the initial values used to simulate the
trials. Results correspond to a set of 500 realizations for an example vaccine
with εβ = 0, εp = 0.4, εr = 0.4.
A final question to address concerns the range of applicability of the
method. Since the key step of the proposed approach relies on the calibra-
tion of the distribution of infection-to-disease progression times, the size and
duration of it must be big enough to ensure sufficient statistics. As explained
before, there exists a minimum value of εp (that is εp,min = 1− 1p), that gen-
erates an upper bound for εr as these two parameters are linked through the
disease ratio ρ. Notwithstanding this, the inference of εr is agnostic to the
value of ρ or εp, and, as a consequence, for poor statistical settings –most
often in the case of vaccines delaying fast-progression– some individual trial
realizations lead to vaccine descriptor estimates that lie beyond these epi-
demiologically meaningful intervals for parameters εp and εr. In figure 5.5E
we represent the fraction of stochastic realizations that yield valid inferences
of vaccine descriptors, for the same five vaccines represented in figure 5.1E.
For a trial with a cohort size of 3000 individuals and follow-up period of
4 years, only a vaccine acting exclusively through εr yields a probability of
observing a trial incompatible with this method that surpasses 10%. Those
ill-defined realizations are excluded from subsequent analyses.
5.3 Results
5.3.1 Method’s evaluation: uncertainty reduction in im-
pact evaluations
In the previous section, we described how we simulated stochastic realiza-
tions of clinical trials of different vaccines, and inferred, from each realization,
the vaccine descriptors (εβ, εr, εp), in a way that is blind to the "real" values
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used to generate the synthetic trials. Next, we are interested in quantifying
the extent to which impact forecasts might benefit from having access to the
specific values (εβ, εr, εp). To this end, we feed the epidemic model with these
parameters, simulating the introduction of the vaccines in Ethiopia in 2025,
and estimate impact forecasts in number of TB cases prevented within the
period 2025-2050 (Figure 5.6A).
To evaluate the advantages of this approach in this context, we compare
the impact forecasts generated using the procedure described above to the
most extreme impacts that can be obtained if, after measuring V Einf and
V Edis from the synthetic trials, the efficacy against disease is mapped to all
sort of possible combinations of values (εr, εp) that are compatible with it,
a procedure that could be assimilated to the uncertainty provided by state
of the art efficacy evaluation. As it can be seen in figure 5.6A, the degen-
eration between possible mechanisms underlying protection against disease
translates into exacerbated levels of uncertainty that almost systematically
prevent the rejection of the null hypothesis of null vaccine impact; an obser-
vation that is valid for a wide range of values of V Edis.
On the contrary, analyzing simulated trials’ data using this method sub-
stantially contributes to reduce the associated uncertainty of impact fore-
casts, in a factor ranging from 23% to 63% in the examples showed. The
foreseen impacts showed in Figure 5.6A have two sources of uncertainties in-
volved, those that come from the evaluation of vaccine parameters and those
coming from the spreading model itself, except when we evaluate the real un-
derlying vaccine for which we only have the latter. As shown in Figure 5.6A,
in the case of vaccines that reduce fast-progression, the inferred parameters
of the vaccine introduce a significant increase in the Confidence Interval of
the forecasts. This situation is avoided in the case of vaccines that prevent
fast-progression from taking place, whose confidence intervals are compara-
ble with the uncertainty that is exclusive from the model.
Finally, we are interested in estimating the probability of registering a
successful trial (i.e. a trial associated to a significant estimate in terms of
vaccine descriptors and forecasted impact), as a function of both trial size
and true, underlying vaccine features. To achieve this, we simulated clini-
cal trials of different sizes and durations for the two extreme vaccines among
those represented in figure 5.1E (both of which share the same reference level
of protection V Edis(T = 4) = 50%), which act either by reducing proportion
of fast progressors (εr = 0, εp = 0.50) or by slowing them down in their path
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Figure 5.6: Impact evaluation of synthetic vaccines characterized
with the developed method. A. Real impact (i.e. derive from the real
vaccine parameters), inferred impact (derived from the vaccine parameters
obtained using the method proposed here) and state-of-the-art uncertainty
for 9 different vaccines (3 different levels of efficacy at disease × 3 different
balances between εp and εr). In all cases εβ = 0, N = 3000 and T = 4y.
While the real impact carries only the uncertainty related to the spreading
model; the inferred impact from this approach also involves the uncertainty
given by the characterization of the vaccine. State-of-the-art uncertainty is
obtained after simulating the impact with the two points of the curve (εp, εr)
that will provide the most extreme impacts. B. Proportion of false negatives
in the characterization of the vaccine (i.e. fraction of realizations that leads
to a characterization of εp (left) or εr (right) that is not significantly larger
than zero at a 95% CI). We study two different vaccines: εp-based (left)
and εr-based (right), focusing on the characterization of the positive effect
of the vaccine (i.e. εp and εr respectively). C. Probability of obtaining a
positive impact for the two vaccines under study –εp-based (left) and εr-based
(right)–. We assume that the impact obtained and its associated uncertainty
correspond to a Normal Distribution with 95% CI.
dimensions, the probability of obtaining a valid trial simulation yielding an
inferred value for the corresponding ε statistically significant (95% CI not
crossing zero). In figure 5.6C, we complement these results by characterizing
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how likely it is to obtain a clinical trial result associated to a forecast with
significant impact.
5.3.2 Evaluation of vaccines with protection against in-
fection (εβ > 0)
Throughout this chapter we have explained how we break the degeneracy
of two mechanisms capable to offer protection against disease, and quantified
the importance of this method in terms of posterior evaluation of vaccina-
tion impact. However, as we have discussed, protection against infection
can be totally solved with the current methodology. Therefore, for a vac-
cine that prevents infection the framework presented in this work becomes
unnecessary. Although it is to be expected that future vaccines will most
likely affect pathways from infection to disease, we have repeated some of
the previous analyses with vaccines that act partially against infection (a sit-
uation similar to BCG, who offers a small protection against infection75,192).
More specifically, we include vaccines that are equivalent to those previously
explored, in the sense that are compatible with the same measurements of ef-
ficacy against disease (i.e. V Edis(T = 4 years)) but incorporating an efficacy
against infection given by εβ = V Edis(T=4 years)2 , meaning that, at a first-order
approximation, we can state that half of the protective power of the vaccines
showed in this section is given at the infection process.
As shown in Figure 5.7A, including a protective effect on infection evi-
dently lowers the curve of values compatible with the same measure of efficacy
at disease. The efficacy at infection of these vaccines poses a common ground
of posterior impact that significantly reduces the differences between the five
vaccines analyzed on terms of foreseen impact (Figure 5.7B), being the rel-
ative difference between the first vaccine (εβ = 0.25, εp = 0.35, εr = 0) and
the last one (εβ = 0.25, εp = 0, εr = 0.62) a 29% (26-33) 95% CI, while in
the case of εβ = 0 we have shown relative differences of 51% (45-59 95% CI).
Also, the differences in the time evolution of V Edis (Figure 5.7C) suffer a
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Figure 5.7: Results for a vaccine with εβ > 0. A: Curve of values of
(εp,εr) compatible with a measurement of V Edis = 0.5 after 4 years of follow-
up (assuming εβ = 0.25). B: Predicted impacts obtaining after introducing
the 5 highlighted vaccines in a TB spreading model in Ethiopia evaluated
in the period 2025-2050. C: Evolution of measurement of V Edis for the 5
highlighted vaccines as a function of the follow-up period. (Continued on
next page ...)
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Figure 5.7: (... continued) D: Transition times for the control cohort, and
the vaccine cohort for the two extreme vaccines considered (balance 0-100
and 100-0). E. Probability density of the inferred parameters of the vaccines
(εβ, εr, εp), alongside the inferred parameters (with their respective CI) for
two different vaccines. F: Fraction of correct realizations of a trial as a
function of the follow-up period, for three different cohort sizes and 5 different
vaccines (the 5 vaccines remarked in panel A). G. "Real" impact, inferred
impact (using the proposed method) and state-of-the-art uncertainty for 9
different vaccines.
We see in figure 5.7D the individual transition times for a trial realization
with two different vaccines. A protective effect at infection will reduce the
pool of possible posterior transitions to disease, which might constitute a
problem for the inference of vaccine’s parameters. However, as in this sec-
tion we are comparing equivalent vaccines to those studied before (in the
sense that they showed the same V Edis after 4 years), these vaccines have
a smaller effect in the pathways that protect against disease, so the number
of transitions remains, approximately, the same; and this method is able to
extract correctly the rates of fast-progression.
As for the distribution of inferred parameters (Figure 5.7E), εβ is sig-
nificantly assessed as positive in this examples, as εr in the correspondent
vaccine. The fraction of valid realizations (Figure 5.7F) gets improved with
respect to their counterparts with εβ = 0 Finally, when we study the im-
provement associated with this method with respect to the state-of-the-art
framework, is only slightly reduced with respect to the examples presented
before, ranging from 17% to 59% in the examples showed in Figure 5.7G.
Therefore, even if a significant fraction of a vaccine protective power
comes from prevention of infection, the application of this methodology would
still be pertinent.
5.4 Discussion
Despite TB being one of the diseases for which a vaccine was first devel-
oped, there is still much to learn about the mechanisms that TB vaccines,
both BCG and novel candidates, unfold to disrupt the pathogen’s life cy-
cle. Recent studies have challenged the classical view according to which
BCG works solely by priming T-cell mediated adaptive immune responses,
proposing more complex models of vaccine function. According to these new
views, BCG vaccination is also able to boost host’s innate immune system, so
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providing an additional layer of non-specific, sustainable protection against
infection, (usually referred to as "trained immunity"), which can be observed
both in-vivo and in-vitro .212,213 How these observations might contribute to
explain certain epidemiological aspects of BCG’s behavior is still unclear;
like its ability to reduce M.tuberculosis infection risk;192 its variable pro-
tection levels against TB disease,75 or their correlations with age, latitude
and/or previous exposure to mycobacterial antigens,78,166 or its recently dis-
covered ability to disrupt the transmission chain of TB at other points.116
In any case, there is increasing scientific evidence suggesting that vaccines
confer protection against infection and disease by mediating host-pathogen
interactions in ways that, specially in the TB case, are more complex than
classically accepted. An additional piece of this intricate puzzle, which we
begin to analyze here, is that of understanding the possible repercussions of
these improved vaccine descriptions on disease transmission dynamics.
Throughout this chapter, we have described how vaccine protection against
disease can manifest in different ways at the epidemiological level, e.g., by
slowing down fast progression to disease (εr-based vaccines) and/or prevent-
ing it completely (εp-based vaccines), among others. As we have shown, these
putative mechanisms of action cannot be disentangled by applying simple
survival analysis. This limitation of standard methodologies when applied
to TB is unexpectedly relevant, for we have shown that vaccines relying its
protective action on these two mechanisms, even if they might appear as
equally effective in the context of a clinical trial of vaccine efficacy, behave
in remarkably different ways. As a result, this affects both the feasibility of
their characterization as successful vaccines and the ultimate impact on TB
burden reduction that they can provide. In this sense, εr-based vaccines ap-
pear associated to lower prospected impacts for equivalent lectures of vaccine
efficacy, and they are harder to analyze, as they would require bigger clinical
trials of longer duration in order to be characterized at comparable levels of
statistical significance. Therefore, distinguishing between these two different
mechanisms of action improves early evaluation of TB vaccine candidates
by contributing to a deeper description of vaccines’ expected behavior when
applied on large populations and, more importantly, by avoiding previously
unnoticed biases in their comparison, a crucial aspect in a context where
resources are limited and committed only to the most promising candidates
at each stage. As a result, considering the questions explored in this study
will contribute both to achieve a better interpretation of its outcomes as well
as to improve the probability of success of a clinical trial of vaccine efficacy.
The method here proposed is instrumental in a number of situations, but
167
CHAPTER 5. DESIGNING CLINICAL TRIALS
has intrinsic limitations regarding both the dimensions of the trials that can
be analyzed as well as the types of vaccines that can be characterized more
accurately by using it. On the one hand, the framework proposed in this
work is of application in the most favorable event of a vaccine being able to
prevent TB infection (εβ-based vaccine) too. However, as explored in section
5.3.2, when protection against disease is primarily achieved through a re-
duction of the probability of infection, the considerations made in this work
are quantitatively less relevant. In that case, the appearance of additional
vaccine effects, either via εp or via εr yields more comparable vaccine behav-
iors, because the common, main vaccine effect on reducing the infection rate
defines the impact expected for the vaccine.
On the other hand, we have simulated trials of cohort sizes comprised be-
tween 1000 and 7000 individuals, during follow-up periods between 3 and 7
years. In the limit of short, small trials, low statistics constitutes a fundamen-
tal limitation that reduces the chances of obtaining a successful vaccine char-
acterization, even for highly efficient vaccines. In turn, if the trial size and
duration has to be increased, while increasing cohort size is always positive,
implementing longer follow-ups may require different analytic approaches to
those here presented. The reason is that the fundamental hypothesis behind
this method is that all individuals progressing to disease during the trial
can be associated to immediate progression upon infection: if the trial pe-
riod is arbitrarily extended, such hypothesis does not hold anymore, and this
method for estimating εr and εp would be biased.
In addition, the method of vaccine characterization can in principle be ex-
tended to more complex scenarios where more subtle phenomenologies can be
considered. This includes to study the effect of vaccine heterogeneity, either
within or across age (i.e., immunity waning), as well as to include in the simu-
lated trials the dependence of some of the dynamical parameters on subjects’
age. Admittedly, even if such refinements might be relevant from a quanti-
tative stand, other limitations regarding the amount of information that can
be extracted from a short clinical trial will most likely persist, regardless of
these considerations. This comprises the intrinsic inability to estimate the
effects of a vaccine on the slow dynamics of LTBI from a short-course trial, as
well as the existence of multiple unavoidable sources of uncertainty that af-
fects the precision of model-based impact and cost-effectiveness evaluations,
independently on how precise the efficacy of the vaccine itself is estimated
from a trial.
Despite these limitations, the methodology presented in this work is in-
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strumental for designing clinical trials that are more likely to succeed in the
characterization of novel TB vaccines – and for providing a deeper character-
ization of them–, able to reduce uncertainty in impact forecasts evaluations.
In the next final Chapter we will finally assess the impact of different
vaccines, focused on different age-groups.
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Chapter 6
Impact evaluation of novel TB
vaccines
6.1 Introduction
As has been explained throughout this thesis, it is an unsolved problem
how to determine the performance of a vaccine at its first development steps,
due to the lack of immune correlates of protection against TB disease.214
The field has already suffered the failure of the promising vaccine candidate
MVA85A, that despite achieving great successes at the clinical level and in
animal models,215–221 failed to provide protection against infection or disease
at an efficacy clinical trial.200,201
In this context, transmision modeling is crucial, for models will be the
ultimate tool to quantify the impact expected from a given vaccine and to
compare it with possible alternative candidates. It is crucial to note that an
efficacy estimate emanating from a clinical trial is not the only readout of a
vaccine defining its impact, as we have shown in Chapter 5. In other words,
not always the vaccine with the largest trial-estimated efficacy will translate
into a higher impact, or viceversa.
In TB, several additional factors affect vaccines’ impact in a crucial man-
ner, beyond the intrinsic efficacy of the vaccine. The first one is the age
strata on which the immunization takes pace. Among the different candi-
dates we can identify two different groups: prime vaccines, designed to be
replacements of the current BCG vaccine;117 and boosters, enhancers for the
immunogenic power of BCG.79 As we have explained previously, at least in
principle, these two groups of vaccines are intended to be administered at dif-
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ferent ages: while prime vaccines would be inoculated in newborns as BCG is,
boosters would be used at adolescence, when BCG loses its protective effects.
This is of utmost importance, since age-distributions of pulmonary TB in-
cidence and prevalence of infectious individuals are strongly age-dependent,
with adolescents and young adults having much larger burden levels than
infants, as shown in Chapter 3. This translates into the fact that, a priori,
a vaccine applied on adolescents will be expected to provide a larger impact
than an equivalent vaccine with the same efficacy, applied on newborns, a
result already confirmed by models.101 To that, also contributes the fact that
now, BCG offers few to none protection against TB in those age groups (it
wanes before that) and, since the impact of a new vaccine is to be measured
in comparison with BCG, the old vaccine is much easier to overcome on ado-
lescents/young adults than on children.
However, that general observation is affected by several critical aspects
that should be explicitly considering for compared prime-vs-booster vaccines.
First, achieving similar levels of vaccine coverage is much harder in adoles-
cents than in newborns.222 Second, previous sensitization to environmental
mycobacteria (which will be greater in adolescents than in newborns) can af-
fect the performance of a vaccine. As was shown in Chapter 4, for BCG this
environmental sensitization works by blocking the effect of the vaccine.78,166
Third, new vaccines might suffer from waning of immunity,223 which is hard
to be determined in an early-phase trial. The waning of immunity is a key
parameter to determine the impact and cost-effectiveness of a vaccine.
The proper consideration of all these aspects (which is essential to guide
unbiased decision making in the future), needs comprehensive spreading mod-
els able to provide, very specially, a description of the ways through which
TB spreading is coupled to age-structure. In Chapter 3, we developed a
first approximation of such model,129 including evolving demographic struc-
tures (following predictions) and empirical age-dependent contact patterns
(properly coupled to the evolving demographic structures224 as explained in
Chapter 2). In Chapter 5 we expanded it to include the evaluation of new
vaccines.
Here we use this model to explore how these aspects might impact the
evaluation of novel vaccines, either boosters applied on adolescents or prime
aimed at substituting BCG. That supposes the first framework for vaccine





6.2.1 Modification of the transmission model
We use the transmission model developed in Chapter 3 and expanded
in Chapter 5 to the problem of evaluations of epidemiological interventions.
This expansion consisted in adding a second vaccinated branch with the
exact same Natural History but with a modification in the epidemiological
parameters produced by the vaccine. Thus for every class X that we have
for unvaccinated individuals (see table 3.6 in Chapter 3), we have a class Xv
corresponding to vaccinated individuals that are in the same stage of the dis-
ease and each parameter x in the vaccinated branch transforms to (1− εx)x
(where εx represents the effect of the vaccine to that particular epidemiolog-
ical parameter x).
For this work we will only consider vaccines that prevent disease by mod-
ifying the probability of fast-progression (parameter p). Thus we will have
εp > 0 and εx = 0∀x 6= p. Although having a vaccine that also protects
against infection could be very useful, and it is known that BCG offers some
protection agains infection (even though it is not its main effect),75 in this
chapter I will only focus on the study of vaccines that provide protection
against disease, which is considered the main mechanism of action in BCG.225
In Chapter 5 we also discussed the possibility of having two different path-
ways to prevent disease (the probability of fast-progression and the rate from
infection to disease), and how they could be measured independently. For
the sake of simplicity we have focused on only one interrupting mechanism
from infection to disease, in this case the probability of fast-progression p.
In Chapter 5 we only included newborn vaccination, and a coverage of
100%. In that case, after 2025 (which we consider as the date the vaccination
campaign begins) all newborns are added to the vaccinated branch. Now
we expand this scenario to include an arbitrary coverage level c ∈ [0, 1]
and adolescent vaccination. For newborn vaccination the modification is
trivial as we only have to divide the flux of newborns between both branches
(vaccinated and unvaccinated) according to the coverage c. However, due to
mother-child transmission of the disease, we also introduce newborns to the
latency states. Thus, when newborn vaccination is considered, individuals
are introduced in the system at 6 different states, S, Lf , Ls, Sv, Lvf and Lvs ,
according to the following fluxes:
• Birth of S(0, t) individuals (susceptible newborns, unvaccinated): (1−
cnewb.(t))(1−mcmd(t))∆N(a = 0, t)
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• Birth of Lf (0, t) individuals (infected after birth who develops fast pro-
gression, unvaccinated): (1− cnewb.(t))mcmd(t)p(0)∆N(a = 0, t)
• Birth of Ls(0, t) individuals (infected after birth who develops slow
progression, unvaccinated):
(1− cnewb.(t))mcmd(t)(1− p(0))∆N(a = 0, t)
• Birth of Sv(0, t) individuals (susceptible newborns, vaccinated): cnewb.(t)(1−
mcmd(t))∆N(a = 0, t)
• Birth of Lvf (0, t) individuals (infected after birth who develops fast pro-
gression, vaccinated): cnewb.(t)mcmd(t)(1− εp)p(0)∆N(a = 0, t)
• Birth of Lvs(0, t) individuals (infected after birth who develops slow
progression, vaccinated):




0 if t < 2025
cnewb. if t ≥ 2025
(6.1)
Equation 6.1 simply states that the vaccination campaing (with a cover-
age that we will specify later) begins at 2025, therefore before that year the
coverage is zero and no individual enters in the vaccinated states.
Adolescent vaccination is coupled to the aging process. When unvacci-
nated individuals pass from a = 2 (10-15 years old) to a = 3 (15-20 years
old), a fraction of them (given by the coverage) are moved to the vaccinated
branch. We also consider that only susceptible individuals receive vaccination
(i.e., we are modeling pre-exposure vaccines). For other type of interventions
such as post-exposure vaccines, treatment of LTBI, etc., we should consider
vaccination in other classes as well. Thus, adolescent vaccination can be
reduced to the following fluxes:
• Transition from S(a = 2, t) to S(a = 3, t) (Non vaccinated adolescents):
(1− cadol.(t))S(a = 2, t)/∆t individuals/unit time.
• Transition from S(a = 2, t) to Sv(a = 3, t) (Vaccinated adolescents):
cadol.(t)S(a = 2, t)/∆t individuals/unit time.
where, as for newborn vaccination:
cadol.(t) =
{
0 if t < 2025




The rest of aging process remain as described in Chapter 3, both for the
vaccinated and unvaccinated branches.
6.2.2 Coverage Data
Although we have generalized the modeling framework to any possible
value of the coverage, it is still interesting to perform simulations with a per-
fect coverage of 100%, as this scenario represents the maximum impact we
can extract from a vaccination campaing in an ideal situation.
But, of course, we are also interested on how different levels of coverage
might compromise the performance of a vaccine and, specially, the compar-
ison between adolescents and newborns campaings, as it is expected that
adolescent vaccination will have lower coverage values. When establishing
reasonable coverage values, we assume that a newborn vaccination campaign
would have a similar coverage than BCG. Thus, we will use the data on BCG
coverage, as extracted from WHO database.149 For adolescents we follow the
assumption made by Knight et al. 101 , and we take as coverage values the
school attendance rates. In table 6.1 we show the values for the countries
discussed for this work.
Country Newborn coverage (%) cnewb. Adolescent coverage (%) cadol.
India 89 72
Nigeria 64 49
Table 6.1: Reference coverage values.
As seen in table 6.1, for both countries we consider a higher coverage in
newborn than in adolescent. In order to discuss the importance of achieving
high coverage rates in adolescents, we will also implement lower values than
these reference values, which are highly speculative anyway.
6.2.3 Update of the risk of progressing to disease after
infection
In a recent paper by Andrews et al.226 it was established that in the case
of reinfection, the risk of progressing to disease is reduced by a 79%. We
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incorporate this new information by changing the parameter q (see Chapter
3) to q = 0.21(0.14 − 0.30)C.I.. The model has been recalibrated with this
new parameter, and all results shown in this chapter incorporate this update.
Besides, this value serves as an upper bound of the expected efficacy for a
vaccine, as no vaccine will provide better protection than the actual infection.
Thus, we will consider an initial efficacy of 80% for the vaccines we modelize
(see section 6.2.5).
6.2.4 New reduced model
In Chapter 3 we defined two reduced versions of the model for TB spread-
ing, in order to compare the results obtained with the complete model with
those obtained in more simplistic frameworks:
• Reduced model 1 (RM1): Considers the demographic structure as con-
stant in time, but maintains empiric age-dependent contact patterns.
• Reduced model 2 (RM2): Considers homogenous mixing, but maintains
the evolution of demography.
For simplicity in this chapter we will only compare results with one re-
duced model that combines both classical assumptions:
• Reduced model 3 (RM3): Considers the demographic structure as con-
stant and homogeneous mixing between age-groups.
6.2.5 Vaccine descriptions
A critical point in the modelization of new TB vaccines is the fact that
we already have a vaccine, BCG, whose use is widely spread. Therefore the
population we consider, and we have been modeling in Chapter 3 also, has
the effect of BCG embedded in their epidemiological parameters.
Thus, in order to implement a new vaccine we should consider the mask-
ing effect produced by BCG. This is similar to the masking effect described
in Chapter 4, but in this case previous protection does not come from en-
vironmental sensitization but from BCG. Therefore we do not rule out this
effect, as we know that BCG offers protection to some extent.
For example, if we have a new vaccine that offers exactly the same pro-
tection as BCG, in a clinical trial we will measure an efficacy value of zero,
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which is exactly what we should incorporate in the model, as the unvacci-
nated branch is not really unvaccinated but vaccinated with BCG. Or in a
more extreme situation, if we have a vaccine with an efficacy that is lower
than that of BCG, its effective efficacy will be negative (and it will have a
negative effect on the population if we replace BCG with that new vaccine),
even if its real protective power is positive.
In order to correct for BCG-masking, we first should establish what is
the immunity offered by BCG. In Chapter 4, alongside the parameters of
masking and blocking, we deduced two values for the intrinsic efficacy of
BCG, one at the age of 4.5 years εBCG(4.5) = 0.577 and another at the age
of 16 εBCG(16) = 0.376.78 We modelize the waning of immunity in a vaccine
with an exponential:
ε(t) = ε0 exp(−γt) (6.3)
Thus, a vaccine will be described by two parameters, the initial efficacy
ε0 and the decay rate (the immunity waning) γ. For the case of BCG we
can easily obtain these parameters using the two points that we know, which
give us ε0,BCG = 0.698 and γBCG = 0.087 (i.e. a 8.7% annual decay).
In this work we will consider three different vaccines, whose parameters
are shown in table 6.2. First we will consider an ideal vaccine with no wan-
ing, then a vaccine with a weak annual waning of 1%, and finally a vaccine
with a stronger waning effect (5%) but still less than BCG (we will refer to
this latter vaccine as reference vaccine). All vaccines will present an initial
efficacy of 80%.
Vaccine name ε0,new γnew
Ideal 0.800 0.00
Weak waning 0.800 0.01
Reference 0.800 0.05
Table 6.2: New vaccines’ parameters. The real efficacy of new vaccines
will be given by εnew(t) = ε0,new exp(−γnewt)
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In Figure 6.1 we show the real efficacies for BCG and the hypothetical
new vaccines considered, as well as the effective efficacy of the new vaccine


























































































Reference vaccine in Adolescents
BCG New vac. (real) New vac. (effective)
Figure 6.1: Immunity profiles offered by hypothetical new vaccines.
Values of the efficacy of BCG and the hypothetical new vaccine (real and
effective). We show the vaccines considered in table 6.2, applied on newborns
and adolescents. BCG is the same in all cases.
In equation 6.3 the time variable t stands for the time since the vaccine
is inoculated. Thus, for adolescent vaccination this time starts at 15 years old.
The age description in the model is discrete, thus we need to provide
discrete values for the efficacy for each age-group. We assign the efficacy
corresponding to the medium age of each age-group (2.5 years old for a = 0,
7.5 years old for a = 1, and so on).
Eventually we will also consider the possibility of having a blocking effect
(due to environmental sensitization or BCG itself) that compromises the
efficacy on adolescent vaccination. In that case, the efficacy experienced by
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the immunized individuals is reduced by a factor 1−b where b is the blocking
level considered.
6.2.6 Measurement of impact for epidemiological inter-
ventions
As the ultimate goal is to evaluate and compare epidemiological inter-
ventions, in this case new vaccines, we need to establish a quantitative mea-
surement of the impact of the aforementioned interventions. An immediate
possibility could be to measure the reduction of new TB cases (that we al-
ready used in Chapter 5). Thus, we define the impact in incidence, II(t)
as the difference in TB cases (or deaths) between the baseline and the sce-
nario with the new vaccine that we compute at the end of a certain follow-up
period t:
II(t) = IBaseline(t)− INewVac(t) (6.5)
where I(t) is the acumulated number of TB cases measured from the
start of the vaccination campaign in 2025 until year t. The subindex Base-
line refers to the simulation in which no new vaccine is added, while the
subindex NewVac stands for the scenario with the new vaccine.
In some cases, instead of the absolute impact (total number of cases or
deaths prevented) it might be more useful to compare relative impacts F ,





As we are specially interested in the comparison between adolescent and
newborn vaccination, we will also use the relative difference between impacts
RD :
RDI(t) =
Iadol.I (t)− Inewb.I (t)
Iadol.I (t)
(6.7)
In the last years, the measurement unit disability-adjusted life years
(DALYs)227–230 is growing in popularity.231,232 DALYs can be understood as
the total number of years that a disease is taking from the people. It is the
sum of two different contributions, the years of life lost due to death (YLL)
and the years lost due to disability (YLD), as it is considered that while the
disease is attacking, life is not enjoyed at its full:
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DALY = YLL + YLD (6.8)
The Years of Life Lost (YLL) are defined as:
YLL = M × L (6.9)
whereM is the number of deaths and L is the standard life expentancy at
the age of death (in years). Thus, in simulations we compute the evolution of
YLL as the sum of all TB-related death fluxes (during active disease or after
treatment, vaccinated or unvaccinated), weighted by the life expentancy of






Ṁ(a, t) + Ṁ v(a, t)
)
(6.10)
The evolution of Ṁ(a, t) can be found in Chapter 3. The values of L(a, t)
change with time (life expentancy increases as demographic structure ages).
Fortunately, data on L(a, t) are given by the UN population database,138
which is the same source we use for data on demographic projections.
The Years Lost due to Disability (YLD), are defined as:
YLD = P ×DW (6.11)
where P is the prevalence of the disease, and DW is the disability weight.
In this case we consider as the prevalence of the disease the sum of all classes





DW ( Dp+(a, t) +Dp−(a, t) +Dnp(a, t) (6.12)






+T vp+(a, t) + T
v
p−(a, t) + T
v
np(a, t))
The value for the Disability Weight (DW) is taken from the study by
Salomon et al.233 as 0.331. It is assumed to be the same for all types of TB
as no further data is available.
Thus, the same definitions of impact (absolute and relative) that we have
applied to the incidence, can be applied to DALYs:
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6.3.1 Basal comparison adolescent vs newborn vaccina-
tion
We simulate the introduction of the vaccines described in table 6.2 and
Figure 6.1 in India and Nigeria in 2025. We will begin the comparison with
the ideal situation of having a coverage of 100% and no blocking effect. Re-
sults are shown in Figure 6.2, as well as Table 6.3.
Endpoint Waning Incidence DALYsNewb. Adol. RD(%) Newb. Adol. RD(%)
2050
0% 9.9 (2.8-19.7) 14.2 (5.3-20.2) 30.3 (-5.9-49.6) 65 (24-113) 90 (44-111) 27.4 (-9.9-47.2)
1% 8.5 (2.3-17.0) 13.1 (4.9-18.5) 35.1 (0.5-53.5) 56 (20-98) 83 (41-103) 32.6 (-2.9-51.4)
5% 4.2 (1.1-8.6) 9.5 (3.5-13.5) 56.1 (30.0-69.6) 28 (10-51) 62 (30-78) 54.8 (28.3-68.4)
2100
0% 91.2 (27.1-138.2) 104.6 (38.0-136.0) 12.8 (-10.3-27.3) 474 (167-683) 517 (222-651) 8.3 (-16.2-23.3)
1% 72.5 (20.8-111.9) 90.4 (32.4-118.9) 19.8 (-2.8-34.2) 386 (132-567) 458 (195-584) 15.6 (-8.3-30.5)
5% 26.5 (6.8-44.2) 53.6 (18.6-73.7) 50.5 (32.7-61.6) 153 (47-240) 294 (122-387) 48.0 (29.4-59.4)
Table 6.3: Impact evaluation in India at 2050 and 2100 with different
immunity waning. We present the impact (in millions) in incidence and
DALYs (eqs. 6.5 and 6.13) for newborn and adolescent vaccination beginning
in 2025, as well as the relative difference between both (eqs. 6.7 and 6.15)
The vaccine with no waning, an initial efficacy 80%, full coverage and no
blocking (continuous lines in figure 6.2) corresponds to the maximum impact
we can obtain from a single vaccination campaign. Even though the impact
obtained is quite significant, eradication is not achieved during this century.
Vaccination in adolescents offers a greater and most immediate impact
than vaccination in newborns, a result that was already seen by previous
models.101 However, the distance between both strategies grows shorter as
time goes by, specially when the waning is low and the immunity offered
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Figure 6.2: Basal comparison adolescent vaccination vs newborn vac-
cination. A-D: Incidence and Mortality Rates vs Time for India (A-B) and
Nigeria (C-D) obtained after no vaccination and after applying the vaccines
described in table 6.2 and Figure 6.1 at newborns or adolescents. E-F: Frac-
tion (in %) of DALYs prevented (eq. 6.14) vs Time after the inoculation
of the different vaccine campaigns in India (E) and Nigeria (F). Vaccines
considered in this figure have a coverage of 100% and no blocking.
by the vaccines reaches the eldest age strata. In the case of Nigeria we can
even see an inversion for the ideal case of no waning: if the time window of
impact evaluation is long enough, newborn vaccination offers better perfor-
mance than adolescent vaccination.
The reasons underlying these differences between newborn and adolescent
vaccination become clearer when we analyze the age distribution of the im-
pact provided by those vaccines instead of remaining at the age-aggregated
level.
6.3.2 Age distribution of vaccine impact
In Figure 6.3 we show the accumulated impact from the start of the vac-
cination campaign (either newborn or adolescent) to different endpoints, for
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Figure 6.3: Age distribution of vaccine impact. Accumulated impact
(measured as fraction of cases prevented, eq 6.6) at different endpoints (2050,
2075 and 2100) for the different endpoints. Results are shown for India and
Nigeria, the three levels of waning considered (0%, 1% and 5%) and both
vaccination strategies (adolescents or newborns)
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Without immunity waning a newborn vaccine will eventually cover all
the population as time goes by, significantly improving its performance on
the adult age strata as we expand the observation window. However, an
adolescent focused vaccine will always leave a reservoir of susceptible chil-
dren. Thus, for this case, if the observation window is long enough, newborn
vaccination can offer a greater impact than adolescent vaccine. But when
the immunity offered by the vaccine wanes with time, if we vaccinate only
newborns we might lose the effect of the vaccine before it reaches the age
strata that are most affected by the disease, thus in this case to vaccinate
adolescent would be a better strategy.
The situation in both countries analyzed, India and Nigeria, presents sig-
nificative differences. While in India an adolescent vaccination only provides
minimal protection in the younger age strata (less than 5% in 2050), in Nige-
ria the same vaccination campaign is capable to protect children almost to
the same levels as a newborn focused vaccine.
6.3.3 Effect of demographic evolution and contact pat-
terns
In order to study the effect of demographic evolution and heterogeneous
contact patterns, the novel ingredients added by this thesis, in the evaluation
of vaccines’ impact we repeat the same analysis with a reduced model (RM3)
in which both features are neglected (i.e., demography is constant and mix-
ing is homogeneous). Figure 6.4 is the analogous to Figure 6.2 and Figure
6.5 is the analogous to Figure 6.3.
When impact of new vaccines is evaluated with the reduced model, results
change significantly. In this case newborn vaccination have in most cases a
much better performance than the adolescent counterparts, that is only able
to outperform newborn vaccination for the highest level of waning considered
(5%).
In this model, that assumes homogeneous mixing, adolescents stop being
the most socially active individuals, thus immunizing them does not have the
same effect on stopping transmission. Besides, we are not considering the ag-
ing of the population in this model. Therefore, the youngest age strata will
not lose density of individuals, and will remain as the most populated age-
groups. Thus, in this reduced model, newborn vaccination shows a higher






































































































































































Figure 6.4: Basal comparison adolescent vaccination vs newborn vac-
cination with RM3. A-D: Incidence and Mortality Rates vs Time for India
(A-B) and Nigeria (C-D) obtained after no vaccination and after applying
the vaccines described in table 6.2 and Figure 6.1 at newborns or adoles-
cents. E-F: Fraction (in %) of DALYs prevented (eq. 6.14) vs Time after the
inoculation of the different vaccine campaigns in India (E) and Nigeria (F).
Vaccines considered in this figure have a coverage of 100% and no blocking.
time in the birth rate.
Even when these differences between models can be easily traced back
to the changes in the underlying assumptions, the results are quite puzzling
when we explore past bibliography. Knight et al. 101 show in their model
a clearly greater impact in adolescent vaccination than in newborn vacci-
nation, even for life-long immunization, despite not having in their model
heterogeneity in contact patterns or population aging. One possible expla-
nation to this phenomenon is the description of the vaccination process itself.
In Knight et al. 101 they consider a vaccine that prevent disease by cutting
the fluxes from latency to active disease, that is applied in infected and un-
infected individuals. In this case we consider only pre-infection vaccines, as
we argue that a vaccine probably will not offer more protection than latent
infection. Thus, the coverage in adolescents will be much greater in the work
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Figure 6.5: Age distribution of vaccine impact obtained with RM3.
Accumulated impact (measured as fraction of cases prevented, eq 6.6) at
different endpoints (2050, 2075 and 2100) for the different endpoints. Results
are shown for India and Nigeria, the three levels of waning considered (0%,
1% and 5%) and both vaccination strategies (adolescents or newborns)
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by Knight et al. 101 than in the situation considered here. In high burden
settings prevalence of infection can reach 50% at 15 years of age234 so this
distinction can heavily influence results.
6.3.4 Influence of coverage and blocking
Even when for expected values of waning (from now on we assume 5%
as reference value) the vaccination campaign focused on adolescents obtains
greater impact, there are two aspects that will worsen the performance of
adolescent vaccination and have not been considered yet.
To begin with, we have considered until now an ideal coverage of 100%.
However, as we have discussed earlier, coverages from real vaccination cam-
paigns are rarely close to that number. We will implement now the coverage
values from Table 6.1 as reference. We will also implement lower values of the
coverage in the adolescent campaign, to explore worst-case scenarios. Thus,
we repeat the analysis from Figure 6.2, with the new values of coverage con-
sidered, in Figure 6.6.
With a non-negligible waning and a more realistic coverage, prospects of
the impact of new vaccines are more pessimistic (notice that the y-axis on
panels A-D does not start in zero anymore). In this case, we are not only far
from eradication, but also vaccines can not prevent the rebound in TB bur-
den that is caused by the aging of populations (as we discussed in Chapter
3). For the reference values of coverage, adolescent vaccination works better
than newborn, but this tendency can be reversed if an adolescent campaign
is not able to reach those levels of coverage.
Another effect we must take into account is the possible existence of block-
ing (as defined in Chapter 4, it is the effect of having an underperformance of
the vaccine caused by previous sensitization to environmental mycobacteria),
that won’t appear in newborns but can compromise an adolescent vaccina-
tion campaign. Starting from the reference coverage values and a waning of
5%, we repeat once again the analysis from Figure 6.2 with different values
of blocking in Figure 6.7.
In Chapter 4 we established that the blocking levels suffered by BCG at
school age are 41.1% in Salvador and 96.4%. in Manaus. In this case, we will
explore a 20% of blocking alongside the 41.1% that we have in Salvador. The
different levels of blocking suffered by the adolescent vaccine are analogous
to having different penalizations on coverage, thus results are very similar
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Figure 6.6: Comparison adolescent vaccination vs newborn vaccina-
tion for different coverage levels. A-D: Incidence and Mortality Rates
(Cases per million) vs Time for India (A-B) and Nigeria (C-D) obtained
after no vaccination and after applying the vaccines described in table 6.2
and Figure 6.1 at newborns or adolescents. E-F: Fraction (in %) of DALYs
prevented (eq. 6.14) vs Time after the inoculation of the different vaccine
campaigns in India (E) and Nigeria (F). Vaccines considered in this figure
have no blocking.
to what we obtained in previous Figure 6.6. For low values of blocking the
adolescent campaign is still able to outperform newborn vaccination, but































































































































Figure 6.7: Comparison adolescent vaccination vs newborn vaccina-
tion for different blocking levels. A-D: Incidence and Mortality Rates
(Cases per million) vs Time for India (A-B) and Nigeria (C-D) obtained
after no vaccination and after applying the vaccines described in table 6.2
and Figure 6.1 at newborns or adolescents. E-F: Fraction (in %) of DALYs
prevented (eq. 6.14) vs Time after the inoculation of the different vaccine
campaigns in India (E) and Nigeria (F).
6.4 Conlussions
The ability of a new vaccine to provide a significant impact at reducing
the burden of TB and getting closer to eradication is as low as our ability to
foresee that impact.
As we have seen throughout this chapter, in order to obtain a significant
impact on the population we need vaccines with low immunity wanings, so
protection can reach all age-groups. The same effect could eventually be
achieved by having mass vaccination campaigns at all ages, but probably the
cost of such enterprise would be prohibitive.
The fundamental problem lies in our capacity to determine the waning
of new vaccines. Clinical trials span for short periods of time (a couple of
years,200 maybe 5 in an exceptionally resource consuming trial), but immu-
nity waning is by definition a long-term effect. Thus, it is almost impossible
to extract information about the immunity waning before the deployment
of the vaccine. The situation could not be more worrisome; the information
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taken from these clinical trials is what determines which vaccine candidates
move to the next stage and which are rejected but it leaves aside the most
important parameter of the vaccine, it’s immunity waning.
Furthermore, the forecasts about the performance of new vaccines have
turned out to be very pessimistic. In Chapter 3 we discussed how the ex-
pected aging of the population is often associated with a stabilization, or even
a rebound, in TB burden levels. Now we have seen that, unless we achieve
incredibly lasting immunity, we can not avoid this effect. Most likely, het-
erogeneities in contact patterns and the aging of demography is after the
unexpected underperformance of these vaccines. On the one hand, assor-
tativity prevents the reduction of transmission, as contacts remain mostly
within age-groups; and on the other hand, as population gets older transmis-
sion ceases to play an important role, as most cases in elderly people come
from old infections that a pre-exposure vaccine can not avoid in the short-
term. Thus, as we stated in Chapter 3, we should not rule out these features
when modeling TB spreading, specially for the evaluation of new vaccines.
As for the long debate about which vaccination strategy (newborn or
adolescent) offers a stronger performance we don’t have a clear answer. Al-
though adolescent vaccination offers a faster impact as it targets the age
strata most affected by the disease, it will always leave a reservoir of unpro-
tected children (or with the variable protection offered by BCG to be more
precise). However, a newborn vaccine with a sustained protective power,
holds the promise of protecting eventually the entire population, offering a
better long-term performance than its adolescent counterpart. Besides the
feasibility of an adolescent campaign is a substantial practical difficulty (in
terms of coverage and blocking).
In this work we have limited the study to the case of vaccines that reduce
the probability of fast-progression. The space of parameter on which a new
vaccine could act, that was hinted in Chapter 5, remains vastly unexplored.
Although an effective vaccine could undoubtly play a role in the control
of TB, if the goal is to eradicate the disease during this century other ap-
proaches should be considered as well (post-exposure vaccine, treatment of
LTBI, better diagnostic tools, better treatments, ...)
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The goal of this thesis is to develop a model of TB spreading for the eval-
uation of new vaccines. Specifically we intend with this thesis to achieve a
more advanced description of those processes that depend on the age (demo-
graphic evolution, contacts among age groups, . . . ) than what can be found
in current models. The importance of these advances come for two different
paths. On one hand, the way in which TB develops strongly depends on
the age of the individuals that suffers it. For example, we know that, after
getting infected, newborns and adults tend to develop the disease faster than
school-aged children, who tend to develop asymptomatic latency. We also
know that adults tend to develop the most infectious forms of TB (pulmonary
TB) while children develop other forms of TB (meningeal, milliar, ...) con-
sidered as non contagious. On the other hand, vaccines also act on a different
way depending on the age of the vaccinated individual. Among all possible
effects that might compromise the immunization provided by the vaccine, the
previous exposure to environmental mycobacteria stands out. By definition,
exposure will be greater the older the individual is. In addition, currently
there is a debate about which age group should be immunized: immunizing
adolescents offers more rapid protection (since they are more infectious than
children) but leaves a reservoir of unvaccinated children.
We have seen throughout these thesis that, for all these reasons, it is nec-
essary to update the current models with a more realistic description of those
mechanisms that depend on age. Specifically, in this thesis we propose to
include demographic predictions in the simulations, so that the demographic
pyramids evolve in time in a realistic way instead of being considered con-
stant. In a similar way, we include heterogeneous contact patterns depending
on age, extracted from experimental studies, instead of assuming that indi-
viduals mix among them in a homogeneous way without accounting for age.
Nonetheless, implementing these two ingredients is not as trivial as it
might seem at first. As we discuss in chapter 2, contact patterns must be
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adapted to the demographic pyramid of the population we simulate. In this
chapter we study how (and in which cases) we can adapt contact patterns,
that were measured empirically in a determined location, to other popula-
tions. The fundamental problem, that we have studied in this chapter, is
the lack of reciprocity that is produced when contact patterns, measured
in a certain setting, are used in a different population with a different age
structure. Thus, we have studied in this chapter different methods to adapt
contact patterns and how they influence in the propagation of a SEIR-type
disease.
We have also addressed the differences between contact patterns mea-
sured in different countries. We have concluded after our analysis that con-
tact matrices belonging to African countries show larger assortativity and a
smaller influence of young individuals than European matrices. Our results
warn against the potential biases that could occur when contact matrices
are extrapolated blindly from one country to another. These findings will
be fundamental in our model of TB spreading, in which the age structure
changes at every time step; but also might be useful for the modeling of other
infectious diseases.
In chapter 3 we develop our model of TB spreading. We include hetero-
geneous contact patterns and demographic evolution over a state-of-the-art
natural history with 17 states for the disease (including fast and slow latency,
different types of active disease, different treatment outcomes, etc.). After
abandoning the oversimplifying hypotheses of constant demographic pyra-
mids and homogeneous mixing, we prove how the predictions of the model
are modified. Specifically we have seen how including the predicted aging of
the population produces more pessimistic outcomes (more TB burden) than
when this ingredient is forgotten. Adults suffered a higher TB burden than
children and they are also more efficient spreaders, and thus, the aging of
populations produces higher predicted incidence and mortality. This result
has important consequences regarding the management of Public Health: the
efforts made to lower the incidence of TB in the last decades should be redou-
bled in the future. Also, implementing the heterogeneity in contact patterns
changes the age distribution of the burden of TB, which has implications for
age-focused interventions.
After developing the model of TB spreading, during the next chapters
we study how to correctly describe the mechanism of the vaccine, as well as
the possible effects that might compromise its power. We start studying the
effect of previous exposure to mycobacteria suffered by BCG. In order to do
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that, through chapter 4 we have analyzed the BCG-REVAC clinical trials
to quantify the effects of masking and blocking suffered by this vaccine. We
show how blocking is the effect that most plausibly is behind the variability
that we find in BCG’s efficacy, and we measured its value for two cities in
Brazil: Manaus and Salvador. The possible occurrence of blocking in new
vaccines must be considered in the debate about which age group should
receive immunization, something that usually goes unnoticed.
In addition to these effects that can make a vaccine more or less effective,
there are different ways or mechanisms by which a vaccine can interrupt the
life cycle of the pathogen. In chapter 5 we study how protection against
disease might be achieved via two different (not exclusive) pathways: the
slowdown of rapid progression and/or the prevention of rapid progression
(producing LTBI). These two mechanisms are indistinguishable in a classical
clinical trial but produce very different impacts when evaluating through a
model of TB spreading. We have proposed a new analysis that potentially
could disentangle these two mechanisms, producing much more accurate im-
pacts and increasing the probability of having a successful trial. This new
design of clinical trials does not require to take more data than current trials;
and this framework is potentially extensible to more complex scenarios.
After acquiring all this knowledge about the modeling of TB spreading
and the details of the vaccines, we study the debate about which is the opti-
mal age group to receive vaccination. Prior to this work it was accepted with-
out qualms, that vaccinating adolescents offers a faster and more pronounced
impact than vaccinating neonates. However, previous studies not only did
not consider the new ingredients that we have added to the TB spreading
model (demographic evolution and heterogeneous contact patterns) but also
did not consider many of the details around the description vaccines that we
have studied in this thesis, and did not explore the entire parameter space
of vaccines. When we expand the possibilities offered by the vaccines, the
statement that adolescent vaccination is better than neonatal vaccination
loses generality. Vaccinating adolescents offers a much more immediate im-
pact than vaccinating newborns as correctly pointed out by previous models.
Nonetheless vaccinating adolescents leaves a reservoir of unprotected chil-
dren. That is why a newborn vaccine, if it is able of sustain its immunity
in time, on the long-term can offer a greater impact than adolescent vacci-
nation. Besides there are two extra factors that can affect the comparison
between adolescent and newborn vaccination. On the one hand, the coverage
on adolescent will be, presumably, lower than newborn coverage, and on the
other hand, the blocking that we have studied in chapter 4 will compromise
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adolescent vaccination but will not affect newborn vaccination (because new-
borns have not been exposed to environmental mycobacteria).
Besides the advances proposed by this thesis, there are still many lim-
itations. Our model of TB spreading rely on a series of epidemiological
parameters and TB burden estimations that are subject to strong sources of
uncertainties. Thus, it would be recommendable in a future to improve the
quality of the data introduced as input of the model (and in this sense the
WHO suggests the implementation of prevalence studies), and it would be
specially positive the acquisition of age-stratified data.
We also find enormous limitations in the parameterization of new vac-
cines. The long-term effects of a vaccine, by its own nature, can not be
measured by clinical trials, leaving a wide range of uncertainty in our predic-
tions. Therefore, we should be aware of these limitations when we evaluate
the impact of new vaccines.
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Conclusiones
El objetivo de esta tesis sa desarrollar un modelo de propagación de la
Tuberculosis (TB) para la evaluación de nuevas vacunas. Concretamente pre-
tendemos con esta tesis una descripción más avanzada de aquellos procesos
que dependen de la edad (evolución demográfica, contactos entre grupos de
edad, ...) que la que podemos encontrar en los modelos actuales. La impor-
tancia de estos avances vienen por dos vertientes diferentes. Por un lado, la
forma en que se desarrolla la TB depende enormemente de la edad del indi-
viduo que la padece. Por ejemplo, sabemos que, tras infectarse, los neonatos
y los adultos tienden a desarrollar la enfermedad más rápidamente que los
niños en edad escolar, quienes suelen desarrollar latencia asintomática. Tam-
bién sabemos que los adultos tienden a desarrollar las formas de TB más in-
fecciosas (Tuberculosis pulmonar) mientras que los niños desarrollan formas
de TB (meníngea, miliar, ...) consideradas no contagiosas. Por otro lado,
las vacunas también actúan de forma distinta en función de la edad del indi-
viduo vacunado. Entre todos los posibles efectos que pueden comprometer la
inmunización proporcionada por una vacuna, destaca la exposición previa a
micobacterias ambientales. Por definición, está exposición acumulativa será
mayor cuanto más edad tenga el individuo. Además, actualmente se plantea
el debate de a qué grupo de edad debería inmunizarse: inmunizar adoles-
centes ofrece una protección más rápida (ya que son más infecciosos que los
niños) pero deja un reservorio de niños sin vacunar.
Hemos visto a lo largo de esta tesis que, por todos estos motivos, es
necesario actualizar los modelos actuales con una descripción más realista de
aquellos mecanismos que dependen de la edad. En concreto, en esta tesis
proponemos incluir predicciones demográficas en las simulaciones, de forma
que las pirámides demográficas evolucionen en el tiempo de una manera re-
alista en lugar de ser consideradas constantes. De forma similar, incluimos
patrones de contactos heterogéneos dependientes de la edad, extraídos de
estudios experimentales, en lugar de asumir que los individuos se mezclan
entre sí de forma homogénea sin tener en cuenta la edad.
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Sin embargo, implementar estos dos ingredientes no es tan trivial como
podía parecer en un principio. Como discutimos en el capítulo 2, los patrones
de contacto deben adaptarse a la pirámide demográfica de la población que
simulamos. En este capítulo estudiamos cómo (y en qué casos) los patrones de
contactos, medidos empíricamente en una localización determinada, pueden
ser adaptados a otras poblaciones. El problema fundamental que hemos es-
tudiado aquí es la falta de reciprocidad que se produce cuando se utilizan
unos patrones de contactos medidos en una población determinada, en una
población distinta con una estructura de edades diferente. Así, hemos estu-
diado en este capítulo distintos métodos para adaptar patrones de contacto,
y como influyen en la propagación de una enfermedad tipo SEIR.
También hemos estudiado las diferencias que existen entre los patrones de
contacto medidos en diferentes países del mundo. Hemos concluído tras nue-
stro análisis, que las matrices de contactos de países africanos presentan una
mayor asortatividad y una menor influencia de los individuos más jovenes
que la que encontramos en las matrices europeas. Nuestros resultados ad-
vierten de los sesgos potenciales que pueden producirse cuando se extrapolan
matrices de contacto indiscriminadamente de un país a otro. Estos hallazgos
serán fundamentales en nuestro modelo de propagación de TB, en el que la
estructura por edades cambia en cada paso temporal; pero también pueden
ser de utilidad para la modelización de otras enfermedades infecciosas.
En el capítulo 3 desarrollamos nuestro modelo de propagación de TB.
Como venimos diciendo, incluimos patrones de contacto heterogéneos y evolu-
ción demográfica sobre una historia natural con 19 estados para la enfer-
medad (incluyendo latencia rápida y lenta, distintos tipos de enfermedad
activa, distintas posibilidades de recuperación, etc.). Tras abandonar las
hipótesis sobre-simplificadoras de pirámides demográficas constantes y mez-
cla homogénea, comprobamos como se modifican las predicciones realizadas
por el modelo. Específicamente, hemos visto como incluir el envejecimiento
previsto de las poblaciones produce predicciones más pesimista (carga de Tu-
berculosis mayor) que cuando este ingrediente es olvidado. Los adultos sufren
una mayor carga de Tuberculosis y son propagadores más eficientes, y por
ello el envejecimiento de las poblaciones produce predicciones de incidencia
y mortalidad más elevadas. Este resultado tiene importantes consecuencias
en lo que concierne a la gestión de la Salud Pública: los esfuerzos realizados
para bajar la incidencia de la Tuberculosis en las últimas decadas deberán
ser redoblados en un futuro. También implementar la heterogeneidad en
los patrones de contactos cambia la distribución por edades de la carga de
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Tuberculosis, lo cuál tiene implicaciones para intervenciones centradas en la
edad.
Tras desarrollar el modelo de propagación de TB, durante los siguientes
capítulos estudiamos cómo describir correctamente el funcionamiento de la
vacuna, así como los posibles efectos que pueden comprometer el potencial
de la misma. Empezamos estudiando el efecto de la exposición previa a
micobacterias que sufre la vacuna BCG. Para ello, en el capítulo 4, hemos
analizado los ensayos clínicos BCG-REVAC para cuantificar los efectos de
enmascaramiento y bloqueo sufridos por esta vacuna. Mostramos como el
bloqueo es el efecto que, más plausiblemente, está detrás de la variabilidad
que encontramos en la eficacia de BCG, y medimos su valor para dos ciudades
de Brasil: Manaus y Salvador. La posible aparición de bloqueo en nuevas
vacunas debe ser considerada en el debate sobre qué grupo de edad debería
recibir inmunización, algo que suele pasar desapercibido.
Además de estos efectos que pueden hacer que una vacuna sea más o
menos efectiva, existen distintas vías o mecanismos por los cuales una vac-
una puede interrumpir el ciclo vital del patógeno. En el capítulo 5 hemos
estudiado como la protección contra enfermedad puede conseguirse por dos
vías diferentes (no excluyentes): la ralentización de la progresión rápida y/o
la prevención de la progresión rápida (produciendo LTBI). Estos dos mecan-
ismos son indistinguibles en un ensayo clínico clásico pero producen impactos
muy distintos cuando se evaluan con un modelo de propagación de Tuber-
culosis. Hemos propuesto un nuevo análisis que podría potencialmente de-
senredar estos dos mecanismos, produciendo impactos mucho más precisos
en la evaluación de vacunas y aumentando las probabilidades de tener un
ensayo exitoso. Este nuevo diseño de los ensayos clínicos no requiere tomar
más datos que los ensayos actuales, y este marco es potencialmente extensi-
ble a situaciones más complejas.
Después de adquirir todos estos conocimientos acerca de la modelización
de propagación de Tuberculosis y los detalles de las vacunas, estudiamos
el debate sobre cual es el grupo de edad óptimo para recibir la vacunación.
Antes de este trabajo se aceptaba sin reparos que vacunar adolescentes ofrece
un impacto más rápido y acusado que vacunar neonatos. Sin embargo, los
estudios previos no solo no consideraban los ingredientes que hemos añadido
al modelo de propagación de TB (evolución demográfica y patrones de con-
tacto heterogéneos) sino que tampoco consideraban muchos de los detalles
alrededor de las vacunas que hemos estudiado en esta tesis, y no exploraban
todo el espacio de parámetros propio de las vacunas. Cuando expandimos las
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posibilidades ofrecidas por las vacunas, la declaración de que la vacunación
adolescente es mejor que la vacunación neonatal pierde generalidad. Vacunar
adolescentes ofrece un impacto más inmediato que vacunar neonatos como
bien apuntaban modelos previos. Sin embargo, la vacunación a adolescentes
deja un reservorio de niños sin protección. Es por ello que una vacuna neona-
tal, si es capaz de sostener su inmunidad en el tiempo, a largo plazo puede
llegar a ofrecer un mayor impaco que la vacunación a adolescentes. Además,
hay otros dos factores que pueden afectar la comparación entre vacunación
adolescente y neonatal. Por un lado la cobertura a adolescentes será pre-
sumiblemente inferior que la cobertura neonatal, y por otro, el bloqueo que
hemos estudiado en el capítulo 4 afectará a la vacunación adolescente pero
no a la vacunación neonatal (ya que los recién nacidos no han sido expuestos
a micobacterias ambientales).
A pesar de los avances propuestos por esta tesis, todavía hay muchas lim-
itaciones. Nuestro modelo de propagación de Tuberculosis dependen de una
serie de parámetros epidemiológicos y estimaciones de la carga de Tuberculo-
sis que están sujetos a grandes fuertes de incertidumbres. Sería recomendable
en un futuro mejorar la calidad de los datos que introducimos como input
del modelo (y en este sentido la Organización Mundial de la Salud sugiere la
implementación de estudios de prevalencia), y sería especialmente positivo la
obtención de datos estratificados por edades.
También encontramos grandes limitaciones en la parametrización de las
nuevas vacunas. Los efectos a largo plazo de una vacuna, por su propia nat-
uraleza, no puede ser medida en ensayos clínicos, dejando un amplio rango
de incertidumbre en nuestras predicciones. Por tanto, deberíamos ser con-
scientes de las limitaciones cuando evaluamos el impacto de nuevas vacunas.
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